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Chemotherapy	 Induced	 Peripheral	 Neuropathy	 (CIPN)	 is	 a	 debilitating	
neuropathy	 caused	 by	 commonly	 used	 chemotherapeutics.	 Clinically,	 the	
problem	 of	 CIPN	 is	 compounded	 by	 difficulties	 with	 diagnosis	 and	 limited	
treatment	 options.	 The	 pathophysiology	 of	 CIPN	 remains	 elusive,	with	 current	
mechanistic	 postulates	 focused	 mainly	 on	 the	 peripheral	 nervous	 system.	
However,	 animal	 and	human	models	 of	 non-CIPN	neuropathic	 conditions	 have	
shown	 the	 brain	 to	 be	 central	 to	 the	 development	 and	maintenance	 of	 painful	
neuropathy.	Moreover,	evidence	suggests	that	aberrant	activity	in	key	regions	of	
the	brain	 and	brainstem	could	denote	 individual	 vulnerability	 for	 chronic	pain	
states.	The	impact	of	the	brain	on	CIPN	development	is	unknown.	Assessment	of	





patients	 prior	 to	 chemotherapy	 administration,	 using	 functional	 magnetic	
resonance	 imaging	 (fMRI),	 in	 order	 to	 determine	whether	 baseline	 differences	
exist	between	patients	who	progress	to	CIPN	as	compared	to	those	who	do	not.	






Study)	 was	 developed.	 Cancer	 patients	 scheduled	 to	 receive	 neurotoxic	
chemotherapy	 treatment	 including	 oxaliplatin,	 carboplatin,	 carbotaxol,	 or	
cisplatin,	were	 recruited	 from	 three	NHS	 trusts	 in	 Scotland,	 to	 undergo	 a	 high	
resolution	 (3	 tesla)	 functional	 MRI	 scan,	 at	 a	 single	 time	 point	 prior	 to	
	 6	
commencement	 of	 chemotherapy.	During	 the	 scan	 structural,	 resting	 state	 and	
functional	 data	 were	 collected.	 Functional	 data	 involved	 the	 presentation	 of	
punctate	 stimuli	 (using	 a	 256mN	 von	 Frey	 filament),	 above	 the	 patients’	 right	
medial	malleolus.	While	 receiving	 the	punctate	stimuli,	patients	viewed	 images	
that	had	neutral	or	positive	emotional	content	or	a	baseline	coloured	image	with	
no	 content.	 Sample	 size	was	 based	 on	 previously	 successful	 pain	 fMRI	 studies	
and	pragmatic	estimates.	Acute	CIPN	was	defined	clinically	by	common	toxicity	
criteria	as	necessitating	a	chemotherapy	dose	reduction	or	cessation.	Data	were	




group	 comparison	was	made	 following	 a	 dual	 regression	 approach.	 FEAT	was	
used	for	both	first	and	second	level	functional	analyses.	Group	comparisons	were	
made	using	a	mixed	effects	analysis	 (z	 threshold	2·3	and	2,	 regions	considered	
significant	 at	p<0·05,	 cluster	 corrected).	The	group	was	 split	 by	 sex	 to	 explore	
known	 sex	 differences	 in	 pain	 processing.	 To	 address	 the	 second	 aim	 of	 this	








had	 gynecological	 malignancies	 and	 18	 had	 colorectal	 cancer.	 17	 patients	
developed	acute	CIPN.	Structural	analysis	showed	that	patients	who	developed	












Differences	 in	 brain	 structure	 and	 function	 are	 evident	 between	 patients	 who	
developed	 CIPN	 and	 those	 who	 did	 not.	 Crucially,	 the	 regions	 identified,	 in	
particular	 the	 NAc,	 have	 been	 postulated	 to	 denote	 a	 vulnerability	 for	
progression	to	pain	states.	Although	the	findings	need	further	confirmation	they	
suggest	 a	 paradigm	 shift	 in	 terms	 of	 CIPN	 as	 a	 clinical	 problem.	 Specifically,	 it	






































AMP adenosine monophosphate-activated 









CI confidence interval 
CI chief investigator 
CIPN Chemotherapy induced peripheral neuropathy 
CNS central nervous system 






CS Central sensitisation 
DeOxyHb deoxygenated haemoglobin or deoxyhaemoglobin 




DN diabetic neuropathy 
DNA Deoxyribonucleic acid 










fMRI Functional magnetic resonance imaging 
FMRIB Oxford Centre for Functional Magnetic 
Resonance Imaging of the Brain 
FOV field of view 









IASP International Association for the Study of Pain 
IAPS International	Affective	Picture	System	
IC independence component 








































PS Peripheral sensitisation 
QST quantitative	sensory	testing	
RCT randomised controlled trial 



















TRP transient receptor potential 
TRPM8 Transient Receptor Potential Cation Channel, 
Subfamily M, Member 8 
TSC Trial	Steering	Committee	
VAS visual analog scale 
VBM Voxel based morphometry 
















































































































































































































































































































































































Chemotherapy	 Induced	Peripheral	Neuropathy	 (CIPN)	 is	 a	 neuropathic	 condition	
affecting	the	increasing	number	of	cancer	survivors.	Insight	into	why	some	patients	
develop	 CIPN	 and	 others	 do	 not,	 is	 lacking.	 Treatments	 for	 established	 CIPN	 are	
limited.		The	main	aim	of	this	thesis	is	to	investigate	the	development	of	CIPN	and	
establish	 pilot	 work	 to	 assess	 a	 novel	 treatment	 for	 this	 condition.	 This	
introductory	 chapter	 describes	 pain	 and	 its	 mechanisms,	 with	 a	 focus	 on	
neuropathic	pain	and	 the	 issues	 related	 to	 its	 treatment.	 Subsequently,	CIPN	and	
the	postulated	pathophysiological	mechanisms	underpinning	 its	 development	are	
discussed.	 Key	 questions,	 which	 remain	 unanswered	 in	 CIPN,	 are	 highlighted.	 A	
description	of	why	 functional	magnetic	resonance	 imaging	(fMRI)	 is	a	useful	 tool	












emotional	 factors	 in	 the	maintenance	and	generation	of	acute	and	chronic	pain	
(Colvin	and	Fallon,	2011).	At	a	systems	level	pain	can	be	described	in	terms	of	a	
physiological	progression	 from	peripheral	 input,	via	 the	somatosensory	system	
to	 central	 processing	 within	 the	 brain	 (Fig	 1.1).	 Although	 there	 are	 multiple	
components	of	 the	pain	processing	system	(described	subsequently),	one	of	 its	






by	 which	 peripheral	 information	 is	 conveyed	 to	 the	 central	 nervous	 system.	
Nociceptors	 are	 heterogeneous	 cells,	 typically	 found	 in	 the	 skin	 and	 walls	 of	






Mechanical	 transduction	 is	 still	 being	 elucidated	 and	 might	 involve	 multipass	
transmembrane	 proteins	 called	 piezos	 (Reichling	 et	 al.,	 2013).	 Chemical	
nociception	occurs	via	direct	simulation	of	acid	sensing	ion	channels,	and	other	




through	 sensitisation	 (Reichling	 et	 al.,	 2013).	 This	 ability	 to	 enhance	
responsiveness	or	decrease	the	threshold	needed	for	depolarisation	is	key	to	the	
plasticity	 observed	 in	 the	 pain	 pathway.	 The	 molecular	 mechanism	 by	 which	
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We will focus our discussions on the reward-
motivation-learning network and the DPMS.
The reward-motivation learning network
A recent study61 comes closest to being the 
‘pre-to-post injury’ longitudinal imaging 
study that is ideally needed. The authors performed a longitudinal 
brain imaging study of subacute back pain patients over the course 
of 1 year using a battery of brain imaging measures from the acute 
pain phase onwards. Pain persisted in 12 patients at the end of the 
year, whereas 12 patients had improved. In the persistent pain group, 
gray matter density was decreased, as has been shown to occur in 
other chronic pain conditions. Of particular relevance are the results 
from the first ‘baseline’ imaging session during the acute pain phase. 
Here, greater functional connectivity or ‘coupling’ of the nucleus 
accumbens (NAc) with the PFC predicted pain persistence by more 
than 80%. This implies that corticostriatal circuitry might be caus-
ally involved in the transition from acute to chronic pain. Notably, 
this increased coupling remained constant throughout the transition 
to chronic pain, despite gray matter density decreasing in the NAc. 
In an additional analysis, the authors discovered brain white 
matter connectivity differences in the PFC at an early time point, 
which was again more pronounced in the group that went on to 
develop chronic pain. These changes may reflect structural vulner-
abilities, as measured by diffusion tensor imaging and fractional 
anisotropy calculations. Importantly, as with the functional connec-
tivity measures, these white matter fractional anisotropy differences 
accurately predicted pain persistence over the next year, and this 
was validated in a second cohort of subacute back pain patients62. 
Although it is unknown whether these differences in function and 
structure were present pre-injury and therefore represent an a priori 
risk for pain, this study nevertheless highlights how the brain’s reward-
motivational learning circuitry is potentially relevant in predicting 
the transition from acute to chronic pain. In an earlier study, the 
authors had already reported results that hinted at a possible bias in 
the reward network before chronic pain development63. They found 
differential NAc responses to acute noxious thermal stimuli in con-
trols and chronic back pain patients, implying that an altered valence 
to acute pain exists between patients and controls.
Indeed, studies in the past have noted the relevance of reward cir-
cuitry in pain64, and other related networks, such as those relevant to 
dopaminergic signaling, have also been described. Thus, patients with 
fibromyalgia have disrupted dopaminergic reactivity65. Furthermore, 
placebo analgesia in healthy controls can be predicted by dopamine-
related traits, with magnitude of analgesia correlated to gray matter 
density in the insula, ventral striatum and PFC66. A link between the 
ability to experience analgesia and the brain reward network is also 
supported by findings from our laboratory. Baseline responses to a 
painful stimulus were found in reward networks, involving, for exam-
ple, the ventral tegmental area and the NAc. This baseline activity was 
predictive of both subsequent opioid induced behavioral analgesia 
and its neural expression via the DPMS60.
Despite these results, the precise role of the reward-motivation 
learning system in pain remains unclear and may depend on 
context. We found that the hedonic value of pain could be ‘flipped’, 
fundamentally altering its emotional value from threat to reward. This 
change was mediated by activity in reward regions working in concert 
with the DPMS67, providing further evidence for the importance of 
these networks in pain appraisal, a key feature of ongoing, chronic 
pain states. Dispositional optimism and pessimism, key trait factors 
relevant in pain, powerfully influence unexpected reward/analgesia 
outcomes, with diametrically opposite NAc activity distinguishing the 
pessimists from optimists67. Combined with data already discussed, 
it seems likely that transition to and continuation of chronic pain 
is dependent on the state of motivational/learning and reward 
mesolimbic-prefrontal circuitry of the brain.
The DPMS
The DPMS is a powerful network that regulates nociceptive process-
ing in the dorsal horn of the spinal cord and thereby controls which 
signals enter the brain. As such, it is important in influencing what 
pain you ultimately experience68,69. The brainstem’s component of 
the DPMS involves, among other nuclei, the periaqueductal gray 
and the rostral ventromedial medulla (RVM). There is bidirectional 
central control of nociception that can either alleviate pain in 
situations in which antinociception is necessary for survival (driven 
by ‘off ’ cells), as in sporting competition or battle, or can facilitate 
nociceptive processing (driven by ‘on’ cells), thereby contributing 
to the maintenance of heightened pain states. This was confirmed 
recently in several brainstem-imaging studies of chronic pain and 
central sensitization, a key dorsal horn event that amplifies incoming 
nociceptive inputs70. The anterior cingulate cortex, amygdalae and 
hypothalamus are also part of the DPMS, and these connections to 
the brainstem are the means by which cognitive and emotional vari-
ables interact with nociceptive processing to influence the resultant 
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Figure 4 Various brain networks may be involved 
in conferring vulnerability to painful conditions, 
particularly the reward-motivation network 
(purple regions) and the DPMS (green regions). 
Evidence has been found for differences in 
structure, wiring, function and neurochemistry. 
rACC/mACC, rostral/medial anterior cingulate 
cortex; vlPFC, ventrolateral prefrontal cortex; 
dlPFC, dorsolateral prefrontal cortex;  
mPFC, medial prefrontal cortex;  
OFC, orbitofrontal cortex; insula/S2, insular  
and secondary somatosensory cortex;  
S1, primary somatosensory cortex;  
Am, amygdala; Hip, hippocampus;  
Hypo, hypothalamus; Thal, thalamus;  
PAG, periaqueductal gray; VTA, ventral tegmentum.
	
	
Fig	 1.1:	 The	 pain	 pathway.	 Noxious	 stimuli	 are	 converted	 by	 specialized	
receptors	 (nociceptors)	 to	 electrical	 signals	 and	 conveyed	 via	 two	 nerve	 fibre	
types	(A-Delta	and	C)	to	the	dorsal	horn	of	the	spinal	cord.	Prior	to	entering	the	
spinal	 cord	 the	 impulse	 passes	 through	 the	 dorsal	 root	 ganglion	 (DRG).		
Pl sticity,	 known	 to	 be	 important	 in	 conv rsion	 fr m	 acute	 to	 chronic	 pain	
states,	 is	 demonstrable	 	 the	 ent re	 primary	 afferent	 nociceptor	 complex.	
Changes	can	o c r	anywhere	from	the	neuronal	terminals,	through	to	axons	and	
th 	DRG.	 Signal	 is	 then	 transmitted	 up	 to	 the	 brainstem	 and	 br in	where	 it	 is	
processed	by	the	thalamus,	in ula,	 nterior	cingulate	cort x	and	somatosenso y	
cortices	amongst	many	other	cortical	and	subcortical	regions.	Descending	signal,	





A-Beta	 fibres	 play	 a	 role	 in	 development	 of	 all dynia	 (see	 later)	 but	 are	 not	
classified	as	part	of	 the	pain	neuro-axis.	These	contain	nociceptors,	which	after	
activation	initiate	depolarization.	Primary	afferent	neurons	synapse	in	the	dorsal	
horn	 of	 the	 spinal	 cord.	 Prior	 to	 entering	 the	 spinal	 cord	 the	 nerve	 impulse	
passes	 through	 the	 dorsal	 root	 ganglion.	 The	 ganglion	 is	 made	 up	 of	 afferent	
nerve	 c ll	 bodies.	 This	 is	 a	 key	 area	 where	 dynamic	 changes	 occur	 and	 pain	
	 24	
processing	 may	 alter	 from	 acute	 to	 chronic	 states,	 including	 progression	 to	
neuropathic	pain	states	(see	1.1.1.1).		
	
The	 circuitry	 of	 the	 dorsal	 horn	 is	 complex	 and	 understanding	 of	 the	 exact	
connections	 is	 continually	 evolving	 see	 figure	 1.2	 for	 diagrammatic	




and	 innocuous	stimuli	 (Spoors	and	Kiff,	2010).	Specifically,	within	 laminae	 I	A-
Delta	 fibres	 synapse	 with	 projection	 neurons	 and	 some	 small	 interneurons,	
which	 contribute	 to	 the	 spinothalamic	 tract.	 Projection	 neurons	 cross	 the	
midline	and	ascend,	relaying	 information	up	to	the	thalamus	and	then	onto	the	
somatosensory	 cortex	 (Todd,	 2010).	 C	 fibres	 synapse	 within	 laminae	 II	
(substantia	gelatinosa).	Signal	is	conveyed	from	this	laminae	to	laminae	I,	IV,	V,	
by	 small	 interneurons	 which	 then	 join	 the	 spinothalamic	 tract.	 Additionally,	
axons	 of	 these	 neurons	 decussate	 to	 ascend	 in	 the	 contralateral	 spinothalamic	
and	 spinoreticular	 tracts	 to	 reach	 the	 brainstem,	 thalamus	 and	 somatosensory	
cortex	 (Spoors	 and	 Kiff,	 2010).	 Lamina	 III	 through	 to	 VI	 mostly	 receive	
innocuous	input	from	A-Delta	and	A-	Beta	fibres.	However,	this	region,	like	other	
laminae	in	the	dorsal	horn,	can	undergo	dynamic	changes	leading	to	chronic	pain	








Figure 1. Laminar organisation of the dorsal horn and primary afferent inputs
Rexed3 divided the grey matter of the cat dorsal horn into a series of parallel laminae based
on variations in the size and packing density of neurons, and this scheme has since been
applied to other species. a | A transverse section of rat mid-lumbar spinal cord that is
immunostained using an antibody (NeuN) that specifically labels neurons. Laminar
boundaries are indicated by the dashed lines. Laminae I and II (also known as the marginal
zone and substantia gelatinosa, respectively) constitute the superficial dorsal horn, and are
characterised by the presence of numerous small neurons. Lamina II can be divided into
outer (IIo) and inner (IIi) parts, with the latter having a somewhat lower density of neurons.
Image is modified, with permission, from REF. 157. b | Primary afferents arborise within
the dorsal horn in an orderly way: a laminar termination pattern based on fibre diameter and
function is superimposed on a somatotopic distribution that determines mediolateral and
rostrocaudal location. The central terminations of the major primary afferent types
(excluding proprioceptors) are shown. In the 1970s and 1980s a series of intra-axonal
labelling studies revealed the projections of different types of myelinated afferents153-155.
These showed that Aβ tactile and hair afferents end mainly in laminae III-VI with some
extension into lamina IIi, the precise arrangement depending on their function153. Aδ hair-
follicle afferents arborise on either side of the lamina II/III border, whereas Aδ nociceptors
end mainly in lamina I, with some giving branches to laminae V and X154. More recent
studies have identified myelinated nociceptors with conduction velocities in the Aβ range
that arborise throughout laminae I-V134 (not shown). Peptidergic primary afferents (which
also include some Aδ nociceptors8) arborise mainly in lamina I and IIo, with some fibres
penetrating more deeply, whereas most non-peptidergic C fibres form a band that occupies
the central part of lamina II156.
Todd Page 24












Figure	 1.2	 Organis tio 	 of	 th 	 Dorsal	 Horn.	 Left	 hand	 panel	 (a)	 showing	
organisation	 of	 the	mid	 lumbar	 rat	 spinal	 chord.	 Panel	 on	 right	 (b)	 showing	 a	





It	 is	 important	 to	 note	 that	 naturally	 occurring	 pain	modulation	 occurs	 at	 the	
level	of	 the	brainstem,	dorsal	horn	and	also	via	 the	endogenous	opioid	system.	
Although	descending	modulatory	pathways	originate	 in	multiple	 regions	of	 the	
cortex	 and	 brainstem,	 a	 numb r	 of	 brainstem	 nucl i	 warrant	 special	mention.	
Specifically	the	periaqueductal	grey	(PAG),	rostraventral	medulla	(RVM),	nucleus	
tractus	 solitaries	 (NTS),	 parabrachial	 nucleus	 (PBN),	 and	 the	 dorsal	 reticular	





channel	 opening	 and	 decreased	 neurotransmitter	 release.	 Post	 synaptic	
inhibition	 hyperpolarizes	 neurons	 via	 potassium	 channel	 opening	 (Spoors	 and	
Kiff,	 2010).	 A	 key	 modulator	 of	 these	 changes	 is	 substance	 P	 acting	 on	 the	




Aberrant	descending	 facilitation	and	 inhibition	has	been	shown	 in	both	human	
and	 animal	 experiments	 to	 be	 a	 key	 factor	 contributing	 to	 the	 generation	 and	
maintenance	of	mechanisms	such	as	central	sensitisation,	relevant	in	chronic	(in	
particular	 neuropathic)	 pain	 states	 (Zambreanu	 et	 al.,	 2005,	 Lee	 et	 al.,	 2008,	






involved	 in	 nociceptive	 signal	 transmission.	 The	 thalamus	 appears	 to	 serves	 a	
specific	role	as	a	relay	centre.	Similarly	to	the	brainstem	areas	described	above	
thalamic	 nuclei	 have	 a	 bidirectional	 spinal	 and	 supraspinal	 connectivity	 that	
enables	varied	nociceptive	 transmission	 to	higher	centres	 (Tracey	and	Mantyh,	
2007).			
	




insula	 cortex,	 anterior	 cingulate	 cortex	 (ACC),	 and	 prefrontal	 cortex.	 These	
regions	are	not	unique	to	pain	processing	and	their	pattern	of	activation	varies	
depending	 on	 the	 specific	 individual	 context	 of	 the	 pain	 experience	 (Lee	 and	
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Fig. 2. Schematic view of the interrelationship between cerebral structures involved in the initiation and modulation of descending controls of nociceptive
information. Note the strategic location of the periaqueductal grey (PAG) and the reciprocal nature of many interconnecting pathways. Direct projections
from the cortex, hypothalamus and nucleus tractus solitarius to the DH are not indicated for clarity—direct pathways to the DH from the periaqueductal
grey and amygdala are very sparse. Abbreviations are as follows: CX, cortex; Hypothal, hypothalamus; Amyg, amygdala; NTS, nucleus tractus solitarius;
PBN, parabrachial nucleus; DRT, dorsoreticular nucleus; RVM, rostroventral medulla; NA, noradrenaline; perikarya 5-HT, serotonergic perikarya; PAF,
primary afferent fibre and DRG, dorsal root ganglion. For further details, see text.
and (3) their influence upon neuronal activity via multiple,
functionally-heterogenous receptors, is essential for a full
understanding, and effective clinical harnessing, of mecha-
nisms of DI and DF. In this light, it is important to remem-
ber that the output component of this system is constituted
by PNs transmitting nociceptive information to the brain.
In other words, the overall influence of specific drugs upon
the activity of PNs is decisive. As a corollary, a thorough
characterisation of the complete complement of inhibitory
and excitatory receptors displayed by PNs, and of the pre-
cise influence of drugs upon their electrical activity, is of
crucial importance. For example, the identification on PNs
of receptors known to exert an inhibitory influence upon
cellular excitability leads inexorably to the conclusion that
their discrete activation will be associated with antinocicep-
tion. Such information may provide insights into analgesic
strategies permitting the circumvention of opposing actions
of transmitters at multiple sites afferent to PNs.
2.2. Preferential modulation by descending pathways of
nociceptive as compared to non-nociceptive information
In Fig. 1, the simplified schema of DH organisation
does not incorporate those PAFs which normally transmit
non-nociceptive information into the DH. In fact, certain
nociceptive-specific PNs and interneurones (INs), predom-
inantly localised in superficial laminae, respond only to
noxious stimuli, whereas others, mostly in deeper lami-
nae, are excited only by non-noxious input (Besson and
Chaouch, 1987; Willis and Coggeshall, 1991; Wall and
Melzack, 1999). Modulation of the former by descending
pathways is of greater relevance to the appreciation of pain.
An additional class of neurone is termed “wide-dynamic
range” or “convergent”. Wide-dynamic range neurones,
which are primarily encountered in deeper laminae, en-
code both innocuous and noxious information from the
skin and other organs in a stimulus-dependent fashion
	
Fig	 1.3	Descending	 Pathways	 involved	 in	 the	 Control	 of	 Pain.	Cort cal	and	
subcortical	 structures	 (such	 as	 the	 amygdala	 and	 hypoth lamus),	 along	 with	
brainstem	 nuclei	 govern	 descending	 inhibition.	 Some	 brainstem	 nuclei:	 RVM,	
NTS	 and	 less	 so	 PAG	 communicate	 directly	with	 the	 dorsal	 horn	 of	 the	 spinal	
cord.	 These	 are	 key	 regions	 that	 have	 been	 suggested	 as	 important	 in	 the	




Physiologically,	 pain	 serves	 an	 important	 evolutionary	 role	 in	 species	 survival.	
Pain	 in icates	 impending	 or	 on	 g ing	 tissu 	 damage	 and	 drives	 behavi ur	
modification	a med	at	lim ting	and	or	avoiding	this.	Clinic lly,	ac te	pain	can	be	
defined	 by	 it	 temporal	 and	 causal	 relationship	 with	 tissue	 injury	 or	 disease	
(Spoors	 and	 Kiff,	 2010).	 In	 contrast	 chronic	 pain,	 which	 persists	 beyond	 the	
period	 of	 tissue	 injury	 and	 healing,	 is	 maladaptive.	 Progression	 from	 acute	 to	
chronic	pain	 remains	 incompletely	understood	but	 is	a	 field	of	active	 research.	




Chronic	 pain	 states	 can	 be	 sub-classified	 into	 inflammatory	 pain,	 neuropathic	
and	 idiopathic	 or	 functional	 pain	 (Costigan	 et	 al.,	 2009).	 Inflammatory	 pain	
results	 from	 tissue	 injury	 and	 the	 ensuing	 inflammatory	 cascade,	 as	 in	 for	
example	 rheumatoid	 arthritis.	 In	 contrast	 dysfunctional	 pain,	 such	 as	
fibromyalgia	occurs	in	the	absence	of	any	(as	yet)	identifiable	nociception,	tissue	
or	nervous	system	damage	or	 inflammation(Costigan	et	al.,	2009).	Neuropathic	
pain	 (as	 discussed	 in	 detail	 below)	 results	 from	 lesions	 or	 disease	 in	 the	
peripheral	and	or	central	nervous	system	(IASP,	2011).	Although	the	aetiology	of	




Central	 sensitization	 (CS)	 is	defined	as	 the	 increased	 responsiveness	of	 central	
nociceptive	neurons	to	their	normal	or	sub-threshold	afferent	input	(IASP	2011).	
The	 processes	 that	 underpin	 CS	 include;	 alterations	 in	 synaptic	 modulators,	
increase	 in	 excitatory	 amino	 acids,	 and	 changes	 in	 ion	 channel	 architecture,	
density	 and	 kinetics	 (Costigan	 et	 al.,	 2009).	 These	 result	 in	 increased	 synaptic	
strength,	with	central	nociceptors	becoming	and	remaining	more	reactive	to	sub-




it,	 is	 known	 as	 ‘wind	 up’.	Wind	 up	 is	 the	 continued	 increase	 in	 response	 to	 a	
series	of	repeated	stimuli	(Latremoliere	and	Woolf,	2009,	Woolf,	1983).	The	key	
fibres	 involved	 are	 C	 fibres	 and	 the	 resulting	 increase	 in	 output	 despite	 an	
unchanging	 input	 is	 an	 important	 manifestation	 of	 CS	 in	 chronic	 pain	 states	
(Herrero	et	al.,	2000).		
1.1.1.1.2	Peripheral	Sensitization	
Peripheral	 sensitization	 (PS)	 similarly	 to	 CS	 is	 a	 heightened	 responsiveness	 of	
the	 peripheral	 nervous	 system	 to	 normal	 or	 sub-threshold	 stimuli.	 The	
mechanisms	 driving	 these	 changes	 relate	 to	 mediators	 up	 regulating	
intracellular	 transduction	 pathways,	 resulting	 in	 the	 increased	 production	 and	
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insertion	of	nociceptor	proteins	into	peripheral	nerve	terminals	(Costigan	et	al.,	




interleukins	 and	 tumour	 necrosis	 factor	 stimulate	 peripheral	 nociceptors	
directly	 (Grace	 et	 al.,	 2014).	 These	 mediators	 increase	 in	 response	 to	 both	
inflammation	and	neuronal	damage.		They	play	a	key	role	in	the	generation	and	
propagation	of	 inflammatory	and	neuropathic	pain.	Various	 immune	mediators	




IASP	 defines	 neuropathic	 pain	 as:	 “Pain	 caused	 by	 a	 lesion	 or	 disease	 of	 the	
somatosensory	nervous	 system”	 (IASP,	2011).	Neuropathic	pain	may	affect	 the	
CNS,	peripheral	nervous	system	(PNS)	or	both.	Neuropathy	is	defined	by	IASP	as:	
“A	 disturbance	 of	 function	 or	 pathological	 change	 in	 a	 nerve:	 in	 one	 nerve,	





Changes	 governing	 the	 development	 of	 neuropathic	 pain	 involve	 CS,	 PS	 and	
reactivity	 to	 inflammatory	 mediators	 as	 described	 above	 (see	 1.1.1.1.1	 to	
1.1.1.1.3).	 These	 occur	 in	 response	 to	 neuronal	 damage	 of	 varied	 aetiology.	
Alterations	 in	the	molecular	architecture	and	function	of	peripheral	nerves,	 the	
dorsal	 root	 ganglion	 (DRG),	 dorsal	 horn	 (DH),	 glia	 and	 CNS	 all	 play	 a	 part	 in	
neuropathic	 pain	 development	 and	 propagation.	 Importantly,	 once	 these	





rather	 than	 etiological	 factors	 should	 be	 the	 focus	 of	 research	 aimed	 at	
progressing	diagnosis	and	treatment	of	neuropathic	pain	(Costigan	et	al.,	2009,	
Colvin	 and	 Dougherty,	 2014).	 	 However	 aetiological	 understanding	 of	
neuropathic	pain	 enables	development	of	preventive	 strategies	 and	preventive	
drugs.	 This	 is	 in	 contrast	 to	mechanistic	 insights,	 which	 allow	 for	 drug	 target	
identification.	 Arguably	 therefore,	 both	 etiological	 and	mechanistic	 research	 is	
needed	 to	 allow	 for	 a	 holistic	 approach	 to	 the	 prevention,	 diagnosis	 and	





Current	 neuropathic	 pain	 treatments	 include	 antidepressants,	 antiepileptic	




efficacy	 of	 neuropathic	 pain	 treatments	 suggest	 limited	 effectiveness	 (Wiffen	
Philip	et	al.,	2013).	Indeed	in	the	case	of	carbamezapine	there	is	insufficient	data	
to	draw	any	concrete	conclusions	regarding	benefit	(Wiffen	Philip	et	al.,	2014).	
This	 pattern	 of	 modest	 effect	 is	 also	 applicable	 to	 antidepressants,	 topical	
analgesics	 and	 tramadol	 in	 neuropathic	 pain	 (Saarto	 and	Wiffen	 Philip,	 2007,	
Derry	et	al.,	2013,	Duehmke	Rudolf	et	al.,	2006).	
	
The	 reasons	 for	 these	 limitations	 are	 multifold,	 reflecting	 problems	 with	 how	
analgesics	are	tested,	their	effectiveness	measured	and	how	they	are	chosen	in	a	






time	 limited	 clinical	 setting	 remains	 non-standard.	 	 This	 results	 in	 varied	
intensity	of	pain	being	treated	with	possibly	non-optimal	drug	regimens.	Finally,	
understanding	of	how	the	various	maladaptive	changes	in	the	pain	pathway	lead	





Assessment	 of	 novel	 drugs	 for	 neuropathic	 pain	 is	 marred	 with	 difficulties.	
Specifically,	the	subjective,	varied	nature	of	individual	pain	and	the	influence	of	
an	 active	 placebo	 response,	 results	 in	 analgesic	 randomized	 controlled	 trials	
(RCTs)	often	describing	small	effect	sizes,	difficult	to	interpret	clinically	(Moore	
et	 al.,	 2010,	 Quessy	 and	 Rowbotham,	 2008,	 Dworkin	 et	 al.,	 2010).	 Moreover,	
measurement	 tools	used	 to	assess	pain	 -	 including	quantitative	sensory	 testing	
(QST),	 a	 non-invasive	 method	 of	 assessing	 pain	 and	 sensory	 dysfunction	 in	
peripheral	 nerves	 (see	 3.1),	 and	 pain	 questionnaires	 -	 are	 often	 inadequate	 at	
standardizing	 pain	 experiences	 in	 the	 context	 of	 neuropathic	 analgesic	 RCTs	




To	 address	 these	 problems	 with	 pain	 RCTs	 the	 Initiative	 on	 Methods,	
Measurement,	 and	 Pain	 Assessment	 in	 Clinical	 Trials	 (IMMPACT)	 was	 set	 up	
(Dworkin	 et	 al.,	 2005).	 The	 initiative	 has	 drawn	 up	 evidence-based	 guidelines	
and	written	reviews	aimed	at	optimizing	the	design	and	execution	of	pain	trials.	
Additionally,	recognizing	the	need	to	translate	basic	mechanistic	findings	in	pain	
research	 into	 effective	 treatments	more	 promptly	 and	 successfully,	 the	 United	
States	Food	and	Drug	Administration	(FDA)	has	also	launched	a	new	partnership	






It	 has	 also	 been	 recognized	 that	 use	 of	 new	 research	 tools,	 such	 as	 functional	
magnetic	 resonance	 imaging	 (fMRI),	 as	 adjuncts	 in	 pain	 RCTs	 may	 also	 help	








the	problem	of	CIPN	 is	 an	 important	healthcare	 concern	 (Cancer	Research	UK,	
2014).	CIPN	can	manifest	with	or	without	severe	pain.		
	
CIPN	 affects	 patients	 receiving	 treatment	 for	 multiple	 cancer	 types	 including:	
colorectal,	 testicular,	 breast,	 lung,	 ovarian,	 and	 haematological	
malignancies(Park	et	al.,	2013).	Implicated	chemotherapy	types	include	taxanes	
(e.g.	 Paclitaxel),	 vinca	 alkaloids	 (e.g.	 vincristine),	 platins	 (e.g.	 Oxaliplatin),	
alkylating	agents	 (e.g.	Procarbazine),	 thalidomide,	bortezomib,	 as	well	 as	other	
newer	drugs	some	of	which	remain	experimental	(e.g.	Cetuximab	and	Suramin).	
Many	of	 these	agents	 cause	CIPN	at	 standard	dose	while	others	 require	higher	
treatment	quantities	(Weimer,	2013).	
1.1.2.1	Clinical	Presentation	
Onset	 of	 CIPN	 is	 clinically	 insidious,	with	 subtle	 neurological	 changes	 abruptly	
progressing	 to	 symptoms	 arising	 from	 large	 sensory	 nerve	 fibres.	 Motor	 and	
autonomic	 nerve	 involvement	 is	 less	 common	 and	 often	 results	 from	 use	 of	
specific	 drug	 types	 including	 thalidomide	 for	 motor	 and	 vincristine	 for	
autonomic	 symptoms	 (Cavaletti	 et	 al.,	 2011a).	 Sensory	 symptoms	 include	
paresthesia	 (pins	 and	 needles),	 allodynia	 (pain	 following	 non-painful	 stimuli)	
especially	 to	 cold,	 hyperalgesia	 (increased	 pain	 following	 painful	 stimuli)	 and	
numbness	 (Park	 et	 al.,	 2013,	 Fallon,	 2013).	 In	 some	 cases	 pain	 may	 not	 be	 a	
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major	 presenting	 feature	 of	 CIPN.	 Distribution	 of	 symptoms	 is	 symmetrical,	
principally	 in	 the	hands	and	 feet,	 reflecting	a	 ‘glove	and	stocking’	presentation.	
Sensory	 symptoms	may	 exist	 without	 associated	 pain.	 However,	 once	 present	
symptoms	 often	 limit	 chemotherapy	 dose	 and	 sometimes	 require	 complete	
cessation	 of	 chemotherapy	 treatment	 (Cavaletti	 et	 al.,	 2011a).	 This	 has	
implications	for	patient	morbidity	and	mortality.	
	
Due	 to	 the	 seemingly	 ‘all	 or	 nothing’	 presentation	 of	 CIPN,	 diagnosis	 remains	
elusive.	Difficulties	 in	diagnosing	CIPN	are	compounded	by	a	non-standardized	
clinical	 approach	 (Cavaletti,	 2012).	 CIPN	 assessment	 methods	 include	 an	
assorted	 combination	 of:	 physical	 examination,	 detailed	 neurophysiological	
testing	and	use	of	multiple	diagnostic	scales	with	varying	degrees	of	sensitivity	





The	 clinical	 course	 of	 CIPN	 is	 varied.	 Broadly,	 CIPN	 may	 present	 early	 in	 the	
course	 of	 treatment	 or	 after	 multiple	 chemotherapy	 doses.	 Equally,	 in	 some	
cases	 CIPN	 symptoms	 may	 not	 become	 apparent	 until	 after	 chemotherapy	
cessation,	 in	 a	 phenomenon	 known	 as	 ‘coasting’	 (Cavaletti	 et	 al.,	 2011a).	 It	 is	
clear	 that	chemotherapeutic-drug	specific	 characteristics	of	CIPN	exist	 (Park	et	
al.,	 2013).	 For	 instance,	 oxaliplatin	 induced	 neuropathy	 has	 a	 distinct	 acute	
presentation	 (Argyriou	 et	 al.,	 2012b),	 with	 a	 variable	 progression	 to	 chronic	




Clinically	 the	 terms	 acute	 and	 chronic	 CIPN	 have	 been	 adopted.	 Acute	 CIPN	
refers	 to	 CIPN	 occurring	 during	 chemotherapy	 treatment,	 whilst	 chronic	 CIPN	
denotes	the	condition	continuing	after	chemotherapy	has	ceased.	It	appears	that	
the	pathophysiology	underpinning	these	presentations	is	varied	and	is	likely,	as	





A	 number	 of	 risk	 factors	 for	 CIPN	 have	 been	 postulated,	 however	 there	 is	 no	
overall	 consensus	 as	 to	 their	 importance.	 Risk	 also	 varies	 according	 to	
chemotherapy	 type	with	 treatment	 duration,	 cumulative	 dose	 and	 single	 dose	
administration	 all	 inducing	 different	 risk(Park	 et	 al.,	 2013).	 Some	 of	 the	 non-
chemotherapy	 related	 risk	 factors	 include:	 factors	 predisposing	 to	 other	
neuropathies	 (alcohol	 excess,	 diabetes	 mellitus,	 smoking),	 sensory	 changes	
during	 chemotherapy	 treatment,	 and	 genetic	 status	 (Seretny	 et	 al.,	 2014).	 The	




This	 partly	 reflects	 the	 non-standardized	 approach	 to	 its	 diagnosis	 (see	 2.1.1).		
However,	 another	 important	 consideration	 in	 this	 clinical	 variation,	 are	 the	






et	 al.,	 2013,	 Park	 et	 al.,	 2008,	 Robinson	 et	 al.,	 2014).	 No	 one	 clear	
pathophysiological	 pathway	 leading	 to	 CIPN	 development	 has	 been	 described.	
Reported	 mechanisms	 most	 likely	 reflect	 aspects	 of	 a	 complex,	 multistage	
pathophysiological	process	or	set	of	processes.	Mechanisms	documented	to	date	
are	varied	and	likely	dependent	not	only	on	the	actions	of	specific	chemotherapy	
drugs,	 but	 also	 the	 interactions	 of	 concomitant	 medications	 and	 underlying	
neoplastic	processes.	Therefore	 the	aim	here	will	be	 to	provide	an	overview	of	
the	 known	 genetic,	 molecular	 and	 cellular	 changes	 associated	 with	 CIPN	




Multiple	 single	 nucleotide	 polymorphisms	 (SNPs)	 have	 been	 associated	 with	
increased	 incidence	 of	 CIPN	 (Cavaletti	 et	 al.,	 2011b).	 Some	 SNPs	 have	 been	
replicated	 in	repeat	studies	others	have	not	(Custodio	et	al.,	2014).	The	 lack	of	
reproducible	 associations	 likely	 reflects	 the	heterogeneous	patient	 populations	
studied	as	well	as	varied	technical	approaches	to	assessing	SNPs	(Cavaletti	et	al.,	
2011b).	Importantly,	the	variety	of	proteins	related	to	the	many	identified	SNPs	
highlight	 the	 complexity	 and	 diversity	 of	 mechanisms	 underpinning	 CIPN	
development.	 To	 date	 proteins	 associated	 with	 identified	 SNPs	 include	 those	
related	to	DNA	repair,	cell	cycle	progression,	multidrug	efflux	pumps	as	well	as	
enzymes	 that	 catalyse	detoxification	 reactions	 (e.g.	 conjugation	of	hydrophobic	
compounds	 with	 glutathione)(Cavaletti	 et	 al.,	 2011b,	 Custodio	 et	 al.,	 2014).	
Additionally,	 ion	channel	proteins,	proteins	 involved	 in:	neuronal	development,	




approaches	 to	 genome	 wide	 association	 studies	 (GWAS).	 Therefore	 prior	 to	




Knowledge	 regarding	 the	molecular	 and	 cellular	mechanisms	underlying,	 CIPN	
has	 come	 from	animal	models	developed	over	 the	 last	20	years	 (Authier	et	 al.,	
2009).	 Injection	 of	 mice	 and	 rats	 with	 CIPN	 inducing	 chemotherapeutics	 has	
allowed	 characterisation	 of	 neuro-pathological	 (e.g.	 axonal	 swelling),	
neurophysiological	 (reduced	 conduction	 velocities,	 reduced	 action	 potentials),	
altered	 nerve	 fibre	 density	 and	 behavioural	 changes	 caused	 by	 these	 agents	









chemotherapeutics	 are	 well	 understood,	 the	 actual	 pathways	 leading	 to	
neurotoxicity	remain	unclear	and	are	based	on	postulates	(Argyriou	et	al.,	2012a,	
Miltenburg	and	Boogerd,	2014,	Park	et	al.,	2008).	As	an	example	this	is	true	for	




Taxanes	 prevent	 the	 destabilization	 of	 microtubules,	 a	 function	 important	 in	
axonal	transport	and	cell	division	(Miltenburg	and	Boogerd,	2014).	Even	though	
neurons	 are	 not	 cells	 undergoing	 mitosis,	 the	 interference	 with	 anterograde	
axonal	transport	leads	to	axonopathy	(Park	et	al.,	2008).	Secondary	to	this	injury	
macrophages	 are	 activated	 peripherally	 and	 microglia	 centrally,	 leading	 to	
secondary	 inflammatory	 cytokine	 activation	 and	 further	 neuronal	 damage	
(Argyriou	et	al.,	2012a,	Miltenburg	and	Boogerd,	2014,	Park	et	al.,	2008).	There	
is	 also	 evidence	 that	 taxanes	 exert	 a	 toxic	 effect	 on	 neuronal	 mitochondria,	




interaction	 prevents	 tubulin	 polymerization	 into	microtubules.	 In	 neurons,	 via	
an	unclear	mechanism,	this	leads	to	altered	axonal	arrangement,	orientation	and	
length(Argyriou	et	al.,	2012a).	This	in	turn	causes	impaired	axonal	transport	and	
ultimate	 axonal	 degeneration(Miltenburg	 and	 Boogerd,	 2014).	 Subsequently,	 a	
decrease	 in	 abutting	 myelin	 thickness	 and	 even	 segmental	 demyelination	 is	




Similarly,	 to	 taxanes	 and	 vinca	 alkaloids,	 bortezomib	 binds	 to	 a	 specific	
intracellular	 molecular	 structure.	 Although	 this	 drug	 is	 known	 to	 be	 a	
proteasome	 inhibitor,	 neither	 its	 tumouricidal	 nor	 its	 neurotoxic	 mechanisms	




In	 contrast	 to	 the	 above	 three	 groups	 the	 platinum	 based	 chemotherapeutics	




platinum	 group	 has	 been	 shown	 to	 have	 important	 effects	 on	 ion	 transport	
channels.	This	effect	occurs	specifically	via	gene	up	regulation	and	it	is	known	to	
increase	 the	 excitability	 of	 sodium	 channels	 leading	 to	 neuronal	 hyper	
excitability	 and	 the	 clinical	 phenomenon	 of	 hyperalgesia	 (Miltenburg	 and	
Boogerd,	2014,	Argyriou	et	al.,	2013).	
	
Like	 the	 compounds	 described	 above,	 thalidomide	 –	 a	 more	 recently	 used	
chemotherapeutic	 -	 has	 poorly	 described	 neurotoxic	 mechanisms.	 Current	
postulates	 include	 speculation	 about	 its	 interference	with	 angiogenesis	 around	





to	 the	 high	 permeability	 of	 DRG	 capillaries,	 which	 allow	 transit	 of	 large	
molecules	including	chemotherapeutic	agents	(Argyriou	et	al.,	2012a).	Due	to	the	
importance	of	the	DRG	in	the	pain	pathway:	its	high	plasticity	and	central	role	in	
neuropathic	 pain	 development,	 the	 vulnerability	 of	 this	 structure	 in	 CIPN	 is	





is	dependent	on	more	 than	 just	neuronal	damage.	Activation	of	 astrocytes	 and	
microglia	 in	 response	 to	 chemotherapeutics	 has	 been	 documented	 and	
postulated	 to	play	a	 role	 in	 the	neurotoxicity	underlying	CIPN	(Robinson	et	al.,	
2014,	 Di	 Cesare	 Mannelli	 et	 al.,	 2013).	 Although	 mechanisms	 by	 which	 these	
activations	 lead	 to	CIPN	remain	unclear,	 and	authors	debate	 the	 importance	of	
microglia	 versus	 astrocyte	 activation,	 it	 is	 likely	 that	 these	 changes	 will	 be	 of	
growing	interest	in	future	CIPN	research	(Di	Cesare	Mannelli	et	al.,	2013).		
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components of the peripheral nervous system (Fig. 5). The 
DRG is particularly vulnerable to neurotoxic damage, lack-
ing an effective blood-nerve barrier [118], which may ex-
plain the predominance of sensory symptoms in chemother-
apy-induced neurotoxicity.  
Platinum compounds have long been associated with 
DNA damage, inducing platinum-DNA adducts [3, 4, 14], 
cell death [1, 2] and accumulating in DRG neurons in plati-
num-treated patients [13, 16, 18]. However, the classically 
microtubule-associated taxanes and vinca alkaloids have also 
been associated with neuronopathic damage in the DRG. 
Paclitaxel produced nucleolar changes in large DRG neurons 
[69], and accumulated significantly in DRG neurons in ani-
mal models [119], suggesting that neuronal toxicity may 
underlie aspects of the development of chronic paclitaxel-
induced neurotoxicity. Vincristine has been shown to induce 
morphological changes and neurofilament aggregation in 
large DRG neurons [84]. In addition, thalidomide may target 
neuronal cell bodies in conjunction with other targets of 
neurotoxicity [101, 102]. 
Another major target of chemotherapy is tubulin – a pri-
mary component of microtubules and the basis of cellular 
cytoskeletal structure. Microtubules are central to axonal 
transport processes, providing an obvious target in the etiol-
ogy of neurotoxicity, implicated in paclitaxel [64, 65], vinca 
alkaloid [85] and bortezomib neurotoxicity [113]. Interfer-
ence with axonal transport may interrupt supply of trophic 
factors and disrupt energy mechanisms, and while deficits in 
axonal transport may be reversible, recovery of nerves may 
not be assured. Chronic disruption may lead to retrograde 
degeneration and subsequent neuronal cell death, leading to 
permanent neurological sequelae. 
Direct toxicity at the distal axon may produce ax-
onopathic damage following paclitaxel [70] and vincristine 
treatment [86]. Vincristine neurotoxicity has demonstrated 
much similarity with classical Wallerian axonal degeneration 
and genetic mouse models resistant to Wallerian degenera-
tion are also resistant to vincristine-induced neurotoxicity 
[120]. Clinical features suggest that thalidomide may also 
produce discrete axonal toxicity with a typical presentation 
of length-dependent, distal symptoms, with Wallerian de-
generation demonstrated in nerve biopsies [101, 102].  
Interference with the energy mechanisms of the axon, 























Fig. (5). Mechanisms of chemotherapy-induced neurotoxicity. 
Proposed targets of chemotherapy-induced neurotoxicity in the peripheral nervous system, including damage to DRG neuronal cell bodies (platinum 
compounds, vinca alkaloids, taxanes, thalidomide), demyelination (bortezomib), microtubule-associated toxicity (vinca alkaloids, taxanes, 
bortezomib), mitrochondrial dysfunction (taxanes, bortezomib), axonal membrane ion channelopathy (oxaliplatin), peripheral vasculature 
impairment (thalidomide) and distal axonal injury (vinca alkaloids, taxanes, thalidomide). 
	
	
Figure	 1.4	 Drug	 targets	 thought	 to	 underpin	 peripheral	 nerve	 damage	
important	 in	CIPN	development.	 Image	depicting	the	peripheral	neuron	with	
the	 key	 molecular	 and	 cellular	 structures	 vulnerable	 to	 damage	 by	






Prevention	 of	 CIPN	development	 is	 a	 key	 area	 of	 interest	 in	 oncology.	 To	date	
despite	 extensive	 investigation	 of	 small	 compounds,	 vitamins,	 minerals	 and	
topical	agents,	no	CIPN	preventing	neuro-protective	strategy	has	been	identified	
(Hershman	 et	 al.,	 2014,	Albers	 et	 al.,	 2011).	 Consequently,	 chemotherapy	dose	
reduction	or	cessation	remains	the	only	effective	strategy	for	limiting	CIPN.	This	
has	 obvious	 implications	 for	 patient	 morbidity	 and	 mortality.	 Importantly,	




controlled	 trial	 (RCT)	 has	 shown	 duloxetine	 to	 be	 an	 effective	 measure	 in	




CIPN	and	have	 important	 side	effects	 (Rao	et	 al.,	 2007,	Hammack	et	 al.,	 2002).	
Nonetheless,	 in	 the	 absence	 of	 treatment	 options,	 drugs	 such	 as	 gabapentin,	
nortriptyline	 and	 topical	 ketamine	 are	 recommended	 in	 existing	 CIPN	
management	guidelines(Hershman	et	al.,	2014).	
	
Alternative	approaches	 to	 treatment	of	CIPN	are	under	evaluation.	 Specifically,	
assessment	of	alternative	therapies	such	as	acupuncture	are	in	progress(Garcia	
et	 al.,	 2014).	 Additionally,	 translational	 work	 suggesting	 that	 TRPM8	 agonists	
may	have	a	 role	 in	CIPN	 treatment	 (Proudfoot	et	al.,	2006),	 led	 to	several	 case	
reports	 investigating	 topical	menthol	gel.	These	have	promising	results	 (Colvin	
et	 al.,	 2008,	 Storey	 et	 al.,	 2010)	 and	 a	 subsequent	 phase	 one	 study	has	 shown	
benefit	 in	a	small	cohort	who	received	topical	menthol	gel	(Fallon	et	al.,	2015).	
Nonetheless	no	clear	 long-term	solutions	to	 the	problem	of	post	chemotherapy	




Although	 there	 are	 many	 mechanistic	 questions	 that	 remain	 unanswered	 in	










address	 this	 question	 an	 integrated,	 patient	 centred	 approach	 is	 needed.		





and	 clinical	 research.	 Laboratory	 approaches	 constitute	 a	 complex	 and	diverse	




models	 to	 human	 clinical	 realities	 is	 impacted	 by	 a	 two-fold	 process.	 Firstly	
translation	is	always	reliant	on	the	closeness	of	outcomes	used	in	animal	work	to	






retrospective,	 observational	 work.	 This	 is	 predominantly	 a	 consequence	 of	
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ethical	 constraints,	whereby	 interference	with	patient’s	 chemotherapy	 regimes	
is	 unethical.	 The	 mainstay	 of	 prospective	 observational	 work	 has	 focused	 on	
tracking	 the	 development	 of	 peripheral	 nerve	 changes,	 using	 quantitative	
sensory	 testing	 (QST),	 neurological	 examination,	 nerve	 biopsies	 and	 nerve	
conduction	 studies	 (Argyriou	 et	 al.,	 2012b,	 Attal	 et	 al.,	 2009).	 Recently	 less	
invasive	in-depth	examinations	of	peripheral	nerves	-aimed	at	substituting	nerve	
biopsies,	 such	as	 in	 vivo	 laser	 reflectance	 confocal	microscopy-	have	also	been	
employed	to	predict	CIPN	development(Kosturakis	et	al.,	2014).		
	
A	 more	 global	 approach	 to	 understanding	 CIPN	 has	 been	 reflected	 in	 the	
increasing	 number	 of	 CIPN	 related	 genome	 wide	 association	 studies	 (GWAS).	
These	have	aimed	to	identify	genetic	markers	of	CIPN,	in	the	hope	of	translating	




(CNS)	 as	 a	 component	 of	 CIPN	 development.	 It	 is	 clear	 from	 extensive	 pain	
research	that	peripheral	nerve	damage	leads	to	central	nervous	system	changes	
that	 maintain	 and	 exacerbate	 pain	 conditions	 leading	 to	 chronicity,	 with	
particular	 emphasis	 on	 aberrations	 in	 the	 descending	 pain	modulatory	 system	




The	 ability	 to	 assess	 the	 involvement	 of	 the	 CNS	 in	 human	 pain	 has	 been	
demonstrated	 in	 numerous	 functional	 magnetic	 resonance	 imaging	 (fMRI)	
experiments	(see	1.1.2.4).	To	date	only	one	retrospective	study	has	assessed	CNS	
changes	in	CIPN	using	fMRI	(Boland	et	al.,	2014).		No	prospective	work	has	been	







of	 haemoglobin	 (Hb),	 could	 be	 harnessed	 to	 visualize	 neuronal	 tissue	 function	
(Ogawa	 et	 al.,	 1990).	 This	 was	 in	 contrast	 to	 standard	 magnetic	 resonance	
imaging	 (MRI),	already	used	clinically	 to	gain	structural	diagnostic	 information	
about	multiple	tissue	types.	Like	MRI,	fMRI	utilizes	non-ionizing	radiofrequency	
pulses	 to	 excite	 hydrogen	 ions	 in	 tissue.	 However	 over	 and	 above	 this	 fMRI	
incorporates	 the	 physiological	 changes	 in	 the	 proportions	 of	 oxygenation	








Human	 tissue	 is	 composed	 of	 around	 75%	water	 (H2O).	 Each	 water	 molecule	
contains	 two	 hydrogen	 atoms;	 each	 containing	 a	 simple	 nucleus	made	 up	 of	 a	
single	 proton.	 The	 hydrogen	 proton	 possesses	 a	 natural	 charge	 and	 spin	
frequency	 referred	 to	 as	 a	 magnetic	 moment	 (fig	 1.5).	 In	 tissue	 outside	 a	
magnetic	 field,	 each	 proton	will	 have	magnetic	moments	 occurring	 in	 random	







Figure	 1.5:	 Magnetic	 Moment	 of	 Hydrogen	 Protons	 in	 Tissue.	 Far	 left	 the	
natural	 spin	 or	 magnetic	 moment	 of	 an	 individual	 hydrogen	 proton.	 Middle	
image	shows	 the	 random	direction	of	magnetic	moments	 in	 tissue	outside	of	a	
magnetic	 field.	 On	 the	 far	 right	 the	 alignment	 of	 proton	magnetic	moments	 is	




If	 an	 excitation	 radiofrequency	 (RF)	 pulse,	 at	 90degrees	 to	 the	 plane	 of	 the	
magnetic	 field	 is	 applied	 to	 the	 tissue,	 the	 protons	 will	 flip	 out	 of	 alignment	
perpendicular	to	their	original	plane	(ie	out	of	the	z	plane).	If	the	RF	pulse	is	then	
turned	 off	 and	 the	 protons	 are	 allowed	 to	 return	 to	 alignment	 within	 the	
magnetic	 field,	 they	will	 emit	 energy.	 	This	 energy	 is	 recorded	as	 a	 signal	by	a	
recorder	 coil	 within	 the	 fMRI	 scanner.	 The	 time	 between	 successive	 pulse	
sequences	is	known	as	the	repetition	time	or	TR.	
	
Following	an	RF	pulse,	protons	 in	 the	 ‘excited’	 tissue	undergo	 three	processes,	
which	are	harnessed	to	record	signal	in	MRI	and	fMRI.	The	first	is	restoration	of	
the	magnetization.	This	 is	 referred	 to	as	 the	T1	 (recovery	 time).	The	 second	 is	
the	 loss	 of	 energy	 emitted	 by	 the	 excited	 protons,	 known	 as	 T2	 (signal	 decay	
time).	The	 third	 is	known	as	 the	T2*	and	 is	 related	 to	 the	varied	 rate	of	 signal	
decay	caused	by	local	inhomogenities	in	the	magnetic	field	affecting	each	proton.		










disproportionately,	 to	 accommodate	 increased	 metabolic	 demands	 (increased	
use	of	oxygen).	This	results	in	the	proportions	of	oxygenated	to	deoxygenated	Hb	
changing.	 The	 magnetic	 properties	 of	 these	 two	 types	 of	 Hb	 differ.	 OxyHb	 is	
diamagnetic	 while	 DeOxyHb	 is	 paramagnetic.	 Consequently,	 the	 alterations	 in	
ratio	 between	 the	 two	 types	 of	 Hb	 (increased	 OxyHb:DeOxyHb),	 following	
increased	 neuronal	 activity	 result	 in	 amplified	 MR	 signal,	 termed	 the	 BOLD	
signal	 (Jezzard	 et	 al.,	 2009).	 The	 BOLD	 signal	 or	 effect,	 serves	 as	 a	 stable,	
naturally	 occurring	 contrast,	 enabling	 visualization	 of	 active	 brain	 regions.	
Although	 the	 BOLD	 response	 is	 only	 a	 proxy	 for	 neuronal	 activity,	 work	
investigating	 the	 interplay	 between	 this	 effect	 and	 actual	 neuronal	 activity	
suggests	 that	 it	 is	 a	 stable	 albeit	 imperfect	 surrogate,	 for	 nerve	 cell	 firing	
(Logothetis,	2008).		
	
MR	 signal	 generated	 by	 the	 BOLD	 effect	 is	 recorded	 by	 virtually	 dividing	 the	
brain	 into	 spatial	 sections	 or	 volumes.	 Typically	 signal	 is	 acquired	 in	 series	 of	
volumes.	Within	a	volume,	the	brain	is	further	partitioned	into	cuboidal	sections	
called	voxels,	allowing	signal	location	to	be	more	precisely	recorded.	BOLD	signal	
changes	 are	measured	 in	 every	 physical	 plane	 (z,	 x,	 y),	 as	well	 as	 across	 time	











human	 brain	 in	 vivo,	 its	 use	 is	 subject	 to	 important	 limitations,	 which	 if	 not	
considered	 and	 accounted	 for	may	 lead	 to	 grossly	 spurious,	misleading	 results	
(Bennett	and	Miller,	2010).	A	concept	that	overarches	all	fMRI	limitations	is	that	
of	 signal	 to	 noise	 ratio	 (SNR).	 Scientific	 reliability	 and	 reproducibility	 is	
inherently	 linked	 to	 the	ability	 to	 accurately	detect	 the	 signal	 of	 interest	being	
measured,	 and	 differentiate	 this	 from	 a	 sea	 of	 irrelevant	 noise	 (Bennett	 and	
Miller,	 2010).	 Therefore	 the	 higher	 the	 SNR	 in	 an	 experiment,	 the	more	 likely	
that	signal	of	interest	will	be	accurately	detected.	In	fMRI	experiments	sources	of	
noise	 are	 linked	 to	 a	 number	 of	 influences.	 These	 can	 be	 divided	 into:	 data	
acquisition	 and	 equipment,	 participant,	 and	 data	 analysis	 and	 interpretation	
related	factors;	all	are	discussed	in	turn	below.	
1.1.3.3.1	Data	acquisition	&	equipment	related	noise	




strengths	 (see	 1.1.3.3.2).	 This	 will	 slightly	 decrease	maximum	 achievable	 SNR	
(Bennett	 and	 Miller,	 2010).	 Nonetheless	 the	 general	 accepted	 move	 in	 fMRI	
experimentation	is	toward	higher	magnetic	strength.		
	





Importantly,	 how	 the	 experimenter	 interacts	with	 available	 hardware,	 through	
their	 choice	 of	 image	 acquisition	 parameters,	 also	 impacts	 SNR	 (Bennett	 and	
Miller,	2010).	For	example	doubling	voxel	size	from	1.5	to	3.0mm3	can	improve	
SNR	by	up	to	eight	 fold.	This	however	will	decrease	spatial	resolution	(Bennett	
and	 Miller,	 2010).	 Similarly,	 optimization	 of	 other	 parameters,	 for	 example	
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repetition	time	(TR),	echo	time	(TE),	slice	gap,	and	flip	angles	all	help	optimize	




Participant	 related	 influences	 on	 SNR	 can	be	 broadly	 divided	 into	 two	 groups:	
cognitive	factors	and	factors	related	to	body	physiology.	Cognitive	factors	reflect	
the	influence	of	study	participants	attention,	arousal,	and	emotional	status	on	the	
signal	 being	 measured	 (Bennett	 and	 Miller,	 2010).	 For	 instance,	 a	 participant	
who	received	upsetting	news	the	day	before	a	pain	fMRI	experiment	and	spends	
time	in	the	scanner	reflecting	on	the	impact	of	this	news	on	their	lives,	will	have	






this	has	on	the	magnetic	 field	and	thus	SNR	and	the	 impact	 it	has	on	the	BOLD	
effect	 itself.	Physiological	 functions	such	as	breathing	and	heart	rate,	as	well	as	
anatomical	variability	 such	as	 intracranial	 sinus	size	have	an	 important	 impact	
on	 local	 magnetic	 field	 and	 SNR	 (Brooks	 et	 al.,	 2008).	 Monitoring	 these	
parameters	during	an	experiment	and	adjusting	for	them	in	the	subsequent	data	
analysis	 has	 been	 shown	 to	 improve	 SNR	 (Kongn	 et	 al.,	 2012)	 (fig	 1.5).	 More	
recently	 a	 useful	 technique	 for	 removal	 of	 these	 sources	 of	 noise	 has	 been	
achieved	 through	 the	 combination	 of	 independent	 component	 analysis	 and	
computer	 based	 algorithms	 (ICA)(Salimi-Khorshidi	 et	 al.,	 2014).	 Similarly,	 to	
heart	rate	and	breathing,	head	motion	or	other	movement	in	the	scanner	alters	
the	 local	 magnetic	 field,	 SNR	 and	 data	 quality.	 Explaining	 this	 to	 participants	
beforehand	often	helps	minimize	this	problem.		
	
Finally,	 the	 impact	 of	 individual	 physiological	 parameters	 such	 as	 age,	
comorbidity,	 smoking	 status,	 brain	pathology	 and	associated	pharmacotherapy	
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all	influence	the	BOLD	effect	and	may	alter	SNR	in	a	given	experiment	(Iannetti	
and	Wise,	2007).	This	 is	particularly	 true	 for	 fMRI	studies	 investigating	patient	
populations.	These	factors	are	often	outside	the	experimenter’s	control	and	may	
have	an	unquantifiable	impact	on	the	signal	of	interest.		It	is	therefore	important	





Figure	 1.6	 Physiological	 Noise	 Monitoring	 Setup.	 Showing	 respiratory	
bellows	around	participant	diaphragm.	These	extend	through	the	waveguide	to	
the	 BIOPAC	 (a	 system	 of	 amplifiers	 and	 transducers	 used	 to	 acquire	
physiological	signal),	where	respiratory	rate	is	recorded	for	later	use	in	analysis.	
Also	a	pulse	oximetry	probe	attached	to	the	participant’s	finger	extends	through	





FMRI	 data	 analysis	 can	 broadly	 be	 subdivided	 into	 pre-processing,	 first	 level	
(single	subject)	and	second	level	(between	subject)	analysis	(see	3.3).	Each	stage	
is	 susceptible	 to	 influences	 of	 SNR.	 Pre-processing	 stages,	 during	 which	
adjustment	 for	 known	 sources	 of	 measurement	 error	 can	 take	 place,	 are	
particularly	 important	 to	 optimize	 the	 impact	 of	 SNR	 variability.	 Specifically,	
spatial	 realignment,	 temporal	 filtering,	 use	 of	 high	 pass	 filter	 and	 spatial	
smoothing	are	all	known	to	decrease	the	amounts	of	noise	carried	into	first	and	
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second	 level	 analysis	 stages	 (Bennett	 and	Miller,	 2010).	 Differences	 in	 choices	
regarding	 preprocessing	 stages	will	 influence	 results,	most	 notably	 in	 areas	 of	
lower	 signal.	 Additionally,	 due	 to	 variations	 in	 location,	 shape	 and	 size,	 the	
impact	of	preprocessing	steps,	such	as	for	example	spatial	smoothing,	may	not	be	
uniform	 across	 brain	 areas	 (Haller	 and	 Bartsch,	 2009).	 Standardization	 of	
preprocessing	 approaches	 in	 fMRI	 data	 analysis	 is	 therefore	 considered	 a	
cornerstone	of	minimizing	bias	in	fMRI	experiments	(Jenkinson	et	al.,	2002).	
	
Information	 impacting	 signal	 detection	 at	 the	 first	 and	 second	 level	 stages	 of	
analysis,	centre	on	the	use	of	corrections	for	multiple	comparisons	as	well	as	the	
adjustment	 for	 between	 subject	 and	 between	 session	 variance	 (Haller	 and	
Bartsch,	2009).	At	 first	 level,	 inadequate	correction	for	the	problem	of	multiple	
comparison	 in	 fMRI	 data	 (where	 the	 same	 general	 linear	model	 is	 often	 fitted	
and	tested	at	every	voxel)	can	lead	to	extreme	false	positive	results,	in	the	order	
of	 25,000	 spuriously	 ‘active’	 voxels	 per	 acquisition	 (Haller	 and	Bartsch,	 2009).	
Equally,	 excessively	 conservative	 corrections	 may	 lead	 to	 false	 negatives,	 a	
situation	undesirable	 for	 both	 experimental	 and	 clinical	 fMRI.	 Similarly,	 choice	
made	during	 the	 second	 level	 analysis	may	 lead	 to	 altered	 sensitivity	 of	 signal	
detection	within	a	group.	Therefore,	careful	knowledge	of	the	impact	of	analysis	
decisions,	 as	well	 as	 a	 clear	 understanding	 of	what	 a	 specific	 change	 in	 BOLD	




provided	 an	 objective	 measure	 of	 the	 subjective	 pain	 experience.	 This	 has	
allowed	 for	 a	 greatly	 improved	 understanding	 of	 nociceptive	 processing	 in	
humans	and	a	description	of	the	neuronal	mechanisms	underlying	various	pain	
phenotypes	 (Tracey,	 2005,	 Tracey,	 2011).	 Phenomena	 such	 as	 central	





be	 associated	 with	 conversion	 from	 acute	 to	 chronic	 pain	 states	 (Baliki	 et	 al.,	




The	 aim	 of	 this	 thesis	 is	 to	 use	 fMRI	 to	 explore	 the	 development	 of	 CIPN,	 by	
prospectively	 assessing	 whether	 there	 are	 baseline	 differences	 in	 pain	
processing	 between	 patients	who	 develop	 CIPN	 and	 those	who	 do	 not,	 and	 to	
investigate	 baseline	 variations	 in	 resting	 state	 networks	 and	 subcortical	
structures,	 between	 CIPN	 and	 non	 CIPN	 patients.	 Secondly	 this	 thesis	 aims	 to	


















described	 above	will	 be	undertaken	 (chp.2).	 The	 literature	 review	will	 explore	
two	 parallel	 themes.	 Firstly,	 a	 summary	 of	 CIPN	 –	 its	 epidemiology,	
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developmental	 predictors	 and	 treatment	 methods	 will	 be	 presented.	 This	 is	 a	
systematic	review	and	meta-analysis	of	CIPN	prevalence.		Secondly,	a	description	
of	pain	fMRI	research	detailing	neuropathic	pain,	resting	state	networks	related	
to	 neuropathic	 pain,	 changes	 in	 subcortical	 structures	 and	 analgesic	 trials	
utilizing	fMRI,	will	be	presented.	Methodological	details	of	the	 literature	search	




chapter	 will	 describe	 CIPN	 study	 design	 and	 setting,	 inclusion	 and	 exclusion	
criteria,	 trouble-shooting	 data	 acquisition	 difficulties,	 data	 collection,	 and	
relevant	definitions.	An	overview	of	statistical	methods	utilized	for	fMRI	analysis	
















A	 review	 of	 the	 literature	 related	 to	 this	 thesis	 is	 presented	 in	 this	 chapter.	 The	
literature	 review	 details	 two	 themes.	 Firstly,	 the	 clinical	 problem	 of	 CIPN	 is	
explored,	 describing	 the	 epidemiology,	 risk	 factors	 and	 treatments	 for	 CIPN.	This	
review	was	 undertaken	 as	 part	 of	 a	 now	published	 systematic	 review	 and	meta-
analysis	 investigating	 CIPN	 prevalence.	 Secondly,	 the	 pain	 fMRI	 literature	 is	
reviewed,	with	a	focus	on	functional	and	resting	state	studies	of	neuropathic	pain	
as	well	as	assessment	of	 subcortical	 volume	changes	 in	 chronic	neuropathic	pain	
conditions.	 Finally,	 an	 overview	 of	 fMRI	 use	 in	 analgesic	 trials	will	 be	 presented.	




Chemotherapy	 treatments	 for	 cancer	 have	 an	 array	 of	 side	 effects.	 These	 are	
balanced	 against	 the	 benefits	 of	 cancer	 treatment	 and	 prolonged	 survival.	 As	
survival	has	increased	long	lasting	side	effects	such	as	CIPN	have	become	more	
clinically	 relevant.	 Moreover,	 acutely,	 treatments	 for	 other	 chemotherapy	 side	
effects	 such	 as	 haemopoetic	 stimulating	 drugs,	 which	 limit	 bone	 marrow	
suppression,	 and	 anti	 emetic	 drugs	 that	 mitigate	 severe	 nausea	 have	 become	
available	(Miltenburg	and	Boogerd,	2014).	Consequently,	the	profile	of	CIPN	as	a	
clinical	 problem	 potentially	 limiting	 chemotherapy	 dose	 or	 duration	 has	 risen	
(Hershman	 et	 al.,	 2014).	 The	 need	 for	 understanding	 CIPN	 risk	 factors	 and	
frequency	has	therefore	also	increased.	
	
Investigating	 CIPN	 development	 and	 risk	 factors	 is	 limited	 to	 observational	
studies	 and	 more	 recently	 genome	 wide	 association	 studies	 (GWAS).	 This	 is	
predominantly	 because	 altering	 a	 patient’s	 chemotherapy	 regimen	 in	 order	 to	






used	 to	 identify	 affected	 cases	 (Bhopal,	 2008).	 CIPN,	 as	 discussed	 above	 (see	
1.1.2.1),	 is	 difficult	 to	 uniformly	 define	 because	 of	 its	 variable	 clinical	 course,	
chemotherapy	 specific	 clinical	 presentations,	 and	 previously	 non-standardised	
approach	 to	diagnosis	 (Cavaletti	et	al.,	2013).	Consequently,	 summarising	CIPN	
epidemiology	across	cancer	and	chemotherapy	types	is	limited	by	the	inevitable	
pooling	 of	 non-uniform	 clinical	 entities;	 such	 as	 for	 example	 acute	 oxaliplatin	
induced	CIPN	and	chronic	bortezomib	 induced	CIPN.	Conversely,	 the	benefit	of	
comparing	across	all	 cancer	and	chemotherapy	 types,	 is	 that	 the	resulting	data	
summaries	are	useful	to	a	wider	group	of	clinicians	and	can	be	consulted	when	
planning	 CIPN	 related	 health	 care	 costs.	 Below	 a	 summary	 of	 all	 CIPN	 related	
literature	 is	 presented.	 This	 is	 based	 on	 a	 systematic	 review	 of	 the	 literature.	






in	 a	 defined	 population	 of	 primary	 school	 children).	 Prevalence	 consists	 of	 all	
cases	 of	 a	 disease	 in	 a	 population,	 divided	 by	 the	 population	 at	 risk	 (Bhopal,	







experience	 CIPN	 acutely	 during	 their	 chemotherapy	 treatment	 an	 incidence	
count	would	be	worthwhile.	If,	however,	a	summary	of	patients	limited	by	CIPN	
two	years	following	cancer	treatment	was	needed	than	a	prevalence	count	would	
be	 more	 appropriate.	 The	 CIPN	 literature	 reports	 both	 measures,	 although	
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side	 effects	 such	 as	 CIPN	 has	 become	 important	 for	 chemotherapy	 planning,	
patient	 information	 and	 also	 development	 of	 preventive	measures	 (Park	 et	 al.,	
2013).		
	
The	earliest	 incidence	counts	 for	CIPN	can	be	derived	 from	RCTs	completed	 in	
the	1990’s.	Control	arms	of	RCTs	seeking	to	assess	preventive	measures	for	CIPN	









from	 12%	 to	 67.5%	 (see	 table	 2.1).	 This	 wide	 variation	 in	 documented	
occurrence	of	CIPN,	despite	use	of	the	same	chemotherapeutic	agent,	highlights	
the	 discrepancies	 in	 classification	 and	 therefore	 epidemiological	 counts	
discussed	above	(see	2.1.2).	Each	study	used	different	criteria	for	CIPN	diagnosis	
making	between	study	incidence	comparisons	difficult.	Additionally	studies	used	








variety	 of	 CIPN	 diagnostic	 criteria.	 Consequently,	 the	 biases	 affecting	
observational	 studies	 (see	 appendix	 C)	 and	 CIPN	 epidemiological	 measures	
likely	influence	all	the	counts	presented	here.		
	
The	 highest	 incidence	 of	 CIPN	 reported	 by	 Chaudhary	 et	 al	 was	 96.3%	 in	 27	
patients	 receiving	 a	 combination	 regimen	 of	 bortezomib	 and	 paclitaxel	
(Chaudhry	 et	 al.,	 2008).	 This	 is	 comparable	 to	 the	 96%	 incidence	 reported	 by	




comparatively	 high	 CIPN	 incidence	 of	 92.8%,	 in	 14	 breast	 cancer	 patients	




cisplatin	 chemotherapy,	 also	 suggested	variability	 (42.8%	 to	66.7%)	 (Krishnan	
et	al.,	2005,	Argyriou	et	al.,	2007a,	Antonacopoulou	et	al.,	2009,	Attal	et	al.,	2009).		
It	is	therefore	difficult	to	decipher	whether	differences	in	reported	incidence	are	




and	 CIPN	 prevention	 from	 the	 same	 decade	 show	 similar	 variability	 in	 CIPN	
incidence	(41.6%	to	93.7%)	to	the	cohort	studies	described	above.	The	majority	
of	these	studies	were	also	single	centre	and	had	small	sample	sizes.	Three	of	the	
seven	 did	 not	 randomise	 group	 allocations	 (see	 2.1)	 possibly	 biasing	 findings.	
Various	 cancer	 types,	 CIPN	 assessment	 methods	 and	 chemotherapeutics	 were	
used,	 likely	 causing	 at	 least	 some	 of	 the	 reported	 variability	 in	 incidence.	 A	
notable	exception	 regarding	sample	 size	and	randomisation	 is	 the	 sub-analysis	
of	a	phase	III	multiple	myeloma	treatment	study	carried	out	by	Dimopoulos	et	al	
which	 assessed	 CIPN	 incidence	 in	 340	 patients	 receiving	 bortezomib	
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(Dimopoulos	 et	 al.,	 2011).	 The	 authors	 reported	 a	 CIPN	 incidence	 of	 46.7%	 a	
more	 conservative	 estimate	 compared	 to	 the	 myeloma	 CIPN	 cohort	 studies	
discussed	above.	This	 is	 likely	due	to	robust	methodological	approaches	where	
in	 addition	 to	 a	 large	 sample	 size	 and	 randomisation,	 application	 of	 careful	
exclusion	 criteria	meant	 patients	with	 baseline	 neuropathy	were	 not	 included.	





randomised	 group	 allocation	where	 appropriate.	 	Observational	 cohort	 studies	
have	 included	no	 less	 then	50	patients	 (Kawakami	et	al.,	2012)	and	some	have	
recruited	 up	 to	 855	 (Baldwin	 et	 al.,	 2012)	 for	 genetic	 association	 studies.	 The	
range	of	reported	CIPN	incidence	has	decreased;	83.3%	to	40%	for	observational	
studies	 and	 70%	 to	 32%	 for	 control	 arms	 of	 RCTs,	 with	 differences	 in	 counts	
being	more	easily	attributable	 to	variations	 in	chemotherapy,	cancer	 types	and	
assessment	methods	rather	than	methodological	study	design	inconsistencies.	
	
In	 summary	 conservative	 estimates	 of	 CIPN	 incidence	 are	 agreed	 as	 being	














or	 more.	 The	 authors	 found	 that	 24%	 of	 the	 150	 eligible	 patients	 reported	
symptoms	 of	 CIPN.	 Strength	 of	 this	 study	 included	 a	 large	 sample	 size	 and	
inclusion	of	a	matched	surveillance	cohort.	Comparison	of	the	rate	of	neuropathy	
was	 statistically	 tested	 and	 found	 to	 be	 significantly	more	 burdensome	 in	 the	
chemotherapy	 group	 (Rossen	 et	 al.,	 2009).	 Limitations	 centre	 on	 the	 usual	
limitations	 affecting	 observational	 studies	 (see	 appendix	 C).	 Similarly,	 the	
findings	of	Brydoy	et	al’s	cross	sectional	study	are	strengthened	by	large	sample	
size	and	robust	statistical	methods	used	by	the	authors	(Brydoy	et	al.,	2009).	The	
authors	 assessed	 528	 cancer	 survivors	 and	 found	 29%	 showed	 symptoms	 of	
CIPN.	 They	 used	 both	 self-reported	 measures	 of	 CIPN	 as	 well	 as	 physical	
examination.	 Additionally	 the	 authors	 calculated	 the	 odds	 of	 developing	 CIPN	
related	 to	 chemotherapy	 dose,	 confirming	 previous	 findings	 that	 higher	 doses	
cause	more	CIPN.			
	
The	 averaged	 prevalence	 counts	 from	 the	 above	 two	 studies	 have	 been	
confirmed	by	Glendenning	et	al’s	 robust	 study	 investigating	 the	 long-term	side	
effects	 suffered,	 by	 testicular	 cancer	 survivors	 (Glendenning	 et	 al.,	 2010).	 This	
study	assessed	293	men	of	whom	59	had	symptoms	of	CIPN,	resulting	in	a	CIPN	
prevalence	 of	 20%	 at	 least	 5	 years	 after	 treatment	 cessation.	 Importantly,	 the	





Similar	 to	 the	 testicular	 survivors	 studies,	Mols	 et	al	 have	 recently	 reported	 a	
long-term	CIPN	prevalence	 of	 29%	 in	 colorectal	 cancer	 survivors.	 The	 authors	
assessed	 500	 individuals	 who	 had	 completed	 chemotherapy	 in	 the	 preceding	
two	 to	eleven	years.	 Interestingly,	 the	 study	 reported	 the	 individual	 symptoms	
specified	 by	 patients	 in	 the	 CIPN20	 questionnaire	 (see	 3.1.2).	 Symptoms	most	
bothering	 respondents	 included:	 erectile	 dysfunction	 (42%	men),	 hearing	 loss	
(11%),	 problems	 opening	 jars	 (11%),	 tingling	 in	 fingers	 and	 toes	 (10%)	 and	
challenges	 climbing	 stairs	 (9%)	 (Mols	 et	 al.,	 2013).	 	 Both	 Mols	 et	 al’s	 and	





In	 contrast	 to	 the	 above	 studies	 Kautio	 et	 al	 derived	 prevalence	 counts	 by	
grouping	 a	 cohort	 exposed	 to	 chemotherapeutics	 known	 to	 cause	 high	 CIPN	
rates,	but	used	to	treat	different	cancer	types	within	the	patient	group	(Kautio	et	
al.,	 2011).	 The	 authors	 assessed	 patients	 who	 had	 received	 vinka	 alkaloids,	
platinum	compounds	or	 taxanes	 for	chemotherapy,	using	postal	questionnaires	
and	 a	 subsequent	 screening	 visit	 for	 eligible	 respondents.	 Of	 the	 336	 patients	
who	 responded	 to	 questionnaires	 76%	 reported	 CIPN	 symptoms.	 However,	 of	
these	only	193	came	to	the	screening	visit	and	only	152	were	eligible	for	further	
CIPN	assessments.	When	assessing	CIPN	symptoms	 in	 this	 group	of	152,	using	
the	same	questionnaire	but	administered	in	clinic	CIPN	prevalence	decreased	to	
59%	 and	 showed	 a	 marked	 cancer	 related	 variability	 (74%	 prevalence	 in	
lymphoma	survivors	and	69%	in	colorectal	cancer	survivors).	Kautio	et	al’s	study	
design	 was	 of	 a	 lesser	 methodological	 quality	 than	 the	 two	 studies	 reporting	




In	 summary,	 the	 prevalence	 of	 CIPN	 beyond	 a	 year	 following	 chemotherapy	
cessation	 appears	 to	 range	 from	 20	 to	 59%.	 In	 view	 of	 the	 fact	 that	 4	 studies	
suggest	counts	averaging	around	30%	and	only	one	suggests	higher	prevalence	
the	likelihood	is	that	 long	term	CIPN	affects	around	a	third	of	cancer	survivors.	






seek	 out	 relevant	 studies	 and	 synthesise	 the	 data	 to	 provide	 clinically	 useful	




identified	 and	 data	 summaries	 pooled	 is	 not	 transparent.	 Authors	may	 not	 be	







as	 part	 of	 this	 thesis.	 Details	 of	 the	 methods,	 strengths	 and	 limitations	 of	 the	















more	 annual	 healthcare	 costs	 compared	 to	 non-CIPN	 cancer	 controls.	 	 CIPN	
patients	 also	 used	 18%	 more	 outpatient	 appointments	 and	 had	 24%	 more	
hospitalisations.	The	weakness	of	this	study	lay	in	the	lack	of	availability	of	clear	
codes	for	CIPN	diagnosis	and	a	baseline	assumption	that	CIPN	would	be	coded	as	





Finally,	 the	 pooled	 summary	 of	 CIPN	 literature	 presented	 here	 enables	 a	
calculation	of	the	influence	of	specific	chemotherapy	types	on	CIPN	occurrence.	
Although	it	is	known	that	different	chemotherapy	types	and	doses	alter	the	risks	
of	 CIPN	 a	 statistically	 derived	 numerical	 measure	 for	 all	 chemotherapeutics	
commonly	associated	with	CIPN	had	not	previously	been	available.	This	data	 is	








































































































































































































































































































































































































Johnson$	 RCT	 Multiple	 Grade	 details	 not	 Unclear	if	at	 NCI-CTC	
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by	 chemotherapy	 type.	 **Authors	 report	 both	 acute	 and	 chronic	 CIPN	 grade	
counts,	only	acute	given	here.	TNSc:	Total	Neuropathy	Score,	NCT-CTC:	National	







lead	 to	 effective	 preventive	 strategies	 and	 possibly	 eventual	 improvements	 in	
chemotherapy	regimens.	As	discussed	above	(see	2.1.1)	insight	into	risk	factors	






factors.	 Clinical	 predictors	 are	 those	 related	 to	 clinically	measurable	 variables	
such	as	patients	age,	comorbidity	status	or	pre	chemotherapy	nerve	conduction.	
Genetic	risk	factors	are	associated	with	the	identification	of	SNPs	associated	with	
CIPN.	The	 literature	will	be	 summarised	 in	 the	 context	of	 these	 two	categories	
below.	
2.2.1	Clinical	Risk	Factors	
Attal	 and	 colleagues	 published	 one	 of	 the	 early	 seminal	 papers	 investigating	
predictors	 of	 CIPN	 development	 (Attal	 et	 al.,	 2009).	 This	 prospective	 cohort	
study	followed	48	patients	receiving	oxaliplatin	or	cisplatin	chemotherapy.	The	




(only	 18	 patients	 were	 assessed	 at	 a	 year).	 The	 authors	 described	 cold	
hyperalgesia	as	a	predictor	of	chronic	CIPN	development.			
	
A	 year	 later	 Glendenning	 and	 colleagues	 published	 their	 use	 of	 the	 large	
testicular	 cancer	 register	 to	assess	both	 the	 long-term	prevalence	of	CIPN	 (see	
2.1.3.2)	as	well	as	the	risk	factors	associated	with	its	development	(Glendenning	
et	 al.,	 2010).	 The	 authors	 employed	 multivariate	 analysis	 to	 statistically	
determine	predictors	of	CIPN	and	identified	chemotherapy	dose,	and	patient	age	




A	 similarly	 well-conducted	 predictive	 multivariate	 analysis	 based	 on	 a	 large	
cohort	 was	 published	 in	 2011	 (Dimopoulos	 et	 al.,	 2011).	 Like	 Glendenning’s	
study	this	work	was	strengthened	by	a	robust	sample	size	but	limited	by	a	lack	of	
a	validation	cohort	for	the	predictors	identified.	Any	additional	strength	however	
lay	 in	 it	 being	 based	 on	 a	 prospective	 phase	 three	 trial	 (the	 VISTA	 study)	
investigating	 the	effects	of	bortezomib	 in	patients	with	multiple	myeloma.	This	
lends	 credibility	 to	 the	 identification	 of	 baseline	 neuropathy	 as	 the	 only	
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predictor	 of	 subsequent	 CIPN	 development.	 It	 also	 fits	 with	 the	 early	 sensory	




based	 on	 statistical	 modelling,	 following	 paclitaxel	 and	 cisplatin	 therapy	
(Kawakami	 et	 al.,	 2012).	 The	 authors	 recruited	 a	 sample	 of	 fifty	 patients	 and	
found	 that	 smoking	 history	 and	 low	 creatinine	 clearance	 increased	 the	 hazard	
ratio	of	developing	CIPN.	However	due	to	the	small	sample	size	in	this	study	the	




50	 patients	 due	 to	 receive	 neurotoxic	 chemotherapy	 and	 followed	 them	 up	 to	
determine	 predictors	 of	 CIPN	 (Alejandro	 et	 al.,	 2013).	 The	 authors	 also	 used	
multivariate	modelling	to	determine	CIPN	risk	factors.	In	line	with	larger	studies	
they	 found	 that	 cumulative	 dose	 of	 chemotherapy	 and	 prior	 neuropathy	
predicted	 development	 of	 CIPN	 (Dimopoulos	 et	 al.,	 2011,	 Glendenning	 et	 al.,	
2010).	 They	 additionally	 suggested	 that	 body	 surface	 area	 and	 weight	 were	
related	to	persistence	of	neuropathy	during	chemotherapy.	These	variables	are	






Using	a	 similar	prospective	 cohort	methodology	 to	Alejandro	and	 colleagues,	 a	
recent	multicentre	 study	 recruited	 200	 patients	 due	 to	 receive	 oxaliplatin	 and	
followed	these	patients	 in	order	to	 identify	risk	factors	for	CIPN	(Velasco	et	al.,	
2014).	 	 The	 authors	 used	 the	 standard	 multivariate	 statistical	 modelling	
approach	 to	 determine	 risk	 factors.	 The	 large	 cohort	 and	 detailed	 prospective	
data	collection	methods	strengthened	their	analysis.	They	reported	that	a	larger	
number	 of	 CIPN	 like	 symptoms	 during	 early	 cycles	 of	 chemotherapy	 and	
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decreased	 peripheral	 nerve	 action	 potentials	 (tested	 during	 the	 study)	 were	
predictive	 of	 CIPN	 development.	 These	 findings	 fit	 with	 papers	 by	 Attal	 and	




In	 summary,	 clinical	 risk	 factors	 for	 CIPN	 have	 to	 date	 been	 derived	 from	
predictive	statistical	models.	The	reliability	of	these	models	is	dependent	on	the	
size	of	the	cohort	they	were	based	on	and	the	details	of	the	data	collected	from	
patients.	 Based	 on	 this	 a	 number	 of	 the	 published	 studies	 should	 rather	 be	
considered	 hypothesis	 generating	 only.	 However	 other	 risk	 factors,	 which	 are	
reported	by	multiple	authors	and	are	based	on	at	least	one	large	cohort	may	be	
considered	 as	 likely	 associated	 with	 CIPN	 development.	 These	 would	 include	




Genetic	 risk	 factors	 have	 been	 postulated	 to	 underpin	 CIPN	 development.	 A	
number	of	large	genome	wide	association	studies	(GWAS),	have	reported	single	
nucleotide	 polymorphisms	 (SNPs)	 associated	 with	 CIPN	 (Baldwin	 et	 al.,	 2012,	
Johnson	et	al.,	2011,	Pachman	et	al.,	2011,	Won	et	al.,	2012,	Argyriou	et	al.,	2013).	
Many	studies,	but	not	all,	used	validation	datasets	and	blinding	to	clinical	status	
during	 the	 assessment.	 Reported	 polymorphisms	 encode	 a	 wide	 variety	 of	
proteins	important	in	neuronal	signal	transmission,	apoptosis	and	metabolisms.	
These	 include	 Schwann	 cell	 function	 related	 proteins,	 voltage	 gated	 sodium	
channels,	 receptors	 involved	 in	 neuronal	 apoptosis	 and	 enzymes	 involved	 in	
pyruvate	metabolism.			
	
The	majority	 of	 CIPN	 related	GWAS	 studies	 are	 limited	by	problems	known	 to	
influence	 these	 kinds	 of	 studies	 (Cavaletti	 et	 al.,	 2011b).	 These	 include	
inadequate	 sample	 size,	 lack	 of	 or	 underpowered	 replication	 cohort	 and	
insensitive	CIPN	assessment	tools.	Consequently,	many	reported	SNPs	have	not	
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been	 reproducible	 outside	 of	 the	 original	 study,	 which	 described	 their	
association	 with	 CIPN.	 Notable	 exceptions,	 recently	 published	 in	 relation	 to	





genetic	risk	 factors	 for	CIPN,	 the	usefulness	of	 these	studies	 to	advancing	CIPN	
prevention	and	diagnosis	has	been	postulated	(Postma	et	al.,	2013).	In	particular,	
if	 the	 approach	 to	 these	 studies	 can	 be	 standardised,	 their	 findings	will	 likely	




The	 management	 of	 acute	 CIPN	 centres	 on	 chemotherapy	 dose	 reduction	 or	
complete	 chemotherapy	 cessation.	 Current	 treatment	 options	 for	 chronic	 CIPN	
are	 limited.	 The	 only	 evidence-based	 treatment	 is	 duloxetine,	 a	 serotonin	
noradrenaline	reuptake	inhibitor.	Duloxetine’s	effectiveness	in	chronic	CIPN	was	
however	 only	 assessed	 over	 a	 period	 of	 2	 month	 in	 patients	 with	 oxaliplatin	
induced	peripheral	 neuropathy	 (Smith	 et	 al.,	 2013).	Moreover	 recent,	 post	 hoc	
analysis	of	the	original	duloxetine	trial	data	showed	that	the	best	response	to	the	
treatment	could	be	predicted	in	 individuals	with	high	emotional	 functioning	on	




Evidence	 related	 to	 the	 effectiveness	 of	 topical	 menthol	 gel	 in	 chronic	 CIPN	
patients	also	exists	(Fallon	et	al.,	2015).	A	single	centre	trial	showed	that	82%	of	
patients	 using	 menthol	 gel	 had	 an	 improvement	 in	 pain	 score,	 mood,	
catastrophising,	 walking	 ability	 and	 sensation.	 However,	 this	 trial	 was	
exploratory	 only	 and	 no	 placebo	 treatment	was	 given	 to	 a	 control	 group.	 The	
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findings	 therefore	 need	 to	 be	 confirmed	 with	 a	 larger	 randomised	 controlled	
trial.	No	other	positive	treatment	trials	exist	for	chronic	CIPN.	
	





baclofen,	 amitriptyline	 and	 ketamine	 was	 endorsed	 by	 these	 guidelines,	 as	
experimental	treatment	options	in	chronic	CIPN.	
	
In	 view	 of	 the	 increasing	 cancer	 survivorship	 and	 concomitant	 rising	 CIPN	
prevalence,	 it	 is	 obvious	 that	 novel	 treatments	 for	 chronic	 CIPN	 are	 urgently	
needed.	Importantly,	the	approach	used	to	assess	any	new	medications	needs	to	
take	 into	 account	 the	 difficulties	 related	 to	 analgesic	 trials	 (see	 1.1.1.2.2).	
Thorough	screening	of	agents	prior	to	progression	to	phase	three	trials	with	the	




of	multiple	compounds,	 in	 the	hope	of	 identifying	novel	drug	targets.	However,	
many	potential	agents	have	failed	to	survive	translation	into	human	studies.	An	
example	of	a	promising	agent	under	investigation	was	Acetyl-L-Carnatine	known	
to	 limit	 mitochondrial	 dysfunction,	 showed	 encouraging	 results	 in	 early	 CIPN	
treatment	 as	 well	 as	 CIPN	 prevention	 trials	 (Lin	 et	 al.,	 2006).	 Despite	 this	 a	








CIPN	 in	mice	models	 (Krukowski	 et	 al.,	 2015).	 Translation	 of	 these	 targets	 to	
successful	human	trials	is	still	some	way	off.	An	exception	in	terms	of	successful	
translation	 is	 the	TRP	 receptors	 family,	 also	under	 continued	 investigated	as	 a	
pain	 relief	 target	 (Moran	 et	 al.,	 2011).	 Menthol	 gel,	 a	 TRPM8	 agonist,	 has	 as	




are	 complimentary	 therapies	 such	 as	 acupuncture	 (Garcia	 et	 al.,	 2014).	 These	
remain	 under	 investigation	 but	 are	 turned	 to	 by	 patients	 with	 chronic	 CIPN	
when	 faced	with	 limited	 analgesic	 options.	More	 generally	 in	 terms	 of	 chronic	
neuropathic	 pain,	 use	 of	 brain	 stimulation	 has	 been	 proposed	 as	 a	 viable	




Multiple	 fMRI	 studies	 have	 been	 conducted	 in	 neuropathic	 pain	 patients.	 This	
body	 of	 literature	 has	 given	 insight	 into	 the	 central	 mechanism	 underpinning	
these	 pain	 states.	 A	 summary	 highlighting	 the	 main	 structural,	 functional	 and	
resting	 state	 changes	 reported	 by	 these	 studies	 follows.	 Experimental	
neuropathic	pain	models	in	both	animals	and	humans	have	also	been	utilised	in	
fMRI	studies.	 	The	 later	provides	a	rich	body	of	 literature,	which	will	briefly	be	
reviewed	below.			
2.4.1.1	FMRI	neuropathic	pain	studies	in	patients	
Neuropathic	 pain	 has	 been	 shown	 to	 alter	 brain	 structure,	 function	 and	 also	
resting	 state	 connectivity.	 White	 matter	 structural	 brain	 changes	 have	 been	
demonstrated	 in	 chronic	back	pain,	predicting	 transition	 from	acute	 to	 chronic	
pain	 states	 (Mansour	 et	 al.,	 2013).	 Patients	 with	 neuropathic	 pain	 following	
spinal	 cord	 injury	 have	 shown	 reduced	 grey	 matter	 volume	 in	 their	
somatosensory	and	dorsolateral	prefrontal	cortex	(Yoon	et	al.,	2013,	Mole	et	al.,	
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2014).	 Similarly,	 patients	 with	 complex	 regional	 pain	 syndrome	 (CPRS)	 show	
decreased	grey	matter	volume	in	the	insula	amongst	other	regions	(Barad	et	al.,	
2014).	Indeed	a	recent	meta-analysis	of	studies	assessing	grey	matter	changes	in	
neuropathic	 pain	 showed	 that	 decreased	 volume	 in	 multiple	 structures	 is	
common	(Pan	et	al.,	2015).	Regions	most	 commonly	altered	 include	 the	 insula,	
thalamus,	 superior	 frontal	 gyrus	 and	 post	 central	 gyrus.	 Abnormalities	 in	 the	
structure	of	the	thalamus	and	somatosensory	cortex	have	also	been	confirmed	in	
a	meta-analysis	of	brain	changes	in	trigeminal	neuralgia	(Lin,	2014).	It	should	be	
noted	 that	 the	 underlying	 cellular	 basis	 for	 these	 voxel	 based	 morphometry	
(VBM),	 related	 changes	 is	 still	 unknown.	 Comparative	 animal	 studies	 and	
histology	have	not	confirmed	 that	a	decrease	 in	VBM	equates	 to	neuronal	 loss.	
This	is	supported	by	human	studies	in	osteoarthritis	and	chronic	low	back	pain	





of	 neuropathic	 pain	 has	 mainly	 been	 explored	 using	 positron	 emission	
tomography	 (PET)	 studies	 as	 opposed	 to	 fMRI	 studies.	 This	 is	 because	 PET	
enables	a	constant	baseline	measurement	of	cerebral	blood	flow.	These	studies	
associate	 increased	baseline	activity	 in	 the	 insula,	anterior	cingulate	 (ACC)	and	
posterior	 cingulate	 cortices	 (PCC)	 with	 spontaneous	 pain	 in	 neuropathic	 pain	
patients	 (Seifert	 and	 Maihofner,	 2009).	 FMRI	 specific	 investigation	 of	
spontaneous	pain	in	patients	with	chronic	back	pain	has	shown	activation	in	the	
similar	 regions	 (Baliki	 et	 al.,	 2006).	 Evoked	 pain,	 including	 thermal	 allodynia,	






Resting	 state	 networks,	 which	 underpin	 tonic	 cortical	 connectivity,	 have	 also	
been	 shown	 to	 undergo	 changes	 in	 neuropathic	 pain	 conditions.	 Baliki	 et	 al	
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reported	 alterations	 in	 the	 default	 mode	 network	 (DMN),	 a	 network	 active	
during	 rest,	 in	 patients	 with	 chronic	 back	 pain	 (Baliki	 et	 al.,	 2008).	 These	




2013).	Changes	 in	 resting	 state	networks,	 have	been	 reported	 in	 children	with	
CRPS	 (Becerra	 et	 al.,	 2014).	 Interestingly,	 these	 changes	 reverted	 following	
intensive	physical	and	psychological	therapy.	Becerra	et	al’s	work	highlights	the	
potential	 clinical	 applicability	 of	 resting	 state	 network	 analysis	 in	 chronic	
neuropathic	pain.		
	
In	 terms	 of	 CIPN,	 only	 two	 brain-imaging	 studies	 have	 investigated	 CIPN	
development	 and	 chronic	 CIPN	 (Boland	 et	 al.,	 2014,	 Nudelman	 et	 al.,	 2015).	
These	 have	 shown	 altered	 function	 in	 the	 superior	 frontal	 gyrus	 in	 patients	
displaying	 symptoms	 of	 CIPN.	 Additionally,	 Nudelman	 and	 colleagues	 have	
reported	 decreased	 grey	 matter	 volume	 in	 patients	 with	 CIPN	 a	 year	 after	




Experimental	 models	 of	 neuropathic	 pain	 used	 in	 fMRI	 studies,	 can	 be	
subdivided	 into	 those	utilised	 in	humans	and	 those	used	 in	animals.	Review	of	
the	animal	neuropathic	pain	model	literature	is	beyond	the	scope	of	this	thesis.	It	
is	 however,	 important	 to	 note	 that	 multiple	 animal	 neuropathic	 studies	 have	
utilised	 fMRI	 to	 investigate	 changes	 in	 animal	 brains	 before,	 during	 and	 after	
induction	of	neuropathic	pain	(Chang	et	al.,	2014,	Hubbard	et	al.,	2015,	Baliki	et	
al.,	2014).	These	have	upheld	the	changes	reported	in	humans	and	have	proven	
useful	 in	 probing	 causal	 mechanisms	 underpinning	 not	 only	 the	 development	




In	 humans,	 experimental	 models	 of	 neuropathic	 pain	 used	 in	 fMRI	 studies	
include	heat	 and	 cold	 induced	allodynia	using	 an	MRI	 safe	 thermode,	punctate	
mechanical	hyperalgesia,	capsaicin	(TRPV1	receptor	agonist)	 induced	allodynia	
and	 hyperalgesia,	 and	 menthol	 induced	 cold	 hyperalgesia(Brooks	 et	 al.,	 2005,	
Iannetti	et	al.,	2005,	Lee	et	al.,	2008,	Wanigasekera	et	al.,	2011).	fMRI	studies	in	
healthy	 volunteers	 has	 helped	 identify	 a	 ‘neurologic	 signature’	 of	 noxious	 heat	
(Wager	et	al.,	2013).	Regions	consistently	activated	when	processing	this	type	of	
stimulus	 include	 the	 anterior	 and	 posterior	 insulae,	 PAG,	 thalamus,	 secondary	
somatosensory	 cortex	 and	 anterior	 cingulate	 cortex.	 Similar	 regions	 are	
activated	by	noxious	cold	(Atlas	et	al.,	2014,	Tracey	et	al.,	2000).	
	
Indeed,	 brain	 processing	 related	 to	 all	 models	 of	 neuropathic	 pain	 reveals	
activation	 in	 these	 same	 consistently	 reproducible	 regions	 (Seifert	 and	
Maihofner,	2009).	This	highlights	the	fact	that	although	there	are	no	pain	specific	




To	 date	 fMRI	 has	 not	 been	 used	 as	 an	 adjunct	 in	 any	 trials	 related	 to	 CIPN	
treatment.	Use	of	fMRI	as	an	adjunct	to	CIPN	treatment	RCTs	has	been	suggested	
following	 review	 of	 the	 literature	 presented	 here	 (Seretny	 et	 al.,	 2013).	
Implementation	of	an	FMRI	paradigm	 for	 further	assessment	of	menthol	gel	 in	
chronic	 CIPN	 is	 planned	 as	 discussed	 in	 chapter	 6.	 	 More	 broadly	 in	 terms	 of	
general	neuropathic	analgesic	trials,	currently	there	 is	an	on-going	neuropathic	















A	 comprehensive	 overview	 of	 methods	 used	 in	 this	 thesis	 is	 presented	 in	 this	
chapter.	The	chapter	itself	is	split	into	two	sections.	The	first	describes	the	general	
aims,	 design	 and	 recruitment	 of	 the	 CIPN	 study.	 A	 detailed	 description	 of	 the	
embedded	 fMRI	study,	which	 is	 the	 focus	of	 this	 thesis,	 is	presented.	Secondly,	 the	
chapter	 deals	 with	 fMRI	 data	 analysis	 methods.	 Subsequent	 chapters	 detailing	
exploration	 of	 key	 study	 hypotheses	 will	 refer	 back	 to	 this	 methods	 section	 for	
clarity	and	in	order	to	avoid	repetition.		
3.1	CIPN	Study	Overview	
Clinical	 development	 of	 CIPN	 remains	 inadequately	 characterised	 (Delforge	 et	
al.,	 2010).	 Previous	 studies	 have	 utilised	 single	 assessment	modalities	 such	 as	
neurophysiological	 testing	and	clinical	 reporting	 to	diagnose	CIPN	(Argyriou	et	
al.,	 2007a).	 The	 aim	 of	 the	 CIPN	 study	was	 to	 prospectively	 characterise	 CIPN	
using	multiple	modalities;	(QST),	fMRI,	CIPN20	questionnaire	and	confocal	laser	
scanning	 microscopy	 (vivascope ®)	 techniques.	 The	 goal	 was	 to	 describe	 the	
natural	history	of	CIPN,	gain	insight	into	underlying	mechanisms	and	identify	the	
sub-cohort	 of	 patients	 who	 may	 benefit	 from	 pre-emptive	 management.	
Specifically,	 this	 early	preventive	 approach	 it	would	 include	 closer	monitoring,	










1	For	 the	 fMRI	 study	 16	 healthy	 age,	 sex,	 matched	 controls	 were	 also	 recruited	 and	 scanned	
towards	 the	end	of	 the	study	 in	early	2015.	This	was	done	 in	anticipation	of	possible	reviewer	
comments	for	future	publications.	The	healthy	volunteer	data	was	not	analysed	for	the	purposes	
of	 this	 thesis	 due	 to	 time	 constraints	 and	 will	 only	 be	 mentioned	 in	 terms	 of	 recruitment	
eligibility.		
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To	 prospectively	 characterise	 the	 psychophysical	 properties	 of	 chemotherapy	
induced	 peripheral	 neuropathy	 according	 to:	 1)	 Quantitative	 Sensory	 Testing	
(QST)	thresholds	and	2)	modified	QST	(punctate	stimuli	only)	during	functional	
Magnetic	 Resonance	 Imaging	 (fMRI),	 to	 determine	 the	 proportion	 of	 patients	






change	 over	 time	 in:	 physical	 function	 (outcome	 measures:	 slotted	
grooved	peg	board	to	assess	hand	dexterity)	and	patient	rated	symptoms	
of	 peripheral	 neuropathy	 (outcome	 measures:	 Visual	 Analogue	 Scale	
(VAS),	Brief	Pain	 Inventory	(BPI)	and	CIPN-20),	Rydel-Seiffer	Graduated	













Fife	 Oncology	 Clinic	 and	 Forth	 Valley	 Royal	 Hospital	 Oncology	 Clinic	 by	
oncologists	and	research	staff.	They	were	approached	for	recruitment	only	after	





to	 coincide	 with	 their	 hospital	 visit.	 If	 appropriate	 patients	 consenting	 to	 the	
main	 study	were	 asked	 to	participate	 in	 the	 fMRI	part	 of	 the	 study.	 If	 patients	
expressed	an	interest	in	the	study	but	only	wish	to	take	part	in	the	MRI	part	of	
the	study	this	was	offered	until	the	time	when	the	fMRI	part	of	the	study	closed	
in	May	2015.	A	 flow	diagram	adapted	 from	the	Strengthening	 the	Reporting	of	














































(d) Able	 to	 provide	 informed	 written	 consent	 to	 participation	 in	 the	 study	
after	explanation	of	the	study	protocol.	
(e) Have	 the	 ability	 to	 complete	 questionnaire	 assessments	 in	 English	
language.		




(a) Neurological	 conditions	which	may	 influence	 findings	 (such	 as	Multiple	
Sclerosis	or	residual	signs/symptoms	from	a	previous	stroke).	
(b) Patients	 with	 pre-existing	 neurological	 or	 chronic	 pain/neuropathic	
conditions.	








(g) In	the	opinion	of	 the	Research	Team	or	their	usual	medical	 team,	would	
be	unable	to	complete	the	study	protocol	for	any	other	reason.	






given	 study	 information	 sheets	 and	 had	 a	 minimum	 of	 24hours	 to	 consider	







(c) Able	 to	 provide	 informed	 written	 consent	 to	 participation	 in	 the	 study	
after	explanation	of	the	study	protocol.	




(a) A	 current	 cancer	 diagnosis	 (excluding	 basal	 cell	 skin	 cancer	 or	 early	
localised	prostate	cancer	on	‘watch	and	wait’/	active	monitoring)		
(b) Risk	 factors	 for	 peripheral	 neuropathy	 such	 as	 diabetes,	 chronic	
alcoholism	 and	 previous	 history	 or	 current	 use	 of	 drugs	 which	 cause	
peripheral	neuropathy.	
(c) Neurological	 conditions	which	may	 influence	 findings	 (such	 as	 remitted	




(e) Suffering	 from	 significant	 psychiatric	 illness,	 which	 would	 hinder	 their	
completion	of	the	study.	








to	 the	 difficulties	 in	 studying	 neuropathic	 pain	 conditions.	 CIPN	 like	 other	
neuropathic	 conditions,	 is	 difficult	 to	 quantify	 clinically	 or	 using	 quantitative	
sensory	 testing	 (QST).	 As	 discussed	 above	 (see	 1.1.3.4	 and	 2.4)	 fMRI	 has	 been	
used	to	understand	pain	processing	in	both	health	and	illness.	In	particular	fMRI	
allows	 for	 an	 objective	 quantification	 of	 pain	 states.	 To	 date	 the	 influence	 of	







undergo	 an	 fMRI	 scan	 at	 the	 clinical	 research-imaging	 centre	 (CRIC)	 at	 the	




Post	 scan	 follow	up	depended	on	whether	 the	patients	had	 consented	 for	only	
the	 fMRI	 sub-study	 or	 had	 opted	 to	 also	 take	 part	 in	 the	 detailed	 quantitative	
sensory	 testing	 study	 arm.	 If	 patients	 consented	 to	 only	 the	 fMRI	 they	 were	
followed	up	with	the	CIPN20	questionnaire	only.	The	CIPN20	questionnaire	was	
chosen	 as	 this	 is	 the	 only	 questionnaire	 available,	 which	 is	 specific	 for	 CIPN	
development	 (see	 discussion	 in	 section	 3.2).	 The	 questionnaire	 was	
administered	over	the	phone	or	in	clinic	prior	to	each	subsequent	chemotherapy	
cycle	 and	 then	 at	 3,	 6,	 9	 and	 12	 months	 after	 chemotherapy	 completion.	 If	






















since	 diagnosis	 but	 is	 not	 to	 scale	 as	 timings	 varied.	 Standard	 time	 between	
diagnosis	and	recruitment	was	around	7	weeks;	however,	 for	 the	patients	who	
did	 not	 need	 an	 operation	 this	 was	 shorter.	 Time	 between	 recruitment,	 fMRI	
scan	and	first	chemotherapy	cycle	also	varied	for	some	patients,	as	it	was	within	
the	same	week	for	most,	but	for	others	up	to	2	weeks.	Number	of	follow	up	time	





the	 research	 questions	 outlined	 above,	 clinical	 knowledge	 and	 literature	
detailing	previous	 successful	 fMRI	pain	experiments.	Past	 research	and	 clinical	
experience	suggested	that	both	thermal	(Attal	et	al.,	2009)	and	mechanical	(Park	
et	 al.,	 2009)	 nociceptors	 are	 involved	 in	 CIPN	 development.	 Consequently,	
assessment	 of	 the	 brain	 response	 to	 both	 punctate	 and	 thermal	 stimuli	 was	
planned	in	the	experiment.	However	following	study	set	up	and	several	healthy	
volunteer	 scans	 over	 many	 months,	 thermal	 stimuli	 was	 removed	 from	 the	
experiment	 due	 to	 practical	 limitations	 related	 to	 equipment	 associated	 noise	




The	 final	 experimental	 paradigm,	 shown	 in	 figure	 3.3	 included	 64	 punctate	



















von	 Frey	 filament).	 An	 average	 of	 4	 stimuli	 was	 delivered	 during	 a	 block	 of	
images.	 Boxes	 from	 top	 left:	 top	 showing	 coloured	 jittered	 image	 with	 no	
content,	termed	‘snow’.	Example	positive	(middle)	and	neutral	(bottom)	images	
from	 international	 affective	 picture	 system	 (IAPS).	 Images	 were	 presented	 in	
blocks	 containing	 ten	 images	 of	 each	 kind,	 with	 each	 image	 displayed	 for	 10	
seconds,	throughout	the	whole	duration	of	experiment.	No	image	was	repeated.	









felt	 to	 be	 viable	 experimentally	 for	 two	 reasons.	 Firstly,	 previous	 fMRI	 pain	
studies	 have	 shown	 strong	 engagement	 of	 the	 descending	 pain	 modulatory	
system	 (DPMS)	 in	 healthy	 volunteers	 following	 stimulation	 with	 von	 Frey	






to	 affective	 processing	 was	 included	 in	 the	 experiment.	 There	 is	 evidence	
demonstrating	 altered	 pain	 processing	 related	 to	 emotional	 states	 and	 diverse	
emotional	input	(de	Wied	and	Verbaten,	2001,	Ploghaus	et	al.,	2001,	Berna	et	al.,	
2010).	 It	 has	 been	 shown	 that	 affective	 stimuli	 processing	 differs	 between	
healthy	volunteers	and	patients	(Kamping	et	al.,	2013).	Whether	this	is	also	true	
of	patients	who	develop	CIPN	is	unknown.	Therefore	during	the	fMRI	experiment	
in	addition	 to	being	presented	with	punctate	 stimuli	patients	were	also	 shown	





IAPS	 are	 a	well-validated	 dataset	 of	 images	 known	 to	 have	 emotional	 valence.		
For	this	experiment	only	positive	and	neutral	images	were	selected	(fig	3.4).	All	




IAPS	without	providing	 any	 context,	was	 shown	 instead	of	 a	 black	 screen.	The	
snow	 image	was	generated	using	a	random	image	generator	 freely	available	at	








image	 was	 displayed	 for	 10seconds.	 No	 images	 were	 repeated.	 Images	 were	
presented	 in	 blocks	 of	 3	 neutral,	 3	 snow,	 and	 3	 positive	 images	 repeated	 in	 a	
pseudo	 randomised	 order	 (i.e.	 positive,	 snow,	 neutral,	 then	 neutral,	 snow,	
positive,	 etc.)	 throughout	 the	 whole	 16	minutes	 of	 the	 sequence.	 During	 each	




The	 following	 sequences	 were	 acquired	 for	 each	 participant	 in	 the	 order	
presented:	 structural	 T1	 weighted	 MPRAGE	 sequence,	 a	 grey	 field	 map	 (see	
3.2.1.3)	 for	 data	 preprocessing,	 a	 resting	 state	 arterial	 spin	 labelling	 (ASL)	




192x192mm.	 This	 equated	 to	 a	 total	 of	 204	 volumes	 for	 the	 resting	 state	








was	 available	 at	 the	 Clinical	 Imaging	 Research	 Centre	 (CRIC),	 no	 ancillary	
equipment	 necessary	 for	 pain	 fMRI	 studies	 was	 available.	 In	 particular,	
physiological	 noise	 monitoring	 and	 MRI	 safe	 heat	 stimulus	 presentation	




As	 detailed	 above	 (see	 1.1.3.3.2),	 collecting	 data	 on	 heart	 and	 respiratory	 rate	
during	 pain	 fMRI	 experiments	may	 help	 optimise	 data	 analysis	 down	 the	 line.	










not	 straightforward.	 Each	 piece	 of	 new	 equipment	 must	 be	 MRI	 compatible.	
Additionally,	 all	 equipment	must	 be	well	 insulated	 as	 to	not	 act	 as	 a	 source	 of	
interference.	Multiple	pieces	of	 equipment	 introduced	 together	are	more	 likely	






Pulseox	 Bellows	 BIOPAC	 HRcable	 RRtube	 Three	way	signal	spli=er	 																
Figure	3.5.	Set	up	of	the	PNM	data	recording	equipment.	The	connection	is	in	the	
following	 order:	 bellows	 around	 participant	 extend	 through	 the	 waveguide	 to	
the	 BIOPAC	 via	 a	 hollow	 plastic	 tube	 (RRtube).	 The	 BIOPAC	 is	 a	 system	 of	
amplifiers	 and	 transducers	 used	 to	 acquire	 physiological	 signal.	 The	 pulse	
oximetry	 probe	 (pulseox)	 is	 attached	 to	 patient	 and	 extends	 through	 a	
connecting	 cable	 to	 a	 filter	 installed	 in	 the	 penetration	 panel.	 From	 here,	 a	
secondary	 cable	 (HRcable)	 connects	 the	 pulse	 oximetry	 to	 the	 BIOPAC.	 The	
BIOPAC	is	connected	via	a	three	way	optical	to	an	electrical	transmitter	box	(far	
right),	 to	receive	scanner	pulses.	This	connection	ensures	 that	scanner	 triggers	
are	 identical	between	 the	BIOPAC	and	presentation	 script.	The	BIOPAC	 is	 then	
connected	to	a	laptop	with	software	able	to	display	the	relevant	waveforms	and	










A	 popular	 system	 used	 in	 other	 fMRI	 centres	 is	 the	 Medoc	 Pathway	 System	
(http://www.medoc-web.com/products/pathway).	 This	 was	 purchased	 and	
installed	at	CRIC	 in	 January	2013.	 	Unfortunately,	despite	 its	MRI	specifications	
the	 system	 did	 introduce	 some	 noise	 into	 the	 scanner	 environment.	 This	 was	
compounded	 by	 the	 simultaneous	 introduction	 of	 the	 PNM	 equipment.	 The	
impact	on	 scan	data	quality	was	unacceptable.	Therefore,	 after	extensive	noise	





Patients	 undergoing	 an	 fMRI	 scan	were	 also	 asked	 to	 consent	 to	 giving	 blood	
samples	 for	 future	 genetic	 analysis.	 These	 samples	 were	 stored.	 Additionally,	
patients	were	 asked	 to	 give	 samples	 of	 saliva	 to	 test	 testosterone	 levels	 at	 the	
time	of	the	scan.	All	scans	occurred	during	the	day,	but	varied	between	afternoon	
and	 mornings	 sessions,	 and	 testosterone	 sampling	 also	 varied.	 Collection	 of	
testosterone	was	 undertaken	 to	 explore	 the	 association	 of	 serum	 testosterone	
levels	 and	 CIPN	development.	 There	 is	 a	 growing	 body	 of	 evidence	 suggesting	
that	testosterone	and	other	hormones	influence	the	occurrence	and	maintenance	
of	chronic	pain	conditions	(Vincent	et	al.,	2013,	Vincent	and	Tracey,	2010).	The	






a	 needle	 prick).	 Due	 to	 a	 protocol	 oversight	 sharpness	 ratings	 were	 only	
introduced	during	 the	 second	half	of	 the	 study	and	 therefore	were	unavailable	
for	 some	 of	 the	 scanned	 participants	 (see	 discussion	 on	 study	 limitations	 in	
chapter	7).		
3.1.3.3	fMRI	Data	Completeness	
FMRI	data	 collection	was	mostly	 complete	as	 follows.	No	participant	withdrew	
from	 the	 study	 during	 the	 scan.	 However,	 a	 small	 number	 of	 sequences	 failed	
during	acquisition	and	in	one	instance	a	field	of	view	was	set	too	small	to	enable	
data	 processing.	 These	 are	 detailed	 in	 table	 3.1.	 Follow	 up	 data,	 including	 the	











Structural	 ASL	RS	 BOLD*	RS	 BOLD*	Functional	(EPI)	
CIPN0002	 ✓	 ✓	 ✓	 ✓	
CIPN0003	 ✓	 ✓	 ✓	 ✓	
CIPN0004	 ✓	 ✓	 ✓	 ✓	
CIPN0005	 ✓	 ✓	 ✓	 ✓	
CIPN0006	 ✓	 ✓	 ✓	 ✓	
CIPN0007	 ✓	 ✓	 ✓	 ✓	
CIPN0008	 ✓	 ✓	 ✓	 ✓	
CIPN0012	 ✓	 ✓	 ✓	 ✓	
CIPN0013	 ✓	 ✓	 ✓	 ✓	
CIPN0015	 ✓	 ✓	 ✓	 ✓	
CIPN0016	 ✓	 ✓	 ✓	 Presentation	software	failure	
CIPN0017	 ✓	 ✓	 ✓	 ✓	
CIPN0018	 ↓ FOV	 ✓	 ✓	 ✓	
CIPN0019	 ✓	 ✓	 ✓	 ✓	
CIPN0020	 ✓	 ✓	 ✓	 ✓	
CIPN0022	 ✓	 ✓	 ✓	 ✓	
CIPN0023	 ✓	 ✓	 ✓	 ✓	
CIPN0024	 ✓	 ✓	 ✓	 ✓	
CIPN0025	 ✓	 ✓	 ✓	 ✓	
CIPN0026	 ✓	 ✓	 ✓	 ✓	
CIPN0027	 ✓	 ✓	 ✓	 ✓	
CIPN0028	 ✓	 ✓	 ✓	 ✓	
CIPNFV01	 ✓	 ✓	 ✓	 ✓	
CIPNFV02	 ✓	 ✓	 ✓	 ✓	
CIPNFV03	 ✓	 ✓	 ✓	 ✓	
CIPNV001	 ✓	 ✓	 ✓	 ✓	
CIPNV002	 ✓	 ✓	 Scanner	failure	 ✓	
CIPNV003	 ✓	 ✓	 ✓	 ✓	
CIPNV004	 ✓	 ✓	 ✓	 ✓	
CIPNV005	 ✓	 ✓	 ✓	 ✓	
Table	3.1.	Summary	table	of	MRI	sequence	acquisition,	ticks	indicate	adequate	






months	 after	 chemotherapy	 completion.	 This	 is	 termed	 acute	 CIPN	 and	 is	
distinguished	 from	 chronic	 CIPN,	 occurring	 three	 months	 or	 more	 after	
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chemotherapy	 cessation	 (Ventzel	 et	 al.,	 2015).	 Insight	 into	 the	 evolution,	 and	
interrelatedness	 of	 acute	 and	 chronic	 CIPN	 is	 lacking.	 Clear	 clinical	 definitions	
are	not	uniformly	available	or	used	across	 centres.	This	has	 caused	 limitations	
for	 research	 purposes	 in	 terms	 of	 outcome	measures,	with	 recent	 attempts	 to	
standardise	practice	(Cavaletti	et	al.,	2013).		
	
One	 standardised	 tool	 currently	 in	 use	 for	 CIPN	 assessment	 in	 research	 is	 the	




in	 a	 large	 international	 cohort	 (http://groups.eortc.be/qol/chemotherapy-
induced-peripheral-neuropathy-eortc-qlq-cipn20)	 and	 is	 currently	 being	




At	 the	 time	of	writing	however,	 follow	up	of	 scanned	patients	was	 incomplete.	
Therefore,	use	of	 the	CIPN20	questionnaire	 as	 a	way	of	defining	CIPN	was	not	
possible	in	terms	of	a	standardised	comparison	of	the	same	time	point	across	all	
patients	 (see	 table	 3.2).	 As	 a	 result,	 a	 decision	 was	made	 to	 define	 CIPN	 in	 a	
clinically	meaningful	way	for	all	analyses	presented	in	this	thesis.	Consequently,	
the	common	toxicity	score	(see	table	3.4)	cut	off	was	used.	If	a	patient	had	any	





Chemotherapy	 dose	 reduction	 as	 a	 consequence	 of	 intolerable	 CIPN	 has	 likely	








Intra	Chemo	 3mo	 6mo	 9mo	 12mo	
CIPN0002	 ✓ ✓	 ✓	 ✓	 D	
CIPN0003	 ✓ ✓	 ✓	 ✓	 ✓	
CIPN0004	 ✓ LTF	 LTF	 LTF	 LTF	
CIPN0005	 ✓ ✓	 D	 D	 D	
CIPN0006	 ✓ ✓	 ✓	 ✓	 ✓	
CIPN0007	 ✓ ✓	 ✓	 ✓	 ✓	
CIPN0008	 ✓ ✓	 ✓	 ✓	 ✓	
CIPN0012	 ✓ ✓	 ✓	 ✓	 ✓	
CIPN0013	 ✓ ✓	 ✓	 ✓	 ✓	
CIPN0015	 ✓ ✓	 ✓	 ✓	 ✓	
CIPN0016	 ✓ ✓	 ✓	 ✓	 ✓	
CIPN0017	 ✓ ✓	 ✓	 ✓	 ✓	
CIPN0018	 ✓	 ✓	 ✓	 ✓	 	
CIPN0019	 ✓ ✓	 X	 X	 X	
CIPN0020	 ✓ 	 	 	 	
CIPN0022	 ✓ X	 X	 X	 X	
CIPN0023	 ✓ 	 	 	 	
CIPN0024	 ✓ 	 	 	 	
CIPN0025	 ✓ ✓	 	 	 	
CIPN0026	 ✓ ✓	 	 	 	
CIPN0027	 ✓ ✓	 	 	 	
CIPN0028	 S S	 S	 S	 S	
CIPNFV01	 ✓ 	 	 	 	
CIPNFV02	 ✓ 	 	 	 	
CIPNFV03	 ✓ 	 	 	 	
CIPNV001	 ✓ 	 	 	 	
CIPNV002	 ✓ 	 	 	 	
CIPNV003	 ✓ 	 	 	 	
CIPNV004	 ✓ 	 	 	 	
CIPNV005	 ✓ 	 	 	 	
Table	 3.2.	 Summary	 of	 follow	 up	 status	 for	 CIPN	 fMRI	 study	 participants.	 D=	





























































International	 Conference	 on	 Harmonisation	 Good	 Clinical	 Practice	 Guidelines	





Data	was	 handled	 in	 accordance	with	 regulatory	 guidelines.	 All	 data	 including	
fMRI	 data	 was	 anonymised	 from	 the	 point	 of	 entry	 into	 the	 study	 with	 each	
subject	 being	 identified	 by	 a	 study	 number	 only.	 Paper	 copies	 of	 any	 study	
related	documents	(Case	Report	Forms	(CRFs),	source	data,	consent	forms,	and	
regulatory	documents)	were	kept	in	a	locked	filing	cabinet	in	a	secure	room	with	








The	aim	of	 acquiring	 and	analysing	 fMRI	 in	 this	 study	 is	 to	 gain	 a	quantitative	
summary	 of	 differences	 in	 both	 brain	 structure	 and	 function	 between	patients	
who	 develop	 CIPN	 and	 those	 who	 do	 not.	 These	 quantitative	 summaries	 are	
derived	 from	 statistical	 inferences.	 For	 functional	 data	 these	 statistical	
comparisons	 are	 made	 between	 BOLD	 signal	 changes	 resulting	 from	 the	
experimental	 stimuli	 presented,	 and	 baseline	 BOLD	 signal.	 For	 structural	 data	
differences	 in	segmented	volumes	of	pre-specified	structures	are	compared.	All	
scan	 data	 for	 the	 CIPN	 study	 was	 analysed	 using	 FMRIBs	 Software	 Library	
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/)	 (Jenkinson	 et	 al.,	 2012).	 Chapter	 6	
detailing	 the	 development	 of	 a	 CIPN	 treatment	 FMRI	 study	 is	 the	 exception	 in	
terms	of	analysis.	Data	presented	 in	 this	chapter	was	analysed	using	Statistical	
Parametric	 Mapping	 (SPM)	 software	 (http://www.fil.ion.ucl.ac.uk/spm/).	 SPM	
analysis	follows	the	principles	of	FSL	data	analysis	outlined	below.	The	software	
packages	 are	 similar	 and	 usage	 depends	 on	 training	 and	 user	 preferences.	
Analysis	of	the	single	MINT3	pilot	scan,	summarised	in	chapter	6	was	carried	by	
a	colleague	(Dr	Liana	Romaniuk)	who	 is	 trained	 in	 the	use	of	SPM	and	not	FSL	
software.	 In	 every	 analysis	 chapter	 key	 confounds	 are	 checked	 and	detailed	 in	
table	 format	 to	 ensure	 no	 overt	 differences	 between	 the	 CIPN	 and	 non	 CIPN	
group	exist,	aside	from	the	neuropathy.		
3.4.2	fMRI	Study	Sample	Size	Calculation	
Sample	 size	 calculation	 for	 fMRI	 studies	 is	 not	 straightforward	 (Friston	 et	 al.,	
1999).	 This	 is	 because	 specification	 of	 the	 alternative	 hypothesis,	 required	 for	
standard	 power	 and	 sample	 size	 calculations,	 cannot	 be	 made	 in	 quantitative	
terms,	 due	 to	 the	 convolution	 of	 the	 hemodynamic	 response	 function	 (Friston,	
2011).	Consequently,	the	standard	approach	used	to	derive	sample	size	for	fMRI	
studies	 is	 to	base	 this	estimate	on	 the	number	of	participants	use	 in	published	
studies	 of	 the	 same	 nature,	 able	 to	 reject	 the	 null	 hypothesis	 in	 one	 or	 more	
voxels.	 Estimates	 of	 12	 to	 16	 subjects	 per	 group	have	been	used	 as	 a	 guide	 in	
fMRI	studies	(Desmond	and	Glover,	2002).	There	have	however	been	recent	calls	
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to	 make	 sample	 size	 calculations	 in	 fMRI	 studies	 more	 stringent	 (Guo	 et	 al.,	
2014).		
	
For	 this	 study	 a	 pragmatic	 approach	 based	 on	 the	 above	 literature	 was	 used.		
Sample	size	was	based	on	previous	successful	pain	fMRI	studies	and	an	estimate	
of	 new	 chemotherapy	 cases	 known	 to	 present	 in	 to	 the	 Edinburgh	 oncology	




In	 order	 to	 compare	 the	 brain	 function	 and	 structure	 of	 individual	 patients	 a	
number	 of	 data	 preparation	 steps	 need	 to	 be	 undertaken	 prior	 to	 statistical	
analysis.	An	overview	of	these	is	given	below.		
3.4.3.1	Brain	Extraction	
Extracting	 the	 brain	 data	 from	 images	 of	 the	 whole	 head	 (see	 figure	 3.6)	 is	
important	in	order	to	robustly	assess	both	structural	and	functional	changes	in	a	
standardised	 way.	 This	 is	 done	 because	 there	 is	 extensive	 variability	 in	 non-
brain	tissues	(skull,	subcutaneous	fat,	eyes),	which	may	bias	subsequent	analysis	
steps.	 In	 FSL	 this	 preprocessing	 step	 is	 performed	 using	 a	 tool	 called	 Brain	




















corresponds	 to	 a	 consistent	 anatomical	 point	 throughout	 the	 duration	 of	 the	
experiment.	 In	 FSL	 a	 tool	 called	 (MCFLIRT)(Jenkinson	 et	 al.,	 2002)	 is	 used	 to	
align	each	acquired	volume	to	a	single	reference	point	(for	this	study	the	middle	
volume).	This	allows	motion	parameters	to	be	extracted	from	the	experimental	
time	series.	These	can	be	 included	in	 later	analysis	as	repressors	of	no	 interest	
and	 are	 also	 summarised	 by	 FSL	 to	 enable	 assessment	 of	 participants	moving	













identification	of	 regions	 activated	during	 an	 fMRI	 experiment	 can	be	 achieved.	
Further	 to	be	able	 to	quantify	and	compare	activation	not	only	within	subjects	
but	also	between	subjects,	 individual	patients’	T1	structural	 images	need	 to	be	
registered	 to	a	standard	brain	 image.	This	enables	certainty	 that	 in	each	of	 the	
voxels	being	compared	the	same	part	of	the	anatomy	from	each	of	the	subjects’	
scans	at	different	time	points	is	present.		The	standard	brain	also	referred	to	as	a	









the	 two	 image	 types	 in	 an	 accurate	 manner	







These	 inconsistencies	 in	 the	 field	can	bias	 the	analysis	of	 fMRI	data	and	where	




2	Talairach	 Space	 is	 the	 original	 standard	 space,	 which	 supplied	 a	 coordinate	 system	 for	 the	
whole	brain.	This	reference	was	derived	from	mapping	a	hemisphere	of	one	post-mortem	brain.	
This	 was	 used	 for	 many	 years	 but	 has	 now	 been	 superseded	 by	 the	 MNI	 space	 and	 other	
population	applicable	MRI	derived	standard	spaces	(eg	for	infants	and	patient	groups).		
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These	were	 reorganised	 into	 two	 folders	 (magnitude	 and	 phase	 images)	 prior	
field	map	preparation,	which	was	done	using	a	tool	called	Fsl_prepare_fieldmap	
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FUGUE/Guide#Making_Fieldmap_Images_f





image	out	whilst	 leaving	 the	desired	 signal	 intact.	 Smoothing	using	 a	Gaussian	
filter	is	also	required	for	subsequent	thresholding	of	data	using	Gaussian	Random	
Field	Theory.	The	default	5mm	smoothing	available	in	FSL	was	used	throughout	





In	 addition	 to	 optimising	 the	 signal	 to	 noise	 ratio	 at	 any	 given	 volume	 the	
consideration	 of	 time	 is	 also	 required	 for	 functional	 data,	which	was	 acquired	
over	16	minutes	 in	 the	 case	of	 the	CIPN	study.	The	artefacts	which	 impact	 the	
data	 over	 time	 include	 low	 frequency	 drifts	 which	 are	 scanner	 related	 (e.g.	
heating	 effects)	 and	 high	 frequency	 noise	 which	 may,	 for	 instance	 be	
physiological	 noise	 related	 (cardiac	 and	 respiratory	 cycles).	Use	 of	 a	 high	pass	









As	 discussed	 above	 (1.1.3.3.2	 and	 3.1.3.2.1)	 in	 order	 to	 correct	 for	 the	
interference	 of	 heart	 and	 respiratory	 rate	 on	 BOLD	 signal,	 data	 on	 these	
variables	 needs	 to	 be	 collected.	 This	 data	 is	 then	 prepared	 using	 an	 FSL	 tool	
called	pnm_	prepare,	which	creates	repressors	which	can	be	used	in	the	set	up	of	
the	individual	subject	statistical	analysis	model	(Brooks	et	al.,	2008).	In	doing	so,	
the	 noise	 is	 regressed	 out	whist	 the	 signal	 of	 interest	 -often	 co-linear	 in	 some	
way,	 particularly	 in	 pain	 experiments-	 remains.	 For	 the	 CIPN	 study	 these	 data	
were	 collected.	 However	 due	 to	 time	 constraints,	 PNM	 regressors	 were	 not	
prepared	 or	 used	 in	 the	 final	model	 set	 up.	 In	 general	 physiological	 noise	was	
instead	removed	using	independent	component	analysis	(ICA)	and	FMRIB's	ICA-
based	Xnoiseifier	 (FIX)	 tool	 (see	 individual	 chapters	 for	 specific	methodology).	
Use	 of	 FIX	 instead	 of	 PNM	 for	 noise	 correction,	 has	 not	 yet	 formally	 been	
compared	 in	 the	 literature.	 It	 is	 possible	 that	 FIX	 leads	 to	 a	 more	 stringent	






Linear	 Optimized	 Decomposition	 into	 Independent	 Components	 (MELODIC)	 is	
the	 tool	 used	 for	 ICA	 in	 this	 thesis	
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/MELODIC).	 This	 analysis	 can	 be	 used	 for	
model	 free	 statistical	 inferences	 such	 as	 assessment	 of	 resting	 state	 networks	
(RSN).	 Additionally,	 ICA	 can	 be	 used	 to	 detect	 noise,	 which	 becomes	
distinguishable	from	signal	because	of	to	its	spatial	distribution	and	time	series	
frequencies.	 Noise	 may	 either	 be	 detected	 by	 manual	 inspection	 of	 the	






the	 data	 prior	 to	 analysis.	 It	 is	 possible	 to	 train	 FIX	 to	 detect	 specific	 ‘bad’	
components	 whilst	 ignoring	 others	 for	 a	 given	 population.	 Training	 FIX	 is	
relatively	 time	 consuming	 when	 long	 experimental	 acquisitions,	 containing	
many	 independent	 components,	 have	 been	 undertaken	 Alternatively,	 a	
standardised	classification	dataset	 for	use	with	FIX	also	exists.	For	this	thesis	a	
random	 set	 of	 classifications	 was	 compared	 between	 FIX’s	 standardised	





Independent Components (MELODIC, Version 3.12, part of FSL), was carried out for 
each subject.  After decomposition, data were de-noised by excluding those 
components clearly showing artifacts caused by head motion, physiological noise, 
misregistration, or signal fluctuations in cerebral spinal fluid.  At this stage 
component maps of one subject was deemed an outlier and excluded from further 
processing.  It possessed an abnormally high number of components, beyond what is 
suggested to be an empirically reasonable threshold of 50 components (25).   
 
In the second stage, group level analysis using a multi-session temporal concatenation 
approach as implemented in MELODIC was performed on the denoised components 
of twelve subjects.  After decomposition, components were visually inspected and the 
signals were mapped using the Talairach Atlas (26).  Components were then 
compared to those present in the current literature (6,7,27).  
V. Results 
F llowi g probabilistic ICA of the concatenated de-noised resting state data, 44 
component maps were identified.  17 of these component maps were attributed to 
noise (see Figure 1).  20 f the remaining 27 component maps d monstrate networks 
alrea y i entified in the current literature. These include the d fault m de (Fig. 2A), 
medial and lateral visual (Fig. 2B-C) networks, visuospatial (Fig. 2D), right and left 
frontoparietal attention (Fig. 2E-F), executive control (Fig 2G), and ensorimotor 
networks (Fig. 2H).  The 7 remaining component maps hav  not been described  e 
RSN literature (Figure 3 for compon nt maps, Table 1 for a list of activated regions).   
 
 
Figure 1. Examples of noise (A) Cerebrospinal fluid artifact (B) Non-neural 
physiological noise occurring at the brainstem (C) Head movement (D) 




demonstrates	 spatial	 maps	 showing	 noise-containing	 components.	
A=cerebrospinal	 fluid	 related	 artefact,	 B=	 physiological	 noise	 affecting	 brain	
stem	regions,	C=	movement	artefact,	D=	susceptibility	artefact	related	to	sinuses.	





Following	 the	 data	 preprocessing	 steps	 described	 above,	 each	 subject’s	
functional	data	was	assessed	using	a	general	 linear	modelling	(GLM)	approach.	
This	statistical	approach	aims	to	detect	voxels	or	clusters	of	voxels	activated	in	
response	 to	 the	 punctate	 stimuli	 and	 IAPS	 images	 presented	 during	 the	 CIPN	
study	experiment.	The	activation	is	compared	to	baseline.	Within	a	voxel	the	HRF	
(see	 1.1.3.2)	 is	 known	 to	 be	 slightly	 delayed	 in	 relation	 to	 actual	 neuronal	
activation	following	experimental	stimuli.	As	a	result,	within	FSL,	the	activation	
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curve	 (derived	 from	 the	 experimental	 events)	 is	 first	 convolved	with	 the	 HRF	
before	being	compared	to	the	actual	 functional	data.	The	goodness	of	 fit	of	 this	
expected	model	to	the	actual	data	is	summarised	as	a	parameter	estimate	(PE).	A	
PE	can	be	converted	to	a	t	statistic	by	dividing	it	by	its	standard	deviation.	The	t	
statistic	 can	 be	 further	 converted	 to	 a	 z	 statistic	 allowing	 for	 standardised	
comparison	within	 normal	 distributions.	 These	 z-scores	 are	 displayed	 at	 voxel	
level	 as	 maps	 and	 thresholded	 using	 Gaussian	 Random	 Field	 theory	 to	 depict	
clusters	of	voxels	activating	together,	thresholded	at	a	p<0.05.		
3.4.5	Second	Level	(Group)	Analysis	
In	order	 to	compare	groups	of	patients	 the	parameter	estimates	obtained	 from	
individual	 subject	 analysis	 are	 taken	 up	 to	 perform	 higher-level	 statistical	




level	 other	 factors	 possibly	 explaining	 variance	between	 groups,	 including	 sex,	




All	 statistical	 analyses	 were	 performed	 using	 SPSS	 version	 22.	 Statistical	
significance	 was	 taken	 as	 p	 ≤	 0.05.	 Where	 appropriate,	 if	 distribution	 of	 a	
variable	 was	 not	 normal,	 the	 median	 was	 used	 instead	 of	 the	 mean.	 	 Group	
means	 were	 compared	 using	 a	 two-sided	 t	 test	 (for	 normally	 distributed	
variables)	 and	 a	 Kolmogorov-Smirnov	 test	 (for	 variables	 with	 a	 skewed	
distribution)	as	 comparison	groups	always	contained	 less	 then	25	patients	per	
group.	 Categorical	 variables	were	 compared	using	Pearson’s	 chi	 square	 test	 or	
Fisher’s	 exact	 test	 when	 group	 size	 did	 not	 fulfil	 expected	 cell	 counts.	 Where	
possible,	95%	confidence	intervals	(CIs)	were	calculated	to	aid	in	interpretation	
of	 the	 results.	 Repeat	 measures	 ANOVA	 was	 used	 for	 subcortical	 structural	
volume	 analysis	 (see	 chp.4).	 In	 chp.5,	 %	 BOLD	 signal	 change	 in	 regions	 of	
interests	 (ROIs)	 was	 compared	 between	 the	 CIPN	 and	 non-CIPN	 groups	 using	
	 100	
independent	 sample	 t-tests	 and	 bootstrapping	 to	 correct	 for	 multiple	
comparisons	in	a	small	sample	size.		
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the	 CIPN	 study.	 Subcortical	 structures	 to	 be	 investigated	 were	 chosen	 a	 priori	
based	 on	 their	 known	 involvement	 in	 pain	 processing	 and	 pain	 vulnerability.	
Analysis	was	limited	to	four	regions;	the	amygdala,	brainstem,	nucleus	accumbens	
and	thalamus	in	order	to	minimise	statistical	bias	occurring	as	a	result	of	multiple	
comparisons.	 Analysis	 of	 the	 function	 of	 participant’s	 brains	 at	 rest,	 was	
undertaken	 to	 investigate	 whether	 there	 were	 any	 baseline	 differences	 in	 the	




Structural	 brain	 differences	 have	 been	 shown	 in	 both	 acute	 and	 chronic	 pain	
patients(Davis	and	Moayedi,	2012).	Structural	changes	in	brain	areas	known	to	
be	associated	with	pain	processing	including	the	anterior	cingulate	cortex;	insula	
and	 somatosensory	 cortex	 have	been	 reported.	 	However,	 perhaps	 the	 regions	
most	 frequently	 implicated	as	altered	 in	pain	states	 include	components	of	 the	
subcortical	 structures,	 such	 as	 the	 thalamus,	 caudate	 nucleus,	 nucleus	
accumbens	and	brainstem	(Barad	et	al.,	2013,	Kregel	et	al.,	2015).		
	












Postulated	 explanations	 for	 these	 differences	 in	 volume	 include	 neuronal	
reorganisation	 and	 central	 nervous	 system	 plasticity	 (Rodriguez-Raecke	 et	 al.,	
2013).	 	Evidence	shows	that	these	regions,	in	particular	the	nucleus	accumbens	
(NAc),	are	important	in	conversion	from	acute	to	chronic	pain	states	and	reflect	
individual	 vulnerability	 to	 chronic	 pain	 development	 (Denk	 et	 al.,	 2014).		
However,	 due	 to	 the	 difficulty	 in	 studying	 development	 of	 pain	 prospectively,	
little	 is	 known	 about	 any	 associations	 between	 subcortical	 structural	 brain	
regions	and	subsequent	pain	development.	Currently	only	one	longitudinal	study	




No	 previous	 prospective	 high-resolution	 neuroimaging	work	 has	 been	 done	 in	
CIPN.	It	is	therefore	currently	unclear	if	CIPN,	in	line	with	other	pain	conditions,	
is	 associated	 with	 any	 structural	 brain	 changes.	 Moreover,	 whether	 structural	
brain	changes	can	be	identified	prior	to	any	onset	of	peripheral	nerve	damage	is	




in	specific	 functional	 tasks	(chapter	5	 in	 this	 thesis).	Over	 the	 last	 two	decades	
however,	 attention	 has	 been	 turned	 to	 understanding	 the	 brain’s	 baseline	




underpin	 cognitive	 and	 perceptual	 processes	 (Cole	 et	 al.,	 2010).	 	 Some	 of	 the	
most	 frequently	 described	 networks	 include	 the	 default	 mode	 network,	 the	








et	 al.,	 2015).	Moreover,	 evidence	 of	 reversal	 of	 pain	 related	RSN	 changes	 after	
appropriate	analgesic	treatment	has	also	been	described	(Ceko	et	al.,	2015).		
	
In	 terms	 of	 cancer	 and	 chemotherapy,	 recent	 assessment	 of	 resting	 state	
networks	has	been	used	to	investigate	the	effects	of	chemotherapy	on	cognitive	
function	(Kesler,	2014).	The	mainstay	of	this	work	has	been	carried	out	in	breast	
cancer	 patients	 after	 chemotherapy	 treatment.	 Investigations	 have	 focused	 on	








1. Volumes	 of	 subcortical	 structures,	 specifically	 the	 thalamus,	 nucleus,	
accumbens,	 amygdala	 and	 brainstem,	 differ	 in	 patients	 who	 go	 on	 to	
develop	 CIPN	 as	 compared	 to	 those	 who	 do	 not	 develop	 CIPN,	 prior	 to	
peripheral	nerve	damage	with	chemotherapy.		
2. Resting	 state	 networks	 differ	 in	 patients	 who	 go	 on	 to	 develop	 CIPN	 as	





amygdala,	 brainstem)	 different	 between	 cancer	 patients	 who	 develop	
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CIPN	 and	 those	 who	 do	 not	 prior	 to	 peripheral	 nerve	 damage	 with	
chemotherapy?		










(see	 3.4.1.1).	 Images	 were	 then	 registered	 and	 segmented	 using	 FSL’s	 model	
based	 tool	 FIRST	 (Patenaude	 et	 al.,	 2011).	 FIRST	 registers	 the	 T1	 brain	
optimising	 the	 registration	 for	 the	 subcortical	 structures.	FIRST	 then	 segments	
all	subcortical	structures.	Following	segmentation	the	volumes	of	four	structures	
chosen	 a	 priori:	 thalamus,	 nucleus	 accumbens,	 amygdala	 and	 brainstem	 were	
measured	using	fslstats.	Structures	were	chosen	based	on	the	evidence	from	pain	





and	whole	brain	 volume	 (WBV),	 the	T1	brain	was	 segmented	using	FSL’s	 tool,	
FAST.	 Volumes	 for	 these	 were	 calculated	 using	 fslstats.	 All	 volumes	 were	
reviewed	prior	to	statistical	analysis.	One	subject	needed	to	be	removed	due	to	
an	 inappropriately	 small	 field	 of	 view	 (FVO),	 which	 prevented	 appropriate	






for	 bilateral	 structures	 (e.g.	 right	 and	 left	 amygdala)	 and	 a	 univariate	 general	
linear	model	was	used	to	analyse	the	brainstem.	These	approaches	were	decided	




Brian	 extraction	 was	 performed	 on	 the	 data	 as	 described	 above	 (3.4.1.1).	
Following	 this,	 independent	 component	 analysis	 (ICA)	using	FSL’s	Multivariate	
Exploratory	 Linear	 Optimized	 Decomposition	 into	 Independent	 Components	
(MELODIC)	 was	 carried	 out.	 Data	 was	 not	 denoised	 using	 FIX	 prior	 to	
concatenated	 ICA,	 as	 the	 stringent	 cleaning	 process	 used	 in	 FIX	 may	 have	
unwittingly	removed	signal	of	interest.	Components	were	reviewed	following	the	
ICA	run	in	order	to	a	priori	decipher	which	components	contained	only	noise	and	
which	 constituted	 signal	 of	 potential	 interest	 for	 further	 evaluation.	 Two	 ICA	
runs:	 one	 high	 dimensionality	 (60	 component	 restriction)	 and	 one	 low	
dimensionality	 (30	 component	 restriction)	 were	 carried	 out.	 This	 was	 done	
because	 restricting	 the	 data	 decomposition	 to	 fewer	 components	 is	 known	 to	
identify	 larger	 RSNs,	 while	 higher	 dimensionality	 decomposing	 more	 readily	
identifies	smaller	more	functionally	homogenous	regions	or	nodes.	In	view	of	the	
fact	 that	 RSNs	 have	 not	 been	 explored	 in	 the	 context	 of	 CIPN	 before,	 a	 broad	
hypothesis	related	to	difference	was	being	tested.	 	Consequently,	without	prior	
specification	of	whether	the	hypothesised	difference	was	expected	in	large	well-
described	 RSNs	 or	 smaller	 more	 discrete	 regions	 of	 these	 networks	 the	 two	




3	Although	 standard	 practice	 is	 to	 adjust	 structural	 volumes	 for	whole	 brain	 volume,	 it	 can	 be	
argued	 that	 this	 potentially	 masks	 biologically	 important	 differences.	 This	 is	 because	 all	
measured	volumes	reflect	glia	and	neuronal	content.	Adjusting	for	whole	brain	volume	assumes	
that	 differences	 in	 WBV	 are	 unimportant	 in	 terms	 of	 global	 brain	 wide	 pathophysiological	




dual	 regression	 step	 of	 the	 analysis.	 Equal	 numbers	 of	 patients	 from	 the	 CIPN	
and	 non	 CIPN	 groups	were	 chosen	 in	 order	 to	 avoid	 biases	 in	 the	 component	
maps	generated.	Eleven	randomly	chosen	individuals	per	group	were	decided	on	
to	 optimise	 sample	 size.	 	 Dual	 regression	 was	 carried	 out,	 using	 FSL’s	 dual	
regression	 tool,	 in	 order	 to	 average	 the	 component	 maps	 from	 each	 group	










sex,	 cancer	 operation	 and	 cancer	 type	 (collinear	 with	 chemotherapy	 type).	
Difference	 in	 baseline	 pain	 score	 was	 marginally	 statistically	 significant.	
Fig	 4.1	 Design	 Matrix	 for	 group	 comparison.	
Showing	 the	 number	 of	 inputs	 and	 the	 group	
classification	 (CIPN	 =	 1	 and	 No	 CIPN	 =0)	 of	 each.	
Design	 for	 testing	 two	 group	 difference	 with	 two-
























































Table	 4.1	 Demographic	 data	 for	 Non	 CIPN	 and	 CIPN	 groups	 included	 in	 the	
structural	analysis.	Mean	age	shown	in	table,	age	range	50-79yo.	For	cancer	type	
and	operation	%	refers	to	within	group	proportion.	Range	of	pain	score	shown	in	




Standard	masks	of	regions	segmented	 for	 this	analysis	are	shown	 in	 figure	4.2.	
The	 mean	 volumes	 for	 each	 group	 and	 the	 statistical	 comparison	 of	 these	
volumes	are	shown	in	table	4.2.	In	the	unadjusted	analysis	the	thalamus,	nucleus	
accumbens	 and	 grey	matter	 volume	were	different	 between	 the	CIPN	 and	non	
CIPN	 group.	 Following	 adjustment	 for	 whole	 brain	 volume	 the	 nucleus	






Figure	4.2	Structures	 segmented	 for	 subcortical	analysis.	All	structures	are	
derived	 from	 the	 Oxford	 Harvard	 Subcortical	 Atlas	 and	 are	 shown	 here	 in	
standard	space	(MNI152	2mm).	Yellow=brainstem,	red=	thalamus	right	and	left,	
blue=amygdala	 right	 and	 left,	 green	 =accumbens	 right	 and	 left.	 This	 atlas	 is	
based	on	T1-weighted	images	of	21	healthy	male	and	16	healthy	female	subjects	





Assessment	 of	 the	 repeated	 measures	 ANOVA	 results	 presented	 below,	
suggested	 that	 there	was	 variance	 in	 the	model	 introduced	 by	 the	 two	 factors	






































































Table	 4.2.	 Group	 differences	 in	 mean	 volumes.	 95%CI	 =	 95%	 confidence	










































































































































after	 adjustment	 for	 whole	 brain	 volume.	 Horizontal	 axis	 showing	 median	
volume.	Error	bars	represent	95%	confidence	intervals.	In	terms	of	size	of	effect,	
between	 group	 difference	 is	 small	 for	 all	 structures	 except	 for	 the	 nucleus	








Table	 4.3	 Exploration	 of	 the	 influence	 of	 laterality	 on	 the	 between	 group	
difference	 in	 volume	 of	 the	 nucleus	 accumbens.	 Analysis	 carried	 out	 using	 a	






Groups	were	matched	 in	terms	of	key	confounding	 factors	(table	4.4).	 	Prior	 to	
dual	 regression,	all	 component	maps	were	 reviewed	 for	both	 the	high	and	 low	


















































Table	 4.4	Demographic	data	 for	 the	No	CIPN	and	CIPN	groups	 included	 in	 the	
resting	state	analysis.	Mean	age	shown	 in	 table,	age	 range	50-79yo.	For	cancer	







Figure	 4.4a	 Examples	 of	 noise	 containing	 components.	 A=	 cerebrospinal	 fluid	
related	 noise.	 B=	 respiratory	 noise.	 C=	 movement	 artefact.	 D=	 susceptibility	






For	 the	 low	 dimensionality	 ICA	 run,	 a	 single	 component	 showed	 a	 significant	
difference	between	those	who	developed	CIPN	and	those	who	did	not	(p	=	0.04).	
This	was	 seen	 in	 a	 small	 region	 of	 the	 right	 somatosensory	 cortex	 of	 patients	





Figure 2. Components seen in the current literature: (A) default mode, (B) medial 
visual, (C) lateral visual, (D) visuospatial, (E) right frontoparietal attention, (F) left 
frontoparietal attention, (G) executive control, and (H) sensorimotor networks. 
 
 
Figure 3. Component maps 6, 8, 18, 23, 29, 31, and 33, which are not seen in the 























The	structural	analysis	 showed	 that	 the	volume	of	 the	nucleus	accumbens	was	
the	 only	 structure	 that	 differed	 significantly	 between	 the	 CIPN	 and	 non–CIPN	
group,	 after	 adjustment	 for	 whole	 brain	 volume;	 F	 (1,26)=10.4,	 p=0.02.	 The	
effect	 size	 of	 this	 result	was	moderate	 r=0.28.	 Exploration	 of	 the	 difference	 in	
influence	 of	 right	 and	 left	 showed	 the	 right	 accumbens	 to	 drive	 the	 variance	
between	 the	groups.	Assessment	of	other	 structures	 showed	 that	 the	 thalamus	




The	 resting	 state	 analysis	 is	 difficult	 to	 interpret.	High	 and	 low	dimensionality	
analysis	 yielded	 varied	 results.	 Low	 dimensionality	 dual	 regression	 showed	 a	
single	significant	difference	in	the	somatosensory	cortex	of	patients	who	did	not	
develop	 CIPN,	 likely	 a	 part	 of	 the	 larger	 sensorimotor	 network.	 The	 high	
dimensionality	 analysis,	 known	 to	 be	 more	 sensitive	 to	 differences	 in	
functionally	homogenous	regions	or	nodes,	yielded	a	greater	number	of	between	











The	 strengths	 of	 this	 experiment	 and	 analyses	 are	 as	 follows.	 Firstly,	 the	
prospective	 design	 of	 this	 study	 has	 enabled	 assessment	 of	 the	 association	 of	
baseline	variance	 in	 subcortical	 structures	and	 the	 subsequent	development	of	




risk	 individuals	 and	 preventative	 approaches’	 as	 compared	 to	 post	 damage	




In	 terms	 of	 the	 analyses;	 the	 statistical	 approach	 used	 for	 between	 group	
comparisons	of	 structural	volumes	(repeat	measures	ANOVA	with	 introduction	
of	whole	brain	as	a	covariate)	enabled	optimisation	of	power	for	group	sample	
size,	minimising	 the	possibility	of	 type	1	error.	Regarding	 the	 ICA	analysis;	 the	
decision	 to	 perform	 a	 high	 and	 a	 low	 dimensionality	 run	 optimised	 the	
investigation	 of	 the	 broad	 hypothesis	 being	 explored.	 This	 approach	 was	 also	
useful	in	determining	future	analysis	steps	for	these	data	(see	4.5.4).	
4.5.2.2	Limitations	
The	 limitations	of	 this	chapter	can	also	be	subdivided	 into	 those	related	 to	 the	
experimental	 design,	 and	 those	 related	 to	 the	 analyses.	 The	possible	 impact	 of	
design	 limitations	 including	 unknown	 confounding	 factors,	 and	 type	 1	 error	
related	 to	 sample	 size.	 In	 terms	 of	 the	 structural	 analysis	 two	main	 problems	
may	have	biased	results.	Firstly,	the	calculation	of	subcortical	structural	volume	
is	 heavily	 dependent	 on	 the	 quality	 of	 the	 registration	 of	 the	 individual	 T1	
images	 to	 standard	 space	 (see	 3.4.1.3).	 These	 were	 automated	 and	 quality	
checked	but	not	optimised	manually.	The	impact	of	imperfect	registration	would	
be	 a	 higher	 incidence	 of	 type	 2	 errors.	 Also	 although	 registration	 with	 FIRST	
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optimises	for	subcortical	volumes,	the	standard	space	template	it	registers	to	is	
MNI152.	 This	 template	 is	 derived	 from	 a	 healthy	 subject	 population.	 The	
applicability	 of	 this	 population	 to	 the	 CIPN	 study	 group	 is	 unknown.	 Evidence	
regarding	the	need	for	population	specific	brain	templates	has	been	suggested	in	
the	 neuroimaging	 literature	 (Mandal	 et	 al.,	 2012).	 Therefore,	 in	 terms	 of	 this	




of	 multiple	 comparisons	 needs	 to	 be	 considered.	 In	 a	 cohort	 of	 29	 patients	





In	 relation	 to	 the	 resting	 state	 network	 analysis,	 recent	 evidence	 in	 clinical	
populations	 suggests	 that	 de-noising	 data	 prior	 to	 ICA	 helps	 increase	 the	
reproducibility	of	clinical	findings,	by	having	a	standardised	approach	to	dealing	
with	 noise	 (Griffanti	 et	 al.,	 2016).	 This	was	 not	 done	 here	 as	 the	 analysis	was	
carried	out	 prior	 to	 this	 publication,	 and	may	be	 a	 limitation	of	 this	 approach.	
Further,	because	equal	numbers	of	participants	have	 to	be	 introduced	 into	 the	
dual	 regression,	 the	sample	size	 for	 this	analysis	was	 limited	 to	22	(eleven	per	
group),	which	may	have	resulted	in	the	analysis	being	insufficiently	powered	to	







The	 nucleus	 accumbens	 (NAc)	 finding	 corroborates	multiple	 lines	 of	 evidence	
from	both	human	and	 animal	 pain	 research.	 In	healthy	human	volunteers	NAc	
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involvement	 in	 processing	 noxious	 stimuli	 has	 been	 shown	 to	 reflect	 aversion	
and	 reward	 responses	 to	 pain	 (Becerra	 and	 Borsook,	 2008).	 	 In	 patient	
populations	 the	 volume	 and	 function	 of	 the	 NAc	 is	 altered	 in	 both	 acute	 and	
chronic	pain	(Baliki	et	al.,	2010).	Baliki	and	colleagues	also	report	changes	in	the	
connectivity	of	the	NAc	as	predictive	of	conversion	to	chronic	pain	states	(Baliki	
et	 al.,	 2012),	 a	 finding	 likely	 pertinent	 to	 future	 analysis	 related	 to	 CIPN	
chronicity	 (see	 4.5.4).	 The	 actual	 circuitry	 of	 the	NAc	 is	 complex	 (Baliki	 et	 al.,	









experimental	 animals.	Chang	and	colleagues’	 findings	are	 further	 supported	by	






such	 studies	 exist	 (Boland	 et	 al.,	 2014,	 Nudelman	 et	 al.,	 2015).	 Boland	 and	
colleagues	 investigate	 function	 in	a	group	of	12	chronic	CIPN	patients,	with	no	
mention	of	 structural	 changes	 in	 this	 group.	 In	 this	 study	 it	was	demonstrated	
that	patients	with	established	CIPN	had	distinct	changes	in	brain	pain	processing	
regions.	 In	 contrast,	 Nudelman	 and	 colleagues	 investigate	 structure	 and	
perfusion	in	a	longitudinal	study	of	breast	cancer	patients.	However	they	do	not	





Although	 no	 direct	 studies	 investigating	 RSNs	 in	 CIPN	 exist,	 a	 number	 of	 pain	
studies,	show	alterations	in	resting	state	connectivity	in	chronic	and	acute	pain	
states.	Specifically,	recent	work	in	fibromyalgia	has	reported	varied	default	mode	
network	 connectivity	 between	 the	 precuneous	 and	 cingulate	 regions	 to	 the	
thalamus	 in	 acute	 pain	 (Ichesco	 et	 al.,	 2016).	 	 More	 akin	 clinically	 to	 CIPN,	
studies	 in	 diabetic	 neuropathy	 (DN)	 have	 found	 that	 compared	 to	 matched	
controls,	patients	with	DN	had	altered	resting	state	connectivity	 in	areas	of	 the	
default	mode	 network	 including	 the	 precuneous,	 thalamus,	 brainstem	 regions,	
insula,	pre	and	postcentral	gyri	as	well	as	the	superior	frontal	gyrus	(Cauda	et	al.,	
2009).	 Another	 study	 investigating	 patients	 with	 acquired	 and	 hereditary	







of	 the	 results	 presented	 here,	 with	 existing	 animal	 and	 human	 work,	 gives	
credence	 to	 their	 likely	 importance.	 Specifically,	 the	 decreased	 volumes	 in	 the	
NAc	in	patients	who	go	onto	develop	acute	CIPN,	suggests	a	vulnerable	cohort	of	
patients	at	risk	of	CIPN	prior	to	nerve	damage	with	chemotherapy.	This	evidence	











is	 a	 possibility.	 For	 this	 to	 happen	 a	 longitudinal	 study	with	 a	 larger	 cohort	 is	





low	and	high	dimensionality	approach	to	this	analysis	 is	 that	 the	source	of	any	
between	 group	 differences,	 likely	 lies	 in	 the	 connectivity	 of	 functionally	
homogenous	regions	(‘nodes’)	as	opposed	to	large	network.		
	
Consequently,	 further	 analyses	 probing	 nodal	 connectivity	 specifically	 are	
warranted.	One	possibility	is	the	use	of	the	new	FSL	tool	FSLnets,	which	enables	






matched	 healthy	 volunteers	 is	 planned.	 The	 aim	 of	 this	 will	 be	 to	 ascertain	 if	
there	 are	 any	 baseline	 differences	 between	 the	 two	 groups,	 which	 may	 be	

















Key	 regions	 known	 to	modulate	 (inhibit	 and	 fascilitate)	 ascending	 nociception	
are	cumulatively	termed	the	descending	pain	modulatory	system	(DPMS).	They	
centre	on	a	network	of	 cortical	 and	brainstem	areas	which	 include,	 the	 rostral	
anterior	 cingulate,	 hypothalamus,	 amygdala,	 nucleus	 cuneiformis	 (NCF)	
mesencephalic	 pontine	 reticular	 formation	 (MPRF),	 rostro-ventral	 medulla	
(RVM)	and	periaqueductal	grey	 (PAG).	Function	and	 interconnectivity	between	
these	regions,	as	well	as	their	connectivity	to	areas	of	the	spinal	cord,	is	complex	
and	 an	 on-going	 area	 of	 research.	 RVM	 neurons	 directly	 project	 to	 the	 dorsal	
horn	 of	 the	 spinal	 cord.	 The	 RVM	 is	 in	 turn	 densely	 innervated	 by	 neurons	
arising	 from	 the	 PAG.	 Importantly,	 there	 is	 bidirectional	 processing	 of	 pain	 in	
this	region,	underpinned	by	the	existence	of	‘off	cells’	and	‘on	cells’	(Heinricher	et	
al.,	2009).	Off	cells	 inhibit	ascending	pain	and	enable	pain	tolerance	in	extreme	
conditions	 such	 as	 during	 sports	 injury	 or	 during	 physical	 combat.	 On	 cells	 in	




been	 documented	 in	 various	 pain	 states.	 Specifically,	 studies	 investigating	
osteoarthritis	 (Gwilym	 et	 al.,	 2009),	 chronic	 pelvic	 pain	 (Vincent	 et	 al.,	 2013),	
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fibromyalgia	 (Fallon	 et	 al.,	 2013),	 and	 experimentally	 central	 sensitisation	 in	
healthy	 humans	 (Lee	 et	 al.,	 2008)	 have	 shown	 changes	 in	 DMPS.	 Moreover,	
changes	in	regions	of	the	DPMS	are	thought	to	be	of	key	importance	in	conferring	
vulnerability	 for	 developing	 chronic	 pain	 (Denk	 et	 al.,	 2014).	 Human	 studies	
investigating	 DPMS	 in	 pain,	 have	 been	 strengthened	 by	 animal	models,	 which	
have	associated	maintenance	of	neuropathic	pain,	with	reversible	abnormalities	
in	these	pathways	(De	Felice	et	al.,	2011)	The	impact	of	DPMS	and	in	particular	




include	 the	 anterior	 cingulate	 cortex	 (ACC),	 dorsolateral	 prefrontal	 cortex	
(dlPFC),	 amygdala	 and	 hypothalamus.	 Activity	 in	 these	 regions	 and	 their	
connections	 to	 the	 brainstem	 areas	 discussed	 above,	 underpins	 the	 known	
cognitive	and	emotional	modulation	of	pain.	The	capacity	to	tolerate	greater	pain	
when	distracted,	in	particular	with	positive	emotional	input,	as	well	as	increased	
pain	 sensitivity	 during	 periods	 of	 negative	 affective	 experiences	 is	 well	
documented	 (Kamping	 et	 al.,	 2013,	 Fox	 et	 al.,	 2013,	 Wiech	 et	 al.,	 2008).	
Specifically	 in	neuropathic	pain,	positive	emotional	state	has	been	shown	to	be	
important	 in	pain	experience	and	response	 to	analgesic	 treatment	 (Petersen	et	
al.,	2014).	Whether	there	is	an	association	between	this	capacity	to	engage	with	
positive	emotion,	as	a	source	of	distraction	and	actual	development	of	pain	states	




cancer,	 prior	 to	 neurotoxic	 chemotherapy	 and	 its	 relationship	 to	 the	
development	 of	 CIPN	 has	 the	 potential	 to	 provide	 insight	 into	 the	 impact	 of	
engaging	 with	 positive	 emotional	 distraction	 on	 painful	 neuropathy.	 In	 effect,	












1. Are	 there	 differences	 in	 descending	 pain	 modulatory	 system	 between	
cancer	patients	who	develop	CIPN	and	those	who	do	not?		
2. Does	 the	 processing	 of	 affective	 images	 differ	 between	 cancer	 patients	





Standard	 data	 pre-processing	 (see	 3.4.1)	 including	 brain	 extraction,	 B0	
unwarping,	 motion	 correction,	 spatial	 smoothing,	 temporal	 filtering	 and	
registration	 to	 standard	 space	was	 undertaken.	 FSL’s	Multivariate	 Exploratory	
Linear	Optimized	Decomposition	into	Independent	Components	(MELODIC)	was	
used	 to	 perform	 ICA	 in	 order	 to	 assess	 noise	 in	 the	 data.	 Data	 de	 noising	was	
carried	out	using	FIX,	with	a	 standard	 training	data	 set	as	discussed	 in	3.4.1.7.	
The	two	research	questions	described	above	were	run	as	separate	analysis	and	
therefore	 the	 first	 and	 second	 level	 model	 set	 up	 is	 described	 separately	 for	
these	below.	From	here	on	in,	the	analysis	pertaining	to	question	one,	related	to	
descending	 pain-modulating	 system,	 will	 be	 referred	 to	 as	 the	 DPMS	 analysis.	
The	 analyses	 addressing	 question	 two,	 detailed	 above,	 and	 related	 to	 the	
influence	 of	 international	 affective	 images	 will	 be	 referred	 to	 as	 the	 IAPS	
analysis.	
5.3.1	Descending	Pain	Modulatory	System	(DPMS)	analysis	
The	 aim	 of	 this	 analysis	 was	 to	 assess	 how	 the	 brains	 of	 cancer	 patients	
processed	punctate	stimuli,	 if	and	how	this	processing	was	affected	by	viewing	
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images	with	emotional	content,	and	relating	 these	 findings	 to	subsequent	CIPN	
development.	 	Consequently,	 the	following	contrasts	of	 interest	where	included	
in	 the	 first	 level	model:	punctate	only	stimulus	 (snow	 image	viewed),	punctate	
during	 positive	 images,	 punctate	 during	 neutral	 images,	 neutral	 and	 positive	
images	 greater	 than	 snow,	 snow	 greater	 than	 neutral	 and	 positive,	 positive	
greater	 than	neutral,	 neutral	 greater	 than	positive,	 snow	greater	 than	positive,	
positive	greater	than	snow,	snow	greater	than	neutral	and	finally	neutral	greater	
than	 snow	 (figure	 5.1).	 Each	 first	 level	 contrast	 was	 cluster	 corrected	 and	
considered	significant	at	a	z	threshold	of	2.3	and	a	p	value	less	then	0.05.		
	
At	 the	 second	 level,	 all	 eleven	 corrected	 parameter	 estimates	 (COPEs)	 were	
introduced	and	a	mean	difference	between	 the	group	 that	developed	CIPN	and	
the	 group	 that	did	not	was	 assessed.	The	 group	 level	 analysis	was	undertaken	
using	a	mixed	effects	model	and	outlier	de-weighting.	The	model	was	corrected	









show	 modelled	 events:	 snow	 punctate,	 temporal	 derivative	 of	 latter,	 neutral	
punctate,	temporal	derivative	of	latter,	positive	punctate,	temporal	derivative	of	
latter,	 neutral	 image	 block,	 temporal	 derivative	 of	 latter,	 positive	 image	 block,	





decided	 on	 a	priori.	 These	were	 chosen	 based	 on	 their	 known	 involvement	 in	
descending	 pain	 inhibition	 and	 included:	 the	 RVM,	MPRF,	 PAG,	 and	 Thalamus.	
ROIs	were	 analysed	using	 FSL’s	 Featquery	 tool	 to	 extract	 percent	BOLD	 signal	
change	from	each	region.	Regions	were	defined	using	masks	drawn	in	standard	
space	and	made	available	from	the	FMRIB	pain	group.	Masks	were	functionally	
defined	and	are	detailed	 in	 the	published	 literature,	amongst	others	(Lee	et	al.,	
2008,	 Vincent	 et	 al.,	 2011).	 ROIs	were	 compared	 using	 the	whole	 dataset	 and	
also	 the	 dataset	 split	 by	 sex.	 The	 sex	 split	was	 based	 on	 known	differences	 in	
pain	processing	between	males	and	females	(Bartley	and	Fillingim,	2013).	CIPN	
and	 non-CIPN	 groups	were	 compared	 using	 an	 independent	 sample	 t	 test	 and	
considered	 significant	 at	 p<0.05.	 To	 correct	 for	 possible	 bias	 induced	 by	 low	
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Figure	 5.2	 Second	 Level	 Design	 Matrix.	 Columns	 from	 right	 to	 left	 show	 the	
exploratory	 variables	 modelled:	 firstly,	 the	 two	 variables	 of	 interest:	 No	 CIPN	
and	 CIPN,	 and	 then	 known	 confounding	 variables	 included	 as	 contrasts	 of	 no	






impact	 of	 emotional	 processing	 on	 the	 DPMS	 when	 punctate	 stimuli	 were	
presented.	 Secondly,	 to	 assess	 if	 there	 were	 any	 differences	 in	 processing	 the	
emotional	content	between	patients	who	developed	CIPN	and	those	who	did	not.	
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Therefore,	 the	 following	 contrasts	 of	 interest	 were	 included	 in	 the	 first	 level	
model:	snow	images,	neutral	images,	positive	images,	snow	greater	than	neutral,	









of	 punctate	 stimuli	 occurring	 during	 snow	 images,	 temporal	 derivative	 of	 the	
latter,	 timing	 of	 punctate	 stimuli	 occurring	 during	 positive	 images,	 temporal	




The	 second	 level	model	 included	all	 twelve	COPEs	 from	 the	 first	 level	 for	each	








to	 chemotherapy	due	 to	morbidity	 in	another.	This	analysis	 therefore	 included	



















































Table	 5.1	 Demographic	 data	 for	 the	 Non	 CIPN	 and	 CIPN	 groups.	 Mean	 age	





There	were	 no	 significant	 results	 surviving	 cluster	 correction	 of	 z=2.3	 for	 any	
contrast.	When	the	z	threshold	was	decreased	to	z=2,	the	contrast	 for	punctate	
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stimuli	 presented	 during	 positive	 images	 (contrast	 2)	 showed	 significantly	
greater	activation	in	the	posterior	division	of	the	right	superior	frontal	gyrus	in	







the	posterior	division	of	 the	 superior	 frontal	 gyrus	 significantly	more	active	 in	
the	 no	 CIPN	 group.	 Image	 coordinates:	 x36,	 y68,	 z66.	 R	 =	 right,	 L=	 left,	 S=	




Exploration	 of	 non-cluster	 corrected	 z	 statistics,	 thresholded	 at	 z=2.3,	 showed	
DPMS	 brainstem	 activation	 in	 both	 the	 CIPN	 and	 non	 CIPN	 group,	 when	
presented	with	punctate	stimuli	alone	(i.e.	viewing	snow	images).	Patients	who	




Figure	 5.5	 Cluster	 uncorrected	 z-statistic	 summary.	 P<0.05	 Rows	 from	 top	 to	
bottom	showing	activation	in	response	to	punctate	stimuli	only,	punctate	during	
positive	 IAPS	 and	 punctate	 during	 neutral	 IAPS	 respectively.	 Patients	who	 did	
not	develop	CIPN	as	compared	to	those	who	did	develop	CIPN	had	activation	in:	
the	 thalamus	 during	 punctate	 only	 stimuli,	 nuclei	 of	 the	 MPRF	 when	 viewing	
emotionally	 positive	 images	 and	 receiving	 punctate	 stimuli,	 and	 right	 lingal	
gyrus,	 parahippocampus,	 insula	 cortex	 and	 precentral	 gyrus	 when	 viewing	
emotionally	 neutral	 images	 during	 punctate	 stimuli.	 Patients	 who	 developed	
CIPN	 as	 compared	 to	 those	 who	 did	 not,	 showed	 activation	 in	 the	 MPRF	 and	
cerebellum	 during	 punctate	 only	 stimulus,	 right	 hippocampus	 and	 left	
insula/operculum	 during	 positive	 images	 and	 punctate	 stimulus,	 and	 PAG,	 left	




Whole	 group	 ROI	 comparison	 did	 not	 yield	 any	 statistically	 significant	
differences	 in	 BOLD	 signal	 change	 between	 patients	who	 developed	 CIPN	 and	
those	 who	 did	 not.	When	 the	 group	 was	 split	 by	 sex,	 females	 who	 developed	


























MPRF	 -0.03	 0.04	 -0.07	 		p=0.04*	
L	RVM	 -0.04	 0.03	 -0.08	 p=0.11	
R	RVM	 -0.03	 0.07	 -0.10	 p=0.17	
PAG	 0.04	 0.06	 -0.02	 p=0.75	
L	Thalamus	 -0.003	 0.05	 -0.05	 p=0.13	
R	Thalamus	 0.012	 0.05	 -0.03	 p=0.19	
Table	 5.2	 Summary	 of	 mean	 signal	 change	 in	 regions	 of	 interest	 in	 females.	
MPRF=	mesencephalic	pontine	reticular	formation,	L	=left,	R=	right,	RVM=	rostra	

















MPRF	 0.02	 -0.04	 0.07	 p=0.11	
L	RVM	 0.03	 -0.02	 0.06	 p=0.38	
R	RVM	 0.02	 -0.01	 0.04	 p=0.44	
PAG	 0.008	 -0.08	 0.09	 p=0.18	
L	Thalamus	 0.04	 -0.07	 0.11	 		p=0.03*	
R	Thalamus	 0.03	 -0.06	 0.09	 p=0.05	
Table	5.3	Summary	of	mean	signal	change	in	regions	of	interest	in	males.	MPRF=	
mesencephalic	 pontine	 reticular	 formation,	 L	 =left,	 R=	 right,	 RVM=	 rostra	








in	 patients	 who	 did	 not	 develop	 CIPN	 (fig	 5.6).	 This	 group	 also	 had	 more	
activation	 in	 the	 left	 inferior	 temporal	 lobe	 particularly	 the	 temporal	 fusiform	
cortex	 abutting	 the	 parahippocampus	 when	 viewing	 positive	 images	 over	 any	




Figure	 5.6.	 Statistically	 significant	activity	 in	 response	 to	viewing	positive	and	
neutral	 images	 in	 patients	 who	 did	 not	 develop	 CIPN.	 Activation	 to	 positive	
images	 is	 depicted	 in	 light	 blue,	 this	 overlays	 an	 almost	 identical	 area	 of	








over	 both	 neutral	 and	 snow	 images	 (p>s+n),	 in	 patients	 who	 do	 not	 develop	







showed	 significantly	 more	 activation	 in	 the	 posterior	 division	 of	 the	 right	
superior	 frontal	 gyrus,	 in	 those	 who	 did	 not	 developed	 CIPN	 as	 compared	 to	
those	who	 did.	 No	 other	 activation	 survived	whole	 brain	 analysis	with	 cluster	
correction.	Review	of	raw	z	statistics	showed	some	suggestion	of	differences	in	




ROI	 analysis	 for	 the	 whole	 group	 did	 not	 yield	 differences	 between	 CIPN	 and	
non-	 CIPN	 patients.	 However,	 when	 the	 group	was	 split	 by	 sex,	male	 patients	







anticipated	 there	was	 no	 difference	 in	 the	way	 the	 snow	 images	 activated	 the	
brains	of	patients.	Snow	images	served	as	the	holding	baseline	in	the	experiment	
and	were	 expected	 to	 have	 the	 same	 impact	 on	 both	 groups.	 Images	 that	 had	








A	key	strength	of	 these	 findings,	as	discussed	previously	(see	4.5.2.1),	 relate	 to	
the	 prospective	 design	 of	 the	 CIPN	 study.	 This	 allowed	 patients	 to	 control	 for	
each	 other	 within	 the	 study	 cohort	 in	 terms	 of	 effects	 of	 cancer	 and	
chemotherapy.	 Moreover,	 in	 terms	 of	 this	 analysis	 the	 fMRI	 experimental	
paradigm	was	 hypothesis	 driven	 and	 based	 on	 strong	 pre-existing	 animal	 and	
human	 literature,	 which	 has	 clear	 evidence	 of	 aberrance	 in	 DPMS	 in	 terms	 of	
pain	vulnerability.		
5.5.2.2	Limitations	





differences	 found	 in	 the	 ROI	 analysis	 when	 the	 group	 was	 split	 by	 gender.	
Additionally,	the	stringent	approach	to	data	cleaning	with	FIX	may	have	removed	




In	 terms	 of	 experimental	 protocol	 a	 key	 oversight	 was	 the	 failure	 to	 take	
sharpness	 ratings	 following	 punctate	 stimuli	 from	 all	 participants	 during	 the	
scan.	Also	valence	ratings	for	IAPS	exist	and	these	were	not	cross	checked	with	
patients	 recruited	 to	 this	 study.	 FMRI	 data	 should	 always	 be	 related	 to	
behavioural	 measures	 to	 aid	 interpretation	 and	 the	 lack	 of	 this	 possibility	 in	
relation	 to	 sharpness	 ratings	 and	 emotional	 valance	 may	 have	 limited	 this	
analysis.	 Finally,	 the	 possible	 impact	 of	 unknown	 confounding	 factors	 should	
always	 be	 considered	 in	 observational	 studies	 and	 is	 listed	 here	 as	 a	 possible	






The	 superior	 frontal	 gyrus	 (SFG)	 has	 recently	 been	 divided	 into	 three	 distinct	
functional	 regions	 (Li	 et	 al.,	 2013).	 The	 posterior	 division,	 activated	 here	 in	
patients	 who	 do	 not	 develop	 CIPN,	 has	 been	 shown	 to	 be	 involved	 in	 the	
reappraisal	of	negative	emotional	stimuli	(Falquez	et	al.,	2014)	and	shown	to	be	
connected	to	aspects	of	the	descending	pain	modulation	system	(Li	et	al.,	2013).	
More	 specifically	 in	 terms	 of	 pain,	 the	 SFG	has	 been	 implicated	 in	 deciphering	
mismatch	between	expected	and	actual	pain	(Ploghaus	et	al.,	2000).	SFG	activity	
has	 also	 been	 demonstrated	 in	 revaluation	 of	 painful	 stimuli,	 and	 related	 to	
emotional	 modulation	 of	 pain	 (Cheng	 et	 al.,	 2007).	 Kong	 and	 colleagues	
associated	 activation	 in	 the	 SFG,	 among	 other	 regions	 as	 important	 in	 the	
cognitive	 aspect	 of	 pain	 encoding	 (Kong	 et	 al.,	 2006).	 Moreover,	 experimental	
models	 of	 pain	 learning	 and	 adaptation,	 connectivity	 between	 the	 anterior	
insular	 cortex	 and	 SFG	 was	 shown	 to	 vary	 between	 direct	 and	 indirect	 pain	
experiences	 (Fan	 et	 al.,	 2016).	 Recent	 review	 of	 grey	 matter	 anomalies	 in	
neuropathic	pain	 states,	has	 reported	 the	 right	SFG	as	one	of	 the	 regions	most	
frequently	showing	decreased	volume	in	neuropathic	pain	(Pan	et	al.,	2015).	
	
The	MPRF	 is	 composed	of	 a	number	of	 brainstem	nuclei	 including	 the	nucleus	
cuneiformis	and	dorsal	 reticular	nucleus.	Similarly	 to	 the	RVM	these	nuclei	are	
known	to	contain	both	‘on	cells’	and	‘off	cells’,	responsible	for	the	facilitation	and	
inhibition	 of	 ascending	 nociception.	 The	MPRF	 is	 known	 to	 be	 involved	 in	 the	
expression	 of	 opioid	 induced	 hyperalgesia	 in	 healthy	 humans	 with	 a	 role	 in	
propagating	 perception	 of	 central	 sensitisation	 (Wanigasekera	 et	 al.,	 2011).	
Although	 there	 is	 no	 previous	 evidence	 of	 gender	 based	 differences	 in	 MPRF	
activity,	varied	RVM	activity,	related	to	MPRF	architecture	in	terms	of	presence	
of	‘on’	and	‘off’	cell	function,	has	been	demonstrated	in	women	with	low	estrodiol	
states	 (Vincent	 et	 al.,	 2013).	 Although	 Vincent	 et	 al’s	 findings	 were	 in	 a	
premenopausal	cohort	of	women	compared	 to	 those	studied	here.	Mechanisms	





with	 brainstem	 DPMS,	 in	 particular	 the	 PAG	 (Wu	 et	 al.,	 2014).	 Moreover,	 the	
thalamus	 has	 strong	 resting	 state	 connectivity	 with	 all	 three	 divisions	 of	 the	





pain	 models	 has	 also	 shown	 desensitisation	 of	 mu-opioid	 receptors	 in	 the	
thalamus	(Hoot	et	al.,	2011).	Importantly,	contralateral	thalamic	depression	has	
been	deemed	as	one	of	the	most	consistent	findings	in	neuropathic	pain	studies	
(Garcia-Larrea	 and	 Peyron,	 2013).	 Although	 there	 appears	 to	 be	 no	 previous	
evidence	 of	 gender	 specific	 decrease	 in	 thalamic	 activity	 in	 neuropathy,	 the	
evidence	 related	 to	 thalamic	 hypoactivity	 in	 neuropathy	 supports	 the	 finding	
presented	here.	
	
As	 previously	 discussed	 (see	 4.5.3),	 there	 are	 limited	 brain	 imaging	 studies	
relating	 CIPN	 to	 brain	 function.	 Interestingly	 however,	 the	 two	 existing	 CIPN	
fMRI	studies	both	report	alterations	in	the	right	superior	frontal	gyrus.	Boland	et	
al	 investigating	 chronic	 CIPN,	 reported	 decreased	 BOLD	 signal	 activity	 during	
heat	pain	in	the	superior	frontal	gyrus	in	chronic	CIPN	patients	as	compared	to	
healthy	 controls	 (Boland	 et	 al.,	 2014).	 This	 study	 did	 not	 report	 any	 altered	
activity	 in	 the	 thalamus	 or	 MPRF,	 but	 did	 note	 alterations	 in	 insula	 activity;	






studies	 (Aldhafeeri	 et	 al.,	 2012,	 Britton	 et	 al.,	 2006).	 Positive	 IAPS	 have	 been	
shown	 to	 activate	 the	 prefrontal	 cortex,	 superior,	 medial	 and	 middle	 frontal	
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gyrus,	 the	 anterior	 cingulate	 cortex	 and	 the	 temporal	 lobe	 bilaterally.	 These	
support	 the	 regions	 identified	 here	 in	 patients	 who	 did	 not	 develop	 CIPN.	
Processing	 of	 positive	 emotional	 content	 has	 been	 associated	 with	 emotional	











As	 hypothesised,	 pain	 modulation	 as	 well	 as	 engagement	 with	 IAPS	 images,	
differed	 between	 patients	 who	 did	 not	 develop	 CIPN	 and	 those	 who	 did.	 The	
finding	of	greater	 functional	activity	 in	the	posterior	division	of	 the	SFG	during	
positive	images	in	patients	who	did	not	get	CIPN	may	be	tentatively	interpreted	
as	a	capacity	in	this	group	to	reappraise	the	negative	punctate	stimulus.	Whether	
this	 reappraisal	 constitutes	 interaction	 of	 the	 SFG	 with	 brainstem	 inhibitory	
regions	 requires	 further	 investigation.	 Future	 connectivity	 analysis	 of	 these	
regions	 is	 planned,	 and	 was	 not	 undertaken	 for	 this	 thesis	 due	 to	 time	
constraints.		
	
Further,	 the	 varied	 engagement	with	 images	 between	 the	 non	 CIPN	 and	 CIPN	
group,	which	showed	the	same	directionality	as	the	SFG	finding	(No	CIPN	group>	
CIPN),	strengthens	the	proposed	interpretation	that	the	non	CIPN	patients	had	a	
capacity	 to	 engage	 cognitive	 modulatory	 influences	 during	 the	 presented	
punctate	stimuli.	Based	on	previously	cited	literature,	it	would	appear	that	this	is	
an	 innate	 ability.	 It	 is	 proposed	 here	 that	 lack	 of	 engagement	 in	 those	 who	








in	 male	 patients	 who	 develop	 CIPN,	 corroborates	 with	 published	 literature	
reporting	 decreased	 thalamic	 function	 and	 connectivity	 in	 neuropathic	 pain	
states.	Similarly	 the	 increased	MPRF	BOLD	signal	 in	women	who	develop	CIPN	
fits	 with	 the	 described	 permissive	 influence	 of	 this	 region	 on	 central	
sensitisation.	 The	 exact	 impact	 of	 ‘on’	 and	 ‘off’	 cells	 in	 this	 area	 needs	 further	
elucidation,	 as	 activity	 in	 both	 would	 result	 in	 the	 statistically	 significant	
increase	 in	 BOLD	 signal	 identified	 in	 the	 analysis.	 However,	 in	 view	 of	 the	
association	 of	 increased	MPRF	 signal	 and	 subsequent	 CIPN	 development,	 it	 is	
possible	 to	postulate	 that	 ‘on’	 cell	activity	predominates,	allowing	a	permissive	
central	 perception	 of	 subsequent	 chemotherapy	 induced	 peripheral	 nerve	
damage.		
	
The	 sex	difference	 suggested	by	 the	ROI	 analysis	 needs	 further	 exploration.	 In	
the	 first	 instance	 a	 whole	 brain	 analysis	 divided	 by	 sex	 is	 planned.	 Secondly,	
more	 detailed	 investigation	 of	 the	 possible	 impact	 of	 gender	 on	 CIPN	
development	 in	 general	 is	 likely	 warranted.	 In	 particular,	 exploration	 of	 the	
influence	 of	 sex	 hormones	 may	 be	 useful.	 In	 this	 study	 salivary	 testosterone	
levels	 were	 tested	 at	 the	 time	 of	 the	 scan.	 These	 yielded	 some	 moderate	
correlations	with	ROI	activity,	which	needs	further	exploration	(see	appendix	G	
for	 further	 discussion).	 Finally,	 how	 these	 findings	 relate	 to	 chronification	 of	
CIPN	remains	to	be	determines	once	long	term	follow	up	data	is	obtained.	
	
In	 summary,	 taken	 together	 this	 analysis	 implies	differences	 in	 the	descending	
pain	modulatory	system	between	patients	who	develop	CIPN	and	those	who	do	
not.	 Specifically,	 it	 appears	 that	 key	 regions	 associated	 with	 top	 down	 pain	
modulation,	including	the	thalamus	and	MPRF	have	altered	activity	in	those	who	
progress	 to	 CIPN,	 at	 baseline	 prior	 to	 peripheral	 nerve	 damage	 and	 clinically	
significant	 pain.	 Additionally,	 response	 to	 positive	 emotional	 images	 and	 the	
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capacity	 to	reappraise	punctate	stimuli	while	viewing	 these	 images	also	differs	
between	 those	 who	 develop	 CIPN	 and	 those	 who	 did	 not.	 Although	 further	
investigation	is	needed,	this	analysis	provides	evidence	of	aberrance	in	key	pain-
processing	 regions	 in	 the	 brain	 prior	 to	 peripheral	 nerve	 damage	 with	





















anticonvulsants,	 which	 often	 have	 intolerable	 side	 effects	 (Smith	 et	 al.,	 2013,	
Manji,	 2011).	 	 The	 only	 effective	 long-term	 option	 in	 severe	 CIPN	 is	
chemotherapy	 cessation.	 These	 measures	 have	 obvious	 negative	 impact	 on	
patient	 morbidity	 and	 mortality.	 Moreover	 dose	 reduction	 may	 not	 improve	
established	CIPN	(Albers	James	et	al.,	2011).		
	
Assessment	 of	 new	 analgesics	 for	 CIPN	patients	 is	marred	with	 the	 difficulties	
that	 affect	 all	 analgesic	 randomised	 controlled	 trials	 (RCTs)(Dworkin	 et	 al.,	
2010).	 Specifically,	 the	 subjective	nature	of	pain	 and	 the	 influence	of	 an	 active	
placebo	 response,	 results	 in	 analgesic	 RCTs	 often	 describing	 small	 effect	 sizes,	
difficult	 to	 interpret	clinically	 (Quessy	and	Rowbotham,	2008).	 In	particular,	 in	
patients	with	 CIPN,	 the	 varied	 individual	 experiences	 of	 neuropathic	 pain,	 not	
easy	 to	 standardise	 clinically	 or	 with	 QST,	 make	 the	 assessment	 of	 new	
analgesics	particularly	difficult	(Maier	et	al.,	2010,	Attal	et	al.,	2011).		
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The	 advent	 of	 fMRI	 as	 a	 research	 tool,	 with	 its	 ability	 to	 detect	 established	
behavioural	 changes,	 has	 greatly	 aided	 in	 unravelling	 neuropathic	 pain	




Most	 recently	 it	 has	 been	 shown	 to	 provide	 useful	 outcome	 measures	 in	
analgesic	 drug	 studies	 (Wanigasekera	 et	 al.,	 2016).	 	 Guidelines	 aiming	 to	
standardise	 the	 implementation	 of	 fMRI	 in	 drug	 trials	 have	 been	 published	
(Schwarz	et	al.,	2011).		
	
To	date	 fMRI	has	not	 been	utilised	 to	 assess	CIPN	 treatment.	 In	 the	 context	 of	
CIPN	where	 treatment	options	are	 lacking	and	new	analgesic	 trials	continue	 to	
report	 negative	 results,	 a	 novel	 approach	 to	 assessing	 potential	 analgesic	
treatment	 seems	 prudent	 (Hershman	 et	 al.,	 2014,	 Gewandter	 et	 al.,	 2014).	 In	
view	 of	 this	 the	 aim	 here	 was	 to	 explore	 the	 feasibility	 and	 usefulness	 of	




Cool	 sensitive	 transient	 receptor	 potential	 melastatin	 (TRPM8)	 channels	 were	
identified	as	a	novel	target	for	neuropathic	pain/dysaesthesia	relief	some	years	
ago(Proudfoot	et	al.,	2006).	Activation	of	these	channels	results	in	recruitment	of	
a	 central	 inhibitory	 loop	 within	 the	 spinal	 cord,	 involving	 metabotropic	





of	 concept	 (PoC)	 study	 using	 menthol	 1%,	 which	 showed	 marked	 clinical	
improvement	 in	 82%	 of	 participants	 (Colvin	 et	 al.,	 2008)	 (Fallon	 et	 al.,	 2015).	
Topical	application	of	 levomenthol	can	initially	be	associated	with	skin	cooling.	
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The	 Menthol	 IN	 Treatment	 (MINT3)	 of	 chemotherapy	 induced	 peripheral	
neuropathy	 fMRI	study,	 is	a	single	centre	randomised,	double	blind,	controlled,	
exploratory	 study	 of	menthol	 gel	 versus	 placebo	 gel.	 Treatment	 allocation	 is	 a	
1:1	ratio.	The	study	is	sponsored	by	the	Academic	and	Clinical	Central	Office	for	
Research	 and	 Development	 (ACCORD)	 for	 NHS	 Lothian	 and	 the	 University	 of	
Edinburgh	 and	 co-ordinated	 by	 the	Edinburgh	Clinical	 Trials	Unit	 (ECTU).	 The	
trial	will	be	conducted	in	accordance	with	the	Declaration	of	Helsinki	and	Good	
Clinical	 Practice.	 The	 study	 has	 been	 registered	 on	 the	 International	
Standardised	 Randomised	 Controlled	 Trials	 Registry	 (ISRCTN:	 69917256)	 and	









	1)	 determine	 the	 cool	 temperature	 range	 causing	 discomfort	 to	 CIPN	patients	
using	a	non	invasive	skin	thermometer,		
2)	 assess	 the	 degree	 to	 which	 3%	 menthol	 gel	 cools	 the	 patient’s	 skin	 on	
application,		
3)	evaluate	 the	 safety	of	menthol	gel	 application	 (assessed	by	no	worsening	of	
pain	and	monitoring	of	unexpected	symptoms/signs).	
	
Therefore,	 the	 primary	 trial	 end	 point	 is	 to	 determine	 if	 there	 is	 an	 analgesic	
effect	of	menthol	which	 is	distinguished	 from	placebo	effects,	using	diminished	





CIPN	 patients	 using	 a	 non	 invasive	 skin	 thermometer	 and	 standardized	 QST	
testing.		





Patients	with	 CIPN	 attending	 the	 palliative	 and	 supportive	 clinic	will	 form	 the	
pool	of	potentially	 suitable	 study	patients.	 Suitable	patients	have	 their	medical	







b) Patients	 have	 experienced	 post	 treatment	 Chemotherapy	 Induced	
Peripheral	Neuropathy	(CIPN)	pain	for	a	minimum	of	3	months.	







g) Patients	 have	 the	 ability	 to	 complete	 questionnaire	 assessments	 in	 the	
English	language.	
h) In	 the	 opinion	 of	 the	 investigator,	 the	 patient	 is	 able	 to	 complete	 the	
various	assessments.	




a) Preexisting	 or	 history	 of	 peripheral	 neuropathy	 due	 to	 any	 cause	 other	
than	chemotherapy	(diabetes,	alcohol,	toxin,	hereditary,	etc.).	
b) Patients	 with	 any	 contraindication	 to	 the	 use	 of	 topical	 therapy	 or	
menthol.	








g) In	the	opinion	of	 the	Research	Team	or	their	usual	medical	 team,	would	
be	unable	to	complete	the	study	protocol	for	any	other	reason.	
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h) Current	 treatment	 of	 ≤	 30	 days	 duration	with	 anticonvulsants,	 tricyclic	
antidepressants,	 MAO	 inhibitor,	 or	 other	 neuropathic	 pain	 medication	
agents	 such	 as	 carbamazepine,	 phenytoin,	 valproic	 acid,	 gabapentin,	
lamotrigine	or	amifostine.	(If	on	a	stable	dose	of	any	of	these	medications	
for	>31	days,	patients	will	be	asked	to	continue	these	for	the	duration	of	




interfere	 with	 application	 of	 the	 menthol	 cream	 and	 potentially	 study	
outcome).	
j) Other	 medical	 conditions,	 which	 in	 the	 opinion	 of	 the	 treating	
physician/allied	 health	 professional	 would	 make	 this	 protocol	
unreasonably	hazardous	for	the	patient.	




The	 trial	 will	 be	 conducted	 in	 NHS	 Lothian	 palliative	 care/	 oncology.	 The	
patient's	direct	clinical	care	team	will	approach	the	patient	in	the	first	instance.	
From	this,	potential	patients	will	be	identified.	At	this	point	further	screening	for	
full	 eligibility	will	 take	place.	 If	 patients	 are	 eligible	 and	give	written	 informed	
consent	 they	 will	 undergo	 the	 baseline	 fMRI	 scan	 at	 the	 Clinical	 Research	
Imaging	Centre	(CRIC)	 in	Edinburgh.	Following	the	scan	(either	on	the	same	or	
next	 day)	 patients	 will	 be	 seen	 at	 the	 Edinburgh	 Cancer	 Research	 UK	 (CRUK)	
Centre,	where	they	will	undergo	other	baseline	assessments,	randomization	and	
receive	 the	 study	medication	along	with	 instructions	 regarding	gel	 application.	
Patients	will	undergo	safety	assessments	weekly.	This	will	involve	a	study	nurse	
calling	the	patient	and	completing	the	side	effects	questionnaire	over	the	phone.	









gel,	 using	 random	 permuted	 blocks	 of	 length	 four4.	 Randomisation	 will	 be	
carried	 out	 at	 the	 Edinburgh	 Clinical	 Trials	 Unit	 (ECTU),	 allowing	 researchers	
and	 participants	 to	 remain	 blinded	 to	 treatment	 allocation.	 Treatment	 will	 be	




























4 Random permuted blocks are blocks of different sizes used to select which study arm the given 
participant will go into. Use of blocking for randomisation ensures that the resulting treatment groups 
are balanced within the study. The size of the next block is randomly chosen from the available block 











Screening	 x	 	 	 	
Consent	 	 x	 	 	
Hx	&	Examination	 	 x	 	 	
Weight	 	 x	 	 	








	 x	 	 	
National	Adult	Reading	
Test	(NART)	




	 x	 x	 x	
Brief	Pain	Inventory	
(BPI)	




	 	 	 	
Quantitative	Sensory	
Testing	(QST)	
	 x	 x	 x	
SKIN	TEMP	 	 x	 	 	
CIPN20	Questionnaire	 	 x	 x	 x	
FMRI	 	 x	 x	 	





patient	codes,	 this	will	enable	 the	principal	 investigator	 to	organise	unblinding	
and	 inform	 the	 relevant	 parties	 (e.g.	 GP,	 Patient,	 hospital	 doctors).	 The	
researchers	will	 remain	 blinded	 to	 the	 patient’s	 treatment	 allocation.	 Should	 a	
participant	wish	 to	withdraw	 from	 the	 study	 they	 can	do	 so	 at	 any	 time.	They	
will	then	receive	best	practice	standard	care.	They	will	be	asked	at	consent	if	in	






marked	 with	 the	 patient’s	 trial	 number	 and	 name.	 	 If	 patients	 run	 out	 of	 the	
preparation	they	will	be	asked	to	contact	the	research	team	and	a	resupply	will	
be	 given	 and	 noted	 for	 adjustment	 during	 data	 analysis.	 Participants	 will	 be	
advised	to	apply	the	gel	twice	daily	over	the	affected	area	and	will	be	provided	
with	instructions	on	how	to	do	this	and	what	quantity	of	gel	to	use.	Participants	
will	 be	 asked	 to	 return	 their	 empty	 tubes	 after	 six	 weeks.	 The	 tubes	 will	 be	
weighed.		The	patient	will	record	start	and	end	date	of	each	tube	in	a	trial	diary.	
To	 mimic	 the	 characteristic	 aroma	 of	 menthol	 Carvone	 is	 contained	 in	 the	
placebo	 gel.	 Active	 Levomethol	 preparation	 as	well	 as	matching	 placebo	 gel	 is	
manufactured	by	Tayside	Pharmaceuticals:	Ninewells	Hospital	&	Medical	School	
Dundee.	If	for	any	reason	participants	needed	to	use	another	topical	application	





Case	 report	 forms	 (CRFs)	 have	 been	 developed	 in	 partnership	 with	 the	 ECTU	
(see	 appendix	 I).	 These	 forms	 will	 be	 completed	 in	 accordance	 with	 the	 CRF	
completion	 guidelines	 issued	 for	 the	 study.	 Queries	 should	 be	 handled	 as	
described	 in	 the	 study	 dataflow	 section	 of	 the	 CRF	 completion	 guidelines.	
Members	of	the	research	team	will	enter	the	data	on	to	the	database.	 	CRFs	for	
the	 study	 will	 be	 returned	 and	 stored	 in	 line	 with	 current	 regulatory	










•	 Evidence	 of	 altered	 activity	within	 the	 pain	 and	 placebo	 networks	 following	
standard	pain	provocation	at	baseline	and	after	six	weeks	of	treatment	(menthol	
or	 placebo)	 will	 be	 identified	 using	 standardized	 MRI	 analysis.	 Collected	
sequences	will	 include	 structural	 data,	 resting	 state	data	 (ASL	 and	BOLD),	 and	





•	 Quantitative	 sensory	 testing	 (see	 appendix	 J	 for	 protocol),	 skin	 temperature	
after	 gel	 application,	 assessment	 of	 cognitive/affective	 components	 of	 pain	







There	 is	 no	 principled	 power	 analysis	 applied	 in	 the	 context	 of	 classical	
inferences	 using	 the	 mass	 univariate	 approach,	 which	 underpins	 BOLD	 signal	
activation	 analysis.	 This	 is	 because	 specifying	 the	 alternative	 hypothesis	 is	 not	




reject	 the	 null	 hypothesis	 in	 one	 or	 more	 voxels(Friston,	 2011,	 Friston	 et	 al.,	
1999).	Based	on	this	approach,	in	our	exploratory	study	32	participants	(16	per	
group)	should	be	an	adequate	sample	to	detect	significant	fMRI	changes,	related	







Blood	 Oxygenation	 Level	 Dependant	 (BOLD)	 imaging	 will	 be	 carried	 out	 at	




priori	 seeding	 in	 the	 placebo	network.	A	 standard	 approach	 to	 functional	 data	
analysis	 (i.e.:	 data	 acquired	 during	 painful	 stimulus	 presentation)	will	 be	 used	
including	 pre-processing,	 first	 level	 and	 second	 level	 analysis	 (Smith,	 2004).	
Region	 of	 interest	 analysis	 will	 be	 decided	 on	 a	 priori	 based	 on	 previously	
published	evidence	regarding	pain	and	placebo	networks.	CIPN20	scores	will	be	
utilised	 as	 regressors	 of	 interest	 in	 the	 second	 level	 fMRI	 analysis.	 ICA	will	 be	












statistics	 will	 be	 used	 to	 report	 temperature	 ranges	 associated	 with	 pain	 and	
discomfort	 at	 baseline.	 Secondary	 outcome	measures	 relating	 to	 occurrence	 of	





records	will	 be	 removed	 from	 any	 formal	 statistical	 analysis,	 unless	 otherwise	
specified.	 An	 intention	 to	 treat	 approach	 will	 be	 undertaken.	 Distributional	
assumptions	 underlying	 the	 statistical	 analyses	 will	 be	 assessed	 by	 visual	
inspection	of	 residual	plots.	Normality	will	 be	 examined	by	normal	probability	
plots.	 If	 the	 distributional	 assumptions	 for	 the	 parametric	 approach	 are	 not	
satisfied,	 further	 data	 transformation	 (to	 alleviate	 substantial	 skewness	 (i.e.	
normalizing)	 or	 to	 stabilise	 the	 variance),	 or	 other	 suitable	 methods	 will	 be	
considered.	 If	 applied	 this	 will	 be	 documented	 in	 the	 statistical	 results	 report	
together	with	the	reasoning	supporting	the	action	taken.	fMRI	data	analyses	will	





the	 Scotland	 A	 Research	 Ethics	 Committee	 (13/SS/0201).	 Two	 substantial	
protocol	 inclusions	 have	 also	 been	 reviewed	 and	 approved	by	 the	 same	 ethics	
committee	since	 the	original	 favourable	opinion	was	granted	 (see	appendix	E).	
Approval	 has	 also	 been	 gained	 from	 the	 Medicines	 and	 Health	 Products	





direct	 clinical	 care	 team.	Patients	will	 be	 given	verbal	 and	written	 information	
and	sufficient	time	(minimum	of	24	hours)	to	review	the	information	and	to	ask	
questions	and	have	them	answered	before	providing	written	informed	consent.	












events	 occur,	 study	 investigators	will	make	 an	 assessment	 of	 severity	 for	 each	
and	record	this	on	the	CRF.	If	the	investigators	become	aware	that	a	serious	AE	
has	occurred	in	a	study	participant,	the	information	will	be	reported	to	the	trial	
sponsor	 immediately	 or	 within	 24	hours.	 The	 Academic	 and	 Clinical	 Central	





grant	 holders-	 chief	 investigator	 (CI)	 and	 principal	 investigator	 (PI)	 in	
Edinburgh,	 a	 trial	 manager	 and	 coordinating	 nurse.	 The	 Trial	 Manager	 will	
oversee	 the	 study	 and	 will	 be	 accountable	 to	 the	 Chief	 Investigator/Principal	
Investigator.	 	 The	 Trial	Manager	will	 be	 responsible	 for	 checking	 the	 CRFs	 for	
completeness,	plausibility	and	consistency.	 	Any	queries	will	be	resolved	by	the	
Investigator	 or	 delegated	 member	 of	 the	 trial	 team.	 A	 Delegation	 Log	 will	 be	
prepared	for	the	trial	site,	detailing	the	responsibilities	of	each	member	of	staff	
working	 on	 the	 trial.	 	 A	 Trial	 Steering	 Committee	 (TSC)	will	 be	 established	 to	
oversee	 the	 conduct	 and	 progress	 of	 the	 study.	 The	 TSC	 will	 be	 composed	 of	







a	summary	report	of	 the	study	will	be	provided	within	1	year	of	 the	end	of	 the	
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study.	 If	patients	do	 respond	 to	 the	 treatment	and	 feel	a	benefit,	 after	 the	 trial	




Trial	 results	 will	 be	 published	 in	 peer-reviewed	 journals	 and	 presented	 at	
national	 and	 international	 conferences.	 Authorship	 will	 be	 determined	 by	
internationally	 agreed	 criteria	 for	 authorship.	Patients	who	gave	 consent	 to	be	
contacted	with	results	at	 the	start	of	 the	 trial	will	be	sent	a	 lay	summary	at	 its	
conclusion.	 Anonymised	 trial	 data	 will	 be	 made	 available	 if	 interested	
researchers	seek	and	are	granted	additional	ethical	approval.	Future	 fMRI	data	
pooling	 to	 investigate	 the	 interaction	 between	 depression	 and	 CIPN	 is	







cohort	 and	 shown	 here	 to	 be	 effective	 in	 terms	 of	 result	 generation.	 Clinically	






particular	 cold	 allodynia	 is	 an	 important	 feature	 of	 this	 neuropathy,	 which	
appears	 to	 be	 demonstrated	 over	 and	 above	 other	 forms	 of	 allodynia	 (Fallon,	
2013).	Consequently,	it	was	decided	that	MINT3	trial	participants	should	receive	





The	 ‘cold	 task’	 described	here,	will	 be	 employed	 to	 test	 baseline	 allodynia	 and	
the	 effects	 of	 levomenthol	 versus	 placebo	 on	 its	 clinical	 and	 central	 (brain)	
manifestations	 in	 requited	patients.	The	 thermal	 stimuli	will	be	presented	as	a	
cyclical	block	design,	oscillating	between	a	thermo	neutral	temperature	of	340C,	
held	for	70	seconds	and	a	cold	temperature	of	50C,	held	for	10	seconds	(fig	6.1).	
Optimally,	 this	 would	 be	 carried	 out	 using	 the	 Medoc	 pathway	 thermode.	
However,	noise	issues	related	to	this	equipment	(see	3.	1.3.2)	persist,	so	instead	










Figure	 6.1	 Cold	 Task	 Paradigm.	 Red	 arrow	 denoting	 scanning	 time.	 Neutral	









included	 a	 learning	 component	 by	 jittering	 the	 number	 of	 allocated	 reward	








points,	 allowing	 assessment	 of	 reward	 and	 motivation	 during	 reinforced	
learning.		
	
This	 task	 is	 planned	 for	 the	 MINT3	 study	 for	 two	 reasons.	 Firstly,	 it	 is	








The	 task	 is	 implemented	 using	 Presentation	 software.	 There	 are	 two	
fundamental	 trial	 types:	 choice	 and	 no-choice,	 each	 presented	 27	 times.	 Each	
trial	begins	with	a	cue	indicating	which	trial	this	would	be	(see	figure	6.2).	After	
a	jittered	period	of	choice/no-choice	anticipation,	the	participant	is	shown	a	two	
colour	 stimuli:	 during	 choice	 trials,	 they	 are	 able	 to	 select	 their	 preferred	
coloured	 shape	 (see	 figure	 6.2).	 	 During	 no-choice	 trials,	 a	 rectangle	 appears	
around	 the	 shape,	 which	 the	 computer	 has	 selected,	 and	 they	 are	 obliged	 to	
select	before	moving	on.	Selection	is	made	via	a	button	press.	Following	selection	
participants	are	presented	with	a	reward	outcome	of	the	selection;	0,	50	or	100	







Figure	 6.2.	 Summary	 of	 Choice	 and	Reward	Task.	 From	 left:	 circle	 indicates	 a	
choice	 trial	 and	 diamond	 a	 no	 choice	 trial.	 In	 the	 choice	 trial	 participants	 can	
choose	a	yellow	or	blue	rectangle.	Their	choice	is	rewarded	with	points	of	0,	50	
or	 100.	 In	 the	 no	 choice	 trial	 participants	 are	 obliged	 to	 choose	 the	 colour	
selected	 by	 the	 computer	 and	 denoted	 by	 a	 rectangle	 around	 it.	 The	 time	 to	





A	 number	 of	 psychological	 measures	 will	 be	 used	 to	 assess	 the	 subject’s	
cognitive	 processing	 capacity.	 These	 include	 the	 digit	 symbol	 substitution	 test	
(DSST)	a	subtest	from	the	Wechsler	collection	of	intelligence	tests,	known	as	the	








For	 assessment	 of	 pain	 and	 affect	 the	 Hospital	 Anxiety	 and	 Depression	 Scale	
(HADS)	 (Zigmond	and	Snaith,	1983)	and	 the	Brief	Pain	 Inventory	 (BPI)	will	be	
implemented.	 A	 standardised	 side	 effects	 questionnaire	 will	 assess	 unwanted	
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Parametric	 Mapping	 version	 8:	 The	 Wellcome	 Department	 of	 Cognitive	
Neurology	and	collaborators,	 Institute	of	Neurology,	London	running	 in	Matlab	
(The	MathWorks,	Natick,	MA)	by	Dr	Liana	Romaniuk	based	in	the	department	of	
Psychiatry	 at	 the	 University	 of	 Edinburgh.	 Dr	 Romaniuk	 was	 involved	 in	 the	
paradigm	design	and	pilot	data	analysis	for	the	MINT3	pilot	presented	here.	The	






As	 part	 of	 the	 feasibility	 testing	 of	 the	 paradigm,	 a	 53	 year	 old	 healthy	 female	
underwent	 the	 pilot	 scan.	 She	 had	 no	 pain	 and	 was	 not	 taking	 any	 regular	
analgesic	medication.	She	 felt	 the	duration	of	 the	scan	was	acceptable	and	 that	
none	of	the	experimental	tasks	were	excessively	difficult	to	take	part	in.	
6.6.1	Punctate	Task	





interest	 analysis,	which	 is	more	 sensitive	 to	 the	 small	 nuclei	 of	 the	 brainstem,	
and	 is	 planned	 for	 the	 MINT3	 trial,	 were	 not	 carried	 out	 here.	 Contrast	
investigating	 the	 effects	 of	 punctate	 stimuli	 during	 positive	 images	 showed	
activation	in	left	superior	frontal	gyrus,	left	post	central	gyrus	and	left	temporal	






Regions	 activating	 in	 response	 to	 cold	 stimulus	 (cold	 >neutral),	 administered	
above	 the	 left	medial	malleolus,	 included	 the	 right	 inferior	 gyrus,	 right	 central	
sulcus	and	right	 insula	(fig	6.4).	The	reverse	contrast	 investigating	areas	active	
when	no	cold	stimulus	was	applied	(neutral>cold)	showed	significant	activity	in	
the	 right	 mid	 occipital	 gyrus,	 right	 precentral	 gyrus	 and	 right	 putamen.	
Additionally	activity	was	seen	in	the	left	angular	and	precentral	gyri.			
	
Figure	 6.3	 Activation	 following	 punctate	
stimulation.	 Activation	 is	 seen	 in	 regions	
known	 to	 be	 involved	 in	 pain	 processing	
including	 the	 insula	 and	 somatosensory	






In	 order	 to	 determine	 what	 impact	 the	 ability	 to	 choose	 had	 on	 activation	
associated	 with	 receiving	 a	 reward,	 the	 reward	 times	 choice	 interaction	 was	
examined	 (Choice	 reward	 100	 >	 Choice	 reward	 0)	 >	 (No-choice	 reward	 100	 >	
No-choice	 reward	 0).	 This	 revealed	 significantly	 greater	 activation	 of	 the	 left	
inferior	frontal/orbitofrontal	cortex	(see	fig	6.5).		(Figure	Z,	MNI	-36	29	-10,	Z	=	
3.97,	 kE	 =	 168,	 p	 =	 0.047	 FWE-corrected).	 The	 inverse	 contrast	 demonstrated	
very	 little	 activation.	 This	 suggests	 that	 the	 receipt	 of	 reward	 that	 has	 been	





Figure	 6.4	 Activation	 following	 cold	
stimulation.	 The	 stimulus	was	 applied	







more	 pilot	 scans	with	 concomitant	 inclusion	 of	 questionnaires	 are	 required	 to	
confirm	 the	above	 fMRI	 results.	Additionally,	 these	are	needed	 to	aid	 timing	of	
patient	 flow	 around	 the	 time	 of	 scan.	 Secondly,	 issues	 related	 to	 licensing	
agreements	 for	 study	 medication	 need	 to	 be	 resolved	 in	 order	 to	 source	 the	










to	 aid	 consistency	 of	 stimuli	 administration.	 Also	 related	 to	 the	 cold	 task,	
decisions	 regarding	 the	 duration	 and	 intensity	 of	 cold	 stimuli	 need	 to	 be	
reviewed,	 in	 particular	 as	 activation	 from	 the	 pilot	 scan	 seems	 to	 suggest	 that	
Figure	 6.5	 The	 reward	 times	 choice	




latent	 haemodynamic	 response	 is	 being	 picked	 up	 in	 pain	 processing	 areas	
during	 the	 neutral	 rest	 condition,	 after	 the	 cold	 stimulus	 has	 been	 removed.	




pilot	 scan	 participant	 that	 this	 task	 needs	 to	 be	 explained	 in	 more	 detail	 to	
patients	prior	to	entering	the	fMRI	scanner.	This	task	proved	slightly	confusing	
for	a	very	well	educated	healthy	participant	and	 is	 likely	 to	be	too	complex	 for	
chronic	pain	patients.	 	 Finally,	 exclusion	of	 the	 IAPS	 images	 from	 the	punctate	
task	 maybe	 necessary	 in	 order	 to	 simplify	 the	 interpretation	 of	 the	 effects	 of	
menthol	gel	on	punctate	allodynia	in	chronic	CIPN.	
	
In	 terms	 of	 the	 protocol	 itself,	 the	 complexities	 of	 setting	 up	 a	 treatment	 trial	
using	fMRI	cannot	be	overstated.	 In	particular,	 the	coordination	of	 the	multiple	
approvals,	 with	 pharmacy	 production	 of	 trial	 medication	 and	 placebo,	 is	
imperative	 to	 study	 success.	 Planning	 is	 key	 to	 achieving	 success	 and	 a	 small	







literature.	 The	 impact	 of	 work	 carried	 out	 and	 presented	 in	 this	 thesis	 can	 be	
divided	 into	 that	 relating	 to	 the	 field	 of	 CIPN	 and	 that	 effecting	 fMRI	 pain	
neuroimaging	at	the	University	of	Edinburgh.	These	contributions	will	be	discussed	
in	 turn	below.	Limitations	of	 this	work	are	also	noted.	The	 chapter	will	 conclude	
with	an	overview	of	future	research	objectives	and	implications	for	clinical	practice	










stimuli	 in	 chronic	 CIPN	 patients	 compared	 to	 healthy	 volunteers,	 while	
Nudelman	 and	 colleagues	 progressively	 looked	 at	 grey	 matter	 volume	 and	
general	brain	perfusion	before	and	after	chemotherapy.	The	study	presented	in	
this	 thesis	 investigated	brain	structure	and	 function	 in	cancer	patients	prior	 to	
chemotherapy	 onset.	 Consequently,	 both	 preparation	 for	 and	 execution	 of	 the	
CIPN	 fMRI	 study	 resulted	 in	 a	 number	 of	 unique	 contributions	 to	 the	 field	 of	
CIPN	research.	These	include	the	following:	
	
1. The	systematic	 review	and	meta-analysis	of	CIPN	 literature,	undertaken	
prior	 to	 recruitment	 to	 the	CIPN	 study,	 enabled	 a	 coherent	 summary	of	
CIPN	 prevalence	 across	 all	 cancer	 and	 chemotherapy	 types.	 A	 formal	







development	 has	 highlighted	 that	 pre-chemotherapy	 differences	 exist	
between	patients	who	develop	CIPN	and	those	who	do	not.	 	Specifically,	
the	nucleus	accumbens	was	found	to	be	smaller	in	patients	who	went	on	
to	 develop	 acute	 CIPN.	 This	 finding	 is	 postulated	 to	 serve	 as	 a	 future	
biomarker,	 useful	 in	 identifying	 individuals	 who	 have	 vulnerability	 for	
CIPN	development.	
	
3. Functional	 responses	 of	 the	 brain	 to	 punctate	 stimuli	 and	 positive	
emotional	 input,	 in	 cancer	 patients	 prior	 to	 chemotheray	was	 shown	 to	
differ	between	patients	who	did	not	develop	acute	CIPN	and	 those	who	
did.	This	was	 the	 first	 study	 to	prospectively	 show	a	difference	 in	brain	
processing	 of	 noxious	 stimuli,	 prior	 to	 chemotherapy	 onset.	 These	
findings	 uphold	 the	 notion	 of	 ‘at	 risk’	 individuals	 in	 terms	 of	 CIPN	
development.	
	




5. Utilisation	 of	 a	 number	 of	 cancer	 types	 requiring	 multiple	 neurotoxic	
chemotherapeutics,	 as	 opposed	 to	 restricting	 recruitment	 to	 a	 single	







is	 undertaken.	 Specifically,	 use	 of	 fMRI	 is	 shown	 to	 be	 an	 acceptable	
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adjunct	 to	 traditional	 study	design,	 in	 terms	of	ethical	and	research	and	
development	 approvals.	Moreover,	 successful	 completion	of	 a	pilot	 scan	
suggests	 that	 using	 a	 collaborative	 approach	 to	 data	 collection	 can	
propagate	not	only	 the	research	question	at	hand	but	also	contribute	 to	
investigation	 of	 co-expressed	 disease	 entities,	 such	 as	 in	 this	 case	
depression.	
	
7. Successful	 completion	 of	 the	 CIPN	 fMRI	 study	 shows	 that	 fMRI	 is	 an	












In	 collaboration	 with	 colleagues	 at	 CRIC	 and	 in	 the	 department	 of	 Psychiatry,	
auxiliary	equipment	was	introduced	into	the	scanner	to	enable	collection	of	pain	
related	fMRI	data.	Specifically,	installation	and	assessment	of	the	Medoc	thermal	
stimuli	 experimental	 equipment	 as	 well	 as	 the	 Biopac	 physiological	 noise	
monitoring	hardware	 and	 software	was	 carried	out,	 as	 described	 in	 chapter	3.	
The	 installation	of	 this	equipment	 required	cross	department	organisation	and	
subsequent	scanner	noise	diagnostics.		
	
These	 efforts	 enabled	 the	 CIPN	 study	 and	 two	 further	 unrelated	 pain	 fMRI	
studies	 to	 be	 conducted.	 One	 of	 the	 studies;	 a	 pilot	 investigating	 the	 use	 of	






The	 findings	 of	 the	 CIPN	 study	 support	 animal	 and	human	 evidence	 regarding	
aberrance	 in	 brain	 structure	 and	 function	 denoting	 vulnerability	 for	
development	 of	 neuropathic	 pain	 states	 (De	 Felice	 et	 al.,	 2011,	Mansour	 et	 al.,	
2013).	 In	 particular	 the	 smaller	 NAc	 volume	 in	 patients	 who	 develop	 CIPN,	
corroborate	 with	 decreased	 NAc	 size	 and	 functional	 connectivity	 reported	 in	
patients	 who	 transition	 to	 chronic	 back	 pain	 by	 Mansour	 et	 al.	 Decreased	
thalamic	activity	 in	 response	 to	punctate	 stimuli	 in	men	who	progress	 to	CIPN	
and	increased	MPRF	activity	in	women	from	this	group	also	fits	with	previously	
described	 aberrant	 activity	 in	 these	 regions	 in	 neuropathic	 pain	 (Gustin	 et	 al.,	
2014).	 The	 identification	 of	 greater	 activity	 in	 the	 superior	 frontal	 gyrus	 in	




Detailed	 limitations	 related	 to	 the	 analyses	 undertaken	 in	 this	 thesis	 are	
described	in	chapters	4	and	5.	In	terms	of	study	conduct,	a	key	limitation	relates	




have	enabled	direct	 intra-subject	 longitudinal	comparison	aiding	 interpretation	
of	 reported	 findings	 and	 enabling	 quantification	 of	 changes.	 Finally,	 a	 larger	
sample	 size	 to	 enable	 a	 minimum	 of	 16	 participants	 per	 group	 would	 be	








the	 functional	 data	 analyses.	 Moreover,	 once	 long	 term	 follow-up	 data	 and	
conversion	to	chronic	CIPN	is	known,	re-analyses	of	data	is	planned.		In	terms	of	
future	 research,	 confirmation	of	 findings	 in	a	new	patient	dataset	 is	necessary.	
Additional	 validation	 of	 findings	 could	 also	 be	 achieved	 by	 translation	 to	 an	
animal	model	 of	 CIPN.	 Specifically,	manipulation	 of	 regions	 identified	 in	 these	
analyses	including	the	NAc,	MPRF,	thalamus	and	superior	frontal	gyrus	could	aid	





and	 dose	 of	 chemotherapy	 and	 the	 damage	 treatment	 induces	 in	 peripheral	
nerves.	 However,	 results	 presented	 in	 this	 thesis	 suggest	 that	 a	 pre-
chemotherapy	brain	 centred	 vulnerability	 for	 CIPN	 exists.	 Viewed	 in	 this	 light,	
clinicians	 may	 need	 to	 consider	 certain	 patients	 as	 having	 a	 baseline	 risk	 for	
CIPN	development	 alongside	 the	 specifics	 of	 chemotherapy	dose	 and	duration.	
Change	 in	 clinical	 practice	will	 however	 only	 be	 possible	 after	 a	 sensitive	 and	
specific	 bedside	 measure	 of	 brain	 related	 CIPN	 vulnerability	 is	 identified.	
Moreover,	 development	 of	 chemotherapeutic	 regimens,	 which	 limit	 CIPN	 but	
retain	 tumorcidal	 activity,	 will	 be	 necessary	 to	 enable	 sustained	 change	 in	
clinical	practice.		
	
In	relation	to	the	set	up	of	 the	MINT3	study,	execution	of	 this	study	 is	possible	
once	study	medication	is	sourced	and	two	further	fMRI	pilot	scans	are	completed	








annually	 in	 the	 UK	 alone.	 Pathophysiological	 understanding	 of	 CIPN	
development	 is	 limited.	 Therefore,	 assessment	 of	 this	 condition	 in	 a	 patient	
model,	as	presented	here,	is	a	useful	contribution	to	the	field.	Taken	together	the	
findings	described	 in	this	thesis	denote	that	there	are	structural	and	functional	
differences	 in	 the	 brains	 of	 patients	who	 develop	 CIPN.	 These	 aberrations	 are	
evident	 before	 peripheral	 nerve	 damage	with	 chemotherapy	 ensues.	 	 This	 is	 a	





Specifically,	 a	 move	 away	 from	 cause	 (chemotherapy)	 and	 effect	 (CIPN)	
paradigms,	 to	 a	 notion	 of	 brain	 centred	 pre-chemotherapy	 risk	 should	 be	
considered.	This	kind	of	change	has	the	capacity	to	redirect	research	focus	to	the	
influence	of	 the	central	nervous	system	in	CIPN.	 It	will	 likely	also	yield	greater	
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a b s t r a c t
Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling pain condition resulting from chemo-
therapy for cancer. Severe acute CIPN may require chemotherapy dose reduction or cessation. There is no
effective CIPN prevention strategy; treatment of established chronic CIPN is limited, and the prevalence
of CIPN is not known. Here we used a systematic review to identify studies reporting the prevalence of
CIPN. We searched Embase, Medline, CAB Abstracts, CINAHL, PubMed central, Cochrane Library, and
Web of Knowledge for relevant references and used random-effects meta-regression to estimate overall
prevalence. We assessed study quality using the CONSORT and STROBE guidelines, and we report findings
according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance.
We provide a qualitative summary of factors reported to alter the risk of CIPN. We included 31 studies
with data from 4179 patients in our analysis. CIPN prevalence was 68.1% (57.7–78.4) when measured
in the first month after chemotherapy, 60.0% (36.4–81.6) at 3 months and 30.0% (6.4–53.5) at 6 months
or more. Different chemotherapy drugs were associated with differences in CIPN prevalence, and there
was some evidence of publication bias. Genetic risk factors were reported in 4 studies. Clinical risk
factors, identified in 4 of 31 studies, included neuropathy at baseline, smoking, abnormal creatinine
clearance, and specific sensory changes during chemotherapy. Although CIPN prevalence decreases
with time, at 6 months 30% of patients continue to suffer from CIPN. Routine CIPN surveillance during
post-chemotherapy follow-up is needed. A number of genetic and clinical risk factors were identified that
require further study.
! 2014 The Authors. Published by Elsevier B.V. on behalf of International Association for the Study of
Pain. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/3.0/).
1. Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a dis-
abling side effect of several commonly used antineoplastic agents.
The development of CIPN may require chemotherapy dose reduc-
tion or cessation, which can increase cancer-related morbidity
and mortality [17,31]. CIPN is a predominantly sensory neuropathy
that may be accompanied by motor and autonomic changes [62].
Similar to other neuropathic pain conditions, pain in CIPN can be
stimulus dependent or independent [66]. The pathophysiology of
CIPN is poorly understood, and treatments to prevent CIPN are
inadequate. Meta-analyses of clinical trials for CIPN prevention
report inconclusive results [1,49]. Treatment options for estab-
lished CIPN are also limited. Clinical trials of antiepileptic or anti-
depressant agents to treat other neuropathic pain conditions
have generally been negative [30,41,54,55]. Only 1 recent, dou-
ble-blind, randomized controlled trial showed improvement in
CIPN symptoms after 5 weeks of treatment with duloxetine [57].
Understanding of the epidemiology of CIPN is also limited [37].
Previous studies have largely focussed on individual chemothera-
peutic agents, with reported CIPN incidence rates ranging from
19% to more than 85% [23]. Annually 165,544 patients survive can-
cer in the United Kingdom, and more than 1 million in the United
States [12,44]. It is therefore important to provide a more precise
measure of the prevalence of CIPN to allow appropriate resource
http://dx.doi.org/10.1016/j.pain.2014.09.020
0304-3959/! 2014 The Authors. Published by Elsevier B.V. on behalf of International Association for the Study of Pain.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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allocation and research planning, and to inform patient decisions
about treatment. Understanding risk factors (including genetic risk
factors) for CIPN may guide future research and treatment.
Previous reviews of CIPN have combined narrative review with
expert opinion, with potential risk of bias [15,28,29]. Here we pres-
ent what we believe to be the first systematic review and meta-
analysis of the incidence and prevalence of CIPN. We also aimed
to assess the influence of potential publication bias on our estima-
tion of CIPN measures, and to seek empirical evidence of the
impact of study design factors.
2. Methods
2.1. Search strategy
We searched Embase, Medline, CAB Abstracts, CINAHL,
PubMed central, Cochrane Library and Web of Knowledge in July
2013 for English-language references. Searches were not limited
by date restrictions. Search terms were free text and included;
[‘‘Chemotherapy Induced Peripheral Neuropathy’’ OR ‘‘Chemo-
therapy Induced Neurotoxicity’’ OR ‘‘Chemotherapy Induced
Neurotoxicity Syndromes’’ OR ‘‘CIPN’’ OR ‘‘Oxaliplatin Induced
Peripheral Neuropathy’’ OR ‘‘Bortezomib Induced Peripheral Neu-
ropathy’’ OR ‘‘Paclitaxel Induced Peripheral Neuropathy’’ OR ‘‘Tax-
ane Induced Peripheral Neuropathy’’ OR ‘‘Cisplatin Induced
Peripheral Neuropathy’’ OR ‘‘Vincristine Induced Peripheral Neu-
ropathy’’ OR ‘‘Thalidomide Induced Peripheral Neuropathy’’ OR
‘‘Platinum Induced Peripheral Neuropathy’’ OR ‘‘Carboplatin
Induced Peripheral Neuropathy’’ OR ‘‘Docetaxel Induced Periphe-
ral Neuropathy’’ OR ‘‘Proteasome Inhibitor Induced Peripheral
Neuropathy’’ OR Neurotoxic Chemotherapy Induced Peripheral
Neuropathy’’ OR ‘‘Cancer Neuropathic Pain’’ OR ‘‘Chemotherapy
Induced Neuropathic Pain’’] [Search 1] AND [‘‘Prevalence’’ OR
‘‘Epidemiology’’ OR ‘‘Occurrence’’ OR ‘‘Burden’’] [Search 2] AND
[‘‘Predictors’’ OR ‘‘Risk Factors’’] [Search 3]. The search strategy
was adapted for each database (see supplementary text A). We
also hand searched reference lists of relevant studies and system-
atic reviews of CIPN prevention trials, and searched the databases
of National Institute for Health and Care Excellence (NICE) and
the Scottish Intercollegiate Guidelines Network (SIGN). Our
review followed an a priori protocol according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [43]. The review protocol was registered on
the PROSPERO website before data extraction (registration no.
CRD42013005524) [11].
2.2. Inclusion and exclusion criteria and study selection
We included prospective observational studies of adult cancer
patients receiving chemotherapy of any type. Our definition of
observational studies included cohort studies in which patients
were prospectively identified and followed up using relevant pre-
defined outcomes of interests. We also included control group data
from randomized controlled trials (RCTs) of CIPN prevention in
which details of the patients who developed CIPN were reported.
Studies were excluded if they described animal models of CIPN,
were investigating CIPN treatment or prevention, included pediat-
ric populations, or investigated other causes of neuropathy in
cancer patients (eg, pre-existing neuropathy such as diabetic
neuropathy or other cancer related causes of neuropathy such as
post-mastectomy).
Two investigators (M.S. and S.R.) independently read and
selected from all the retrieved references and abstracts. Discrepan-
cies between the reviewers’ selections were resolved by discussion.
Full texts of potentially eligible studies were retrieved (Fig. 1).
2.3. Data extraction and quality assessment
We extracted data to a bespoke form, recording the prevalence
or incidence of CIPN, and any reported risk factors or predictors of
CIPN. We included all relevant outcomes determined after the end
of chemotherapy, noting the time (in relation to the end of chemo-
therapy) at which these were assessed. Where information was
incomplete we contacted authors by email. Two investigators
(M.S. and S.R.) extracted data, which were then entered into the
study database. Discrepancies were resolved by discussion and
agreement with a third reviewer (M.F.).
We assessed study quality according to the PRISMA guidelines
[43]. We evaluated risk of bias in individual studies using the fol-
lowing criteria: investigator blinding of any type, presence of a
control group, use of externally validated instruments for CIPN
assessment, clear description of statistical methods used to iden-
tify CIPN predictors, and description of longitudinal follow up.
Adherence of each study to relevant reporting criteria (STROBE or
CONSORT) was assessed [2,61]. We assessed the risk of bias for
our summary estimate by seeking evidence of publication bias,
selective outcome reporting bias (if a published protocol of the
included study was available), reporting of a sample size calcula-
tion, and whether the study reported participants lost to follow-up.
2.4. Data synthesis and analysis
Our primary outcome was the prevalence of CIPN. We used ran-
dom effects meta-regression to quantify heterogeneity and its
potential sources. We hypothesized that chemotherapy type and
the time of CIPN assessment would explain a large proportion of
the observed heterogeneity. Therefore, we included chemotherapy
type, last time point of CIPN assessment, and measures of study
quality as independent variables in our regression model. We also
planned for assessment of risk factors for CIPN across studies. We
assessed publication bias using funnel plots, Egger’s test, and trim
and fill [22]. We appraised studies using STROBE criteria for obser-
vational studies and CONSORT criteria for trials. Where a criterion
was partially met, we considered, for the purposes of this analysis,
that it was completely met, for ease of calculation. In open label
studies (Table 1), we modified the CONSORT criteria by not consid-
ering the point for blinding, to account for the design of these stud-
ies. STATA 13.1 was used for statistical analyses.
3. Results
3.1. Studies included
We identified 4128 potentially relevant studies, and examined
the full text of 138. A total of 31 studies (involving 4179 patients)
[4–9,13,14,18,21,24–27,32–36,38,39,45–48,52,53,60,63–65] met
our inclusion criteria. A total of 30 studies reported the incidence
of CIPN (new CIPN cases divided by the population at risk). One
study reported CIPN prevalence (all CIPN cases divided by popula-
tion at risk) [26]. Because CIPN might have occurred, and resolved,
between study assessments, we calculated the prevalence of CIPN
at the time of each assessment [59].
3.2. Study characteristics
Of the 31 studies included, 15 were prospective cohort studies,
10 were RCTs, 5 were nonrandomized controlled trials, and 1 was a
cross-sectional cohort study. All nonrandomized controlled trials
were open labeled and not blinded. Eight of 10 RCTs (80%) reported
investigator blinding of some type. Blinded assessment of outcome
was reported in 3 of 14 prospective cohort studies. One prospective















cohort study also sought to validate genetic risk factor results in a
control group. Nine of 10 RCTs (90%) described a sample size calcu-
lation. Of all included studies, 22 (71%) reported study participant
dropout, giving reasons. In all, 14 of 31 study authors (45%) dis-
closed funders and/or whether they had a conflict of interest.
Adherence of studies to reporting guidelines is summarized in
Table 1. Of 31 studies, 26 (83.9%) used an assessment tool validated
for CIPN. All studies reporting CIPN risk factors described methods
used to identify these predictors.
3.3. CIPN incidence and prevalence
Of 4179 patients, 1960 developed CIPN (aggregate prevalence
48%). CIPN prevalence was 68.1% (95% CI = 57.7–78.4) within the
first month of the end of chemotherapy, 60.0% (36.4–81.6) at
3 months, and 30.0% (6.4–53.5) at 6 months or later (Table 2).
There was considerable heterogeneity in the estimates from differ-
ent studies (I2 = 98.2, P < .001). The time of assessment accounted
for 36% of the observed heterogeneity (adjusted R2 = 0.365,
P < .001). An overview of the individual incidence reported in
included studies is shown in Table 1. We did not include the
cumulative dose (CD) of chemotherapy (actual dose received) in
our meta-regression because standard and maximally tolerated
doses would differ substantially from drug to drug (study-specific
CD shown in Table 1). As expected, there was co-linearity between
the cancer type and the chemotherapy used; because we reasoned
that it is more likely that CIPN prevalence would be related to drug
than to cancer type, we considered only chemotherapy type in our
regression model (Table 3). The type of chemotherapy used
accounted for 32% of the observed heterogeneity in our sample
(adjusted R2 = 0.315, P < .04).
Methods used to assess the presence or grade of CIPN were too
diverse to include in the meta-regression. Of the 31 included stud-
ies, 8 defined CIPN according to the National Cancer Institute Com-
mon Toxicity Criteria (NCI-CTC), 1 study used the European
Organisation for Research and Treatment of Cancer (EORTC) Qual-
ity of Life Questionnaire 30 (QLQ – 30) combined with neurological
examination, 1 used in-depth neurophysiological examination
(NPS), 1 used a standard neurological examination, and 1 used
the Total Neuropathy Score (TNSc). The remaining 18 studies used
a combination of 2 or more of the above, and 1 study used skin
biopsy (Table 3). To investigate any impact of neurophysiological
CIPN Incidence and Prevalence Systematic 
Review and Meta-Analysis 
PRISMA 2009 Flow Diagram
Records identified through database 
searching
(n = 4109) 
Additional records identified 
through other sources 
(n = 19) 
Records after duplicates removed 
(n = 3657) 
Records screened 
(n = 3657) 
Records excluded 
(n = 3489) 
Full-text articles assessed 
for eligibility 
(n = 168) 
Full-text articles excluded, 
with reasons 
(n = 137): 
Inappropriate Design 
(n = 83) 
CIPN Treatment Study 
(n = 1) 
Incomplete Data Summary 
(n = 48) 
Mixed Cancer Neuropathy 
(n = 5)
Studies included in 
qualitative synthesis 
(n = 31) 
Studies included in 
quantitative synthesis 
(meta-analysis)
(n = 31) 
Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 flow diagram.
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assessment on the reported prevalence of CIPN, we conducted a
post hoc sensitivity analysis. In all, 17 studies (449 patients) used
NPS to assess for CIPN; 16 of these used NPS in combination with
another assessment method. In these 17 studies, CIPN prevalence
was higher; 73.3% (58.6–87.3) within 1 month of chemotherapy
cessation, 70.1% (41.8–98.4) at 3 months, and 39.9% (3.9–76.0) at
6 months or more.
For publication bias, although Egger’s test did not suggest asym-
metry in the funnel plot at a confidence level of P = .05 (95% CI of
intercept !0.64 to 7.8); trim and fill analysis did impute 14
theoretical missing studies. These 2 approaches to assess for
publication bias are known to have different sensitivities [58].
3.4. CIPN risk factors
Eight of the included studies assessed risk factors for CIPN
(Table 4) [8,9,21,26,33,34,48,65]. Four genome-wide association
studies (GWAS), totaling 2671 patients, sought single nucleotide
polymorphisms (SNPs) associated with CIPN [9,33,48,65]. All
GWAS used validation datasets and conducted genotyping blinded
to clinical status. These reported polymorphisms associated with a
range of proteins, including voltage-gated sodium channels, Schw-
ann cell function–related proteins, receptors for cell surface colla-
gen, receptors involved in neuronal apoptosis, neuronal crest cell
development, and an enzyme involved in pyruvate metabolism.
Four studies (701 patients) used statistical modeling to report
clinical risk factors for CIPN [8,21,26,34]. Two of these studies
included 50 patients or fewer. No study used a separate data set
to validate candidate risk factors. Reported clinical risk factors
for CIPN included baseline neuropathy, a history of smoking,
decreased creatinine clearance, and specific sensory changes dur-
ing chemotherapy treatment, including cold allodynia (pain in
response to a nonpainful cold stimulus) and cold hyperalgesia
(exaggerated pain in response to a painful cold stimulus, 20 !C).
4. Discussion
4.1. CIPN prevalence
This systematic review and meta-regression suggests a high
overall prevalence of CIPN, maximum within the first month after
treatment, and falling over time. Approximately one-third of
patients can expect to have chronic CIPN 6 months or more after
the end of chemotherapy; this has a significant negative impact
on long-term quality of life for which effective treatment is needed.
The lack of uniformity in CIPN assessment methods make
between-study comparisons difficult. Authors used 5 assessment
methods (NCI-CTC, TNSc, EORTC QLQ-C30, neuro-physiological
examination, which included nerve conduction studies and/or
quantitative sensory testing, and neurological examination) alone
or in combination. Of these, only the EORTC QLQ-C30 and quanti-
tative sensory testing component of neurophysiological examina-
tion explicitly assess pain as a symptom of CIPN. It is known that
although CIPN most frequently presents with pain, motor and
other sensory symptoms may also be present [40]. Use of combina-
tions of CIPN and pain assessment tools has been suggested as a
Table 1
Overview of included studies.
First author (year) Study type and quality
(CONSORT/STROBE score)




Antonacopoulou (2009)* Prospective cohort 58.8% (42.2–75.3) Colorectal (oxaliplatin) —
Argyriou (2006) Prospective cohort (18/22) 61.5% (35.1–87.9) Breast (paclitaxel) 1980
42.8% (16.9–68.7) Lung (cisplatin) 720
Argyriou (2007) [8] Prospective cohort (19/22) 64% (45.2–82.8) Colorectal (oxaliplatin) 1740
Argyriou (2007) Prospective cohort (19/22) 69.2% (44.1–94.3) Multiple solid (cisplatin and paclitaxel) 126"7
Argyriou (2012) Prospective cohort (19/22) 83.3% (77.3–89.3) Colorectal (oxaliplatin) 1646
Argyriou (2013) Prospective cohort (20/22) 84.5% (79.4–89.5) Colorectal (oxaliplatin) 1651
Attal (2009) Prospective cohort (19/22) 66.6% (44.8–88.4) Colorectal (oxaliplatin) 1278
Baldwin (2012) Prospective cohort (20/22) 67.2% (64.1–70.3) Breast (paclitaxel) —
Cascinu (1995) RCT (18/25) 64% (45.2–82.8) Gastrointestinal (cisplatin) —
Cascinu (2002) RCT (16/25) 78.9% (60.6–97.3) Colorectal (oxaliplatin) 783
Chaudhary (2008)
!
Prospective cohort (13/22) 96.2% (89.2–103) Multiple myeloma (bortezomib and thalidomide) 36
Dimopoulos (2011) RCT (21/25) 46.7% (41.4–52.1) Multiple myeloma (bortezomib) 38"4
Gandara (1995)
"
RCT (18/25) 12.1% (5.6–18"5) Ovarian and lung (cisplatin) 379
Ghoreishi (2012) RCT (19/25) 59.2% (40.7–77.8) Breast (paclitaxel) —
Glendenning (2010)
!
Cross sectional cohort (21/22) 20.1% (15.5–24.7) Testicular (cisplatin and vincristine) 400
Gobran (2013) RCT (13/25) 70% (53.6–86.4) Colorectal (oxaliplatin) 763
Ishibashi (2010) RCT (20/25) 93.7% (81.9–105) Colorectal (oxaliplatin) 72"8
Johnson (2011) RCT (23/25) 32.1% (29.1–34.9) Multiple myeloma (thalidomide) —
19.6% (16.3–22.9) (Vincristine) —
Kawakami (2012)
!
Prospective cohort (14/22) 76% (64.1–87.8) Lung (cisplatin and paclitaxel) —
Kemp (1996) RCT (19/25) 67"5% (59.2–75.8) Gynecological (cisplatin) —
Krishnan (2005) Prospective cohort (16/22) 50% (25.5–74.5) Colorectal (oxaliplatin) 1200
Lin (2006) Randomised trial (15/24) 90% (71.4–108) Colorectal (oxaliplatin) 1200
Milla (2009) Randomised trial (11/24) 92.8% (79.3–106) Colorectal (oxaliplatin) 772
Pace (2003) Randomised trial (11/24) 85.7% (67.4–104) Multiple solid (cisplatin) 420
Pace (2007) Prospective cohort (14/22) 92.8% (79.4–106) Breast (paclitaxel) 1744
Pace (2010) RCT (19/25) 41.6% (21.9–61.4) Multiple solid (cisplatin) 450
Planting (1999) Randomised trial (13/24) 13.5% (2.5–24.5) Multiple solid (cisplatin) 401
Plasmati (2002) Prospective cohort (15/22) 96% (88.3–103) Multiple myeloma (thalidomide) 18
Van der Hoop (1999) RCT (12/25) 41.6% (13.7–69.5) Gynecological (cisplatin) 416
Von Schlippe (2001) Prospective cohort (9/22) 17.2% (3.4–30.9) Testicular (cisplatin) —
Won (2012) Prospective cohort (16/22) 40.6% (30.8–50.4) Colorectal (oxaliplatin) 935
Abbreviation: RCT, randomized controlled trial (note that randomised trials, as opposed to RCTs, did not have blinding or placebo).
— Cumulative or average dose not reported. Reported cumulative dose refers to actual dose received.
* Abstract only available; STROBE assessment not possible. Where upper 95% confidence intervals exceeded 100, only 100% were recorded, as this is clinically interpretable.
!
Study pooled incidence across chemotherapy types included.
"
Study pooled incidence across cancer types.









strategy to improve detection and quantification of pain in CIPN
[67]. There have been recent attempts to standardize CIPN assess-
ment and reporting, and we encourage investigators to consider
these when developing study protocols [15,16].
Three of the 5 largest studies in our sample did not include the
mildest grades of CIPN [9,24,45]. The prevalence of CIPN is there-
fore likely to be higher than reported here. Early detection of mild
CIPN might become important if effective prevention or manage-
ment strategies become available. A lower incidence in these larger
studies is an alternative explanation for the funnel plot asymmetry
detected by trim and fill analysis [58].
Current clinical guidelines support use of NPS methods in the
diagnosis of suspected CIPN [19,56]. Studies using this approach
reported a higher prevalence of CIPN, but whether this is a clini-
cally significant problem is not clear.
We found significant heterogeneity between studies. In meta-
analyses aimed at providing a best estimate of, for instance, drug
efficacy, significant heterogeneity usually limits the usefulness of
pooled data. In contrast, because the etiology and epidemiology
of CIPN are so poorly understood, we believe that investigating
the sources of heterogeneity is important. Specifically, it might
provide insight into the impact of length of assessment and chemo-
therapy type on the incidence and prevalence of CIPN. Further-
more, as expected, a substantial proportion of the heterogeneity
that we observed was accounted for by chemotherapy type, which
was related to the cancer type. Although the primary interest of
many clinicians will be the prevalence of CIPN for specific chemo-
therapeutics, CIPN treatment decisions are routinely based on data
from treatment trials that have recruited patients irrespective of
the chemotherapy that they were prescribed [57].
4.2. Risk factors for CIPN
Four studies used multivariate statistical modeling to identify
clinical risk factors for CIPN [8,21,26,34]. Despite using valid statis-
tical approaches, these studies did not verify identified risk factors
in new population datasets. Consequently, their results are proba-
bly affected by the statistical biases underpinning these types of
predictive calculations [3,42]. To our knowledge, these are the only
studies that describe baseline neuropathy, smoking, and decreased
creatinine clearance as risk factors for CIPN. In contrast, description
of sensory changes during chemotherapy treatment, including
increased pain and nerve hyperexcitability, have previously been
documented as predictors of CIPN [20,42]. The postulated mecha-
nisms underpinning these sensory phenomena include axonal
hyperexcitability and nociceptor sensitization. These processes
may be important in CIPN development, and, to some degree, they
fit with the mechanisms described in other neuropathic conditions
related to systemic diseases, including human immunodeficiency
virus (HIV) and multiple sclerosis [42,64]. There is ongoing debate
about the relative importance of etiology in determining the
underlying mechanisms of neuropathic pain [19,56,62].
Four studies reported genetic risk factors for CIPN. The functions
of the identified genes fit with the postulated pathophysiological
mechanisms underpinning CIPN [50]. The recent comprehensive
review by Cavaletti et al. discusses these mechanisms in detail.
All 4 included studies were, to some degree, affected by the univer-
sal limitations influencing pharmacogenetic studies: inadequate
sample size, CIPN assessment tools, and use and size of a replication
cohort. Despite these possible limitations, the potential clinical use-
fulness of pharmacogenetic studies in CIPN has recently been
Table 2
Comparison of prevalence related to time of CIPN assessment.
Time of assessment
(after cessation of chemotherapy)
Prevalence (95% CI) Studies included Total no. of patients in group




















Van Der Hoop 1999
Won 2012















Abbreviations: CI, confidence interval; CIPN, chemotherapy-induced peripheral neuropathy.
* Studies included longer-term CIPN follow up but did not provide enough details at these later time points to allow use of data in the meta-
regression.
!
Wide confidence interval likely due to small number of studies assessing CIPN beyond this time point.
"
Study considered CIPN only after induction therapy and not during maintenance.
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(count by grade if given)
CIPN assessment time points CIPN assessment
method(s)
Oxaliplatin: 72.3% (95% CI = 59.7–86.8)
Antonacopoulou
(2009)*
Prospective cohort Colorectal NR Unclear TNSc
Argyriou (2007) [8] Prospective cohort Colorectal Grade I (6/16) Baseline TNSc
Grade II (8/16) Cycles 4, 8, 12 NPS
Grade III (2/16) NCI-CTC
Argyriou (2012) Prospective cohort Colorectal Grade I (38/125) Baseline TNSc
Grade II (46/125) Cycles 3, 6 (FOLFOX) NPS
Grade III (41/125) Cycles 4, 8 (XELOX) NCI-CTC
Argyriou (2013)
!
Prospective cohort Colorectal Grade I (62/169) Baseline TNSc
Grade II (46/169) Cycle 6, 12 (FOLFOX) NCI-CTC
Grade III (61/169) Cycles 4, 8 (XELOX)




Cycle 3, 6, 9 NPS
12 ± 2 mo after chemo end (EORTC) QLQ-C30
Cascinu (2002) RCT Colorectal Grade I (4/15) Baseline NCI-CTC
Grade II (6/15) Cycles 4, 8, 12 NPS
Grade III (4/15) Within 2 wk of chemo end
Grade IV (1/15)
Gobran (2013) RCT Colorectal Grade I (7/21) Unclear if at baseline NCI-CTC
Grade II (0/21) At each chemo cycle until end of chemo
(variable no. of cycles)
Grade III (14/21) Longer follow-up for those with CIPN (but
denominator unclear)
Grade IV (0/21)
Ishibashi (2010) RCT Colorectal Grade I (15/15) Baseline NCI-CTC
Grade II (1/15) At each chemo cycle until end of chemo
Grade III (0/15)
Grade IV (0/15)
Krishnan (2005) Prospective cohort Colorectal NR No baseline NCI-CTC




Lin (2006) Controlled trial Colorectal Grade I (1/9) Baseline NCI-CTC
Grade II (5/9) Cycles 4, 8, 12 NPS
Grade III (3/9) Within 2 wk of end of chemo
Grade IV (0/9)
Milla (2009) Controlled trial Colorectal Grade I (0/13) Baseline NCI-CTC
Grade II (9/13) Cycles 5, 9, 12 NES
Grade III (4/13) (Some followed up longer but denominator
unclear)
Won (2012) Prospective cohort Colorectal NR Unclear if at baseline NCI-CTC
At each chemo cycle until end of chemo
(variable no. of cycles)
NES
Cisplatin: 42.2% (95% CI = 21.3–63.1)
Argyriou (2006)
"
Prospective cohort Lung Reported by age group
only
Baseline PNS
Cycles 3, 6 NPS
3 mo after chemo end
Cascinu (1995) RCT Gastrointestinal Grade I (3/16) Baseline NCI-CTC
Grade II (10/16) After 9 and 15 wk of therapy NPS
Grade III (2/16) Within 1 wk after end of chemo
Grade IV (1/16)
Gandara (1995) RCT Ovarian and
lung
Only grade P3 reported Unclear if at baseline NCI-CTC
At each cycle until chemo end (variable no. of
cycles)
Study stopped early after interim analysis due
to high toxicity in intervention group
Kemp (1996) RCT Gynecological Grade I (31/81) Baseline NCI-CTC
Grade II (35/81) Cycles 4, 5, 6 NES
Grade III (15/81) Monthly after chemo for 3 mo
Pace (2003) Controlled trial Multiple solid Grade I (6/12) Baseline TNSc
Grade II (4/12) After 6 cycles NES
Grade III & IV (2/12)
Pace (2010) RCT Multiple solid Only grade P3 reported Baseline TNSc
Every cycle for 3 cycles NPS
1 mo after chemo end
Planting (1999) Controlled trial Multiple solid Grade I (5/5) Baseline NCI-CTC
Cycle 3, 6 NES
3 mo after chemo end
(Longer follow-up but no denominator info)
Van der Hoop (1999) Controlled trial Gynecological Mean vibration threshold Baseline NES
Cycles 2, 4, 6
End of chemo














described [10]. As suggested by Postma et al. adherence of future
studies to standardized study design and methods will likely aid
the advance of personalized oncology, possibly having an impact
on CIPN prevalence in the future.
4.3. Limitations of this review
It is possible that we have omitted relevant studies despite
our detailed search strategy, and we specifically excluded
non–English language studies. Multivariate meta-regression would
have allowed us to investigate interactions between various
factors, but there are too few studies for this approach to be
reliable. Because we expected there to be a broad range of CIPN
assessment methods used, we did not plan to explore their
impact. Our analysis of the impact of NPS as a component of
the assessment of CIPN is post hoc and therefore should be
interpreted with caution. We did not specifically seek out







(count by grade if given)
CIPN assessment time points CIPN assessment
method(s)
Von Schlippe (2001) Prospective cohort Testicular Grade I (4/5) Unclear if at baseline NPS
Grade II (1/5) Every 6 wk for first 6 mo after chemotherapy
Thereafter every 2 mo for median of 4 y (range
2–8 y)
Cisplatin or carboplatin and paclitaxel: 73% (95% CI = 36.2–109.7)
Argyriou (2007) Prospective cohort Multiple solid Mild (2/9) Baseline PNS
Moderate (6/9) Cycle 3, 6 NPS
Severe (1/9) 3 mo after chemo end
Kawakami (2012)§ Prospective cohort Lung % Severity with
cumulative dose
Baseline NCI-CTC
Daily during cycle 1
Cycle 2, 3, 4
Chemo end
Cisplatin and vincristine: 20.1% (95% CI = !26.2 to 66.5)
Glendenning (2010)§ Cross-sectional
cohort
Testicular Only grade P3 reported Recruited patients at least 5 y post-treatment (EORTC) QLQ-C30
Assessed once for this prevalence study NES
Paclitaxel: 70.8% (95% CI = 43.5–98.1)
Argyriou (2006)
!
Prospective cohort Breast Reported by age group
only
Baseline PNS
Cycles 3, 6 NPS
3 mo after chemo end
Baldwin (2012) Prospective cohort Breast Only grade P2 reported Unclear if at baseline NCI-CTC
Cycles 4, 6
Within 1 mo of chemo end
Ghoreishi (2012) RCT Breast Mild (10/16) Baseline TNSc
Moderate (5/16) 1 mo after chemo end NPS
Severe (1/16)
Pace (2007) Prospective cohort Breast Mean neurotoxicity scores
reported
Baseline TNSc
After 12 wk of chemo NPS
After 24 wk of chemo





Grade P I 31.8% Unclear if at baseline NCI-CTC
Grade P II 11% At each cycle
Grade P III 3.6% For 6 months after chemo end for induction (ie,
36 wk from start of induction therapy)





Grade details not reported Unclear if at baseline NCI-CTC
At each cycle
For 6 mo after end of chemo for induction (ie,
36 weeks from start of induction therapy)
Plasmati (2002) Prospective cohort Multiple
myeloma
Grade I (12/24) Baseline NCI-CTC
Grade II (6/24) After 4 mo of chemo NPS
Subclincial (6/24) 3 mo after stem cell transplantation
Bortezomib: 46.7% (95% CI = 0.3–93.1)
Dimopoulos (2011) RCT Multiple
myeloma
Grade I NR Unclear if at baseline NCI-CTC
Grade II (64/159) Every 3 wk until
Grade III (45/159) 1 mo after last chemo dose
Grade IV (1/159) Longer follow-up but no denominator data
Bortezomib and thalidomide: 96.2% (95% CI = 49.7–143)
Chaudhary (2008) Prospective cohort Multiple
myeloma
Grade P2 reported Baseline TNSc
Cycles 2, 4, 6, 8 NPS
End of chemo Skin biopsy
Note skin biopsy at baseline and end of chemo
only
Abbreviations: Chemo, chemotherapy; CIPN, chemotherapy-induced peripheral neuropathy; EORTC, European Organization for Research and Treatment of Cancer; CI,
confidence interval; NCT-CTC, National Cancer Institute Common Toxicity Criteria; NES, neurological examination; NPS, neurophysiological examination (quantitative
sensory testing and/or nerve conduction studies); NR, not reported; PNS, Modified peripheral neuropathy score; RCT, randomized controlled trial; TNSc, total neuropathy
score.
* Abstract only available.
"
Authors report both acute and chronic CIPN grade counts, only acute given here.
!
Raw data obtained from author or reported in paper, allowing counts reported in single study to be split by chemotherapy type.
§ Studies pooled CIPN counts across chemotherapy types included.
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are unable to quantify prevalence of painful CIPN explicitly in
out analysis.
4.4. Strengths of this review
Our meta-analysis quantifies CIPN prevalence across most che-
motherapy and cancer types. This allows our prevalence measures
to be used by clinicians when deciding between chemotherapy
types and regimens. It is also useful for planning future CIPN treat-
ment studies. In addition, these findings may be useful for both
resource allocation and research planning. Our pooled prevalence
also allows direct estimation of economic costs of CIPN resulting
from the chemotherapeutics and cancer types included in our
review [51].
In this first meta-analysis investigating epidemiological mea-
sures of CIPN, we highlight the effect of the time of assessment,
after chemotherapy cessation, on CIPN prevalence. This has impli-
cations for surveillance of CIPN at follow up, clinical care planning,
and patient expectations. Specifically, our results may contribute
to explaining the risks of developing CIPN, and its likely natural
history, to patients at consent for chemotherapy. In broad terms,
around two-thirds of patients will suffer from CIPN in the first
month after chemotherapy, but in only one-half of these will CIPN
have resolved by six months. Finally, we have confirmed the urgent
need for a standardized approach to the diagnosis of CIPN, reaf-
firming ongoing efforts such as those of the chemotherapy-induced
peripheral neuropathy outcome measures standardization study
(CI-PERINOMS) group [67].
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multiple	 outcomes.	 Secondly,	 strict	 control	 of	 the	 quality	 and	 nature	 of	 data	
recording	is	achievable.	Finally,	 it	 is	possible	to	utilize	data	acquired	to	identify	







by	 a	 distorting	 factor	 unequally,	 this	 is	 also	 referred	 to	 as	 systematic	 error.	 In	
contrast	 random	 error,	 also	 known	 as	 non-differential	 error,	 is	 a	 result	 of	 the	
distorting	issue	influencing	both	groups.	In	the	CIPN	literature	the	effects	of	bias	
are	 perhaps	 more	 important	 than	 those	 of	 random	 error,	 as	 the	 groups	 and	
measures	used	tend	to	be	carefully	chosen.		
	
Chance	 and	 confounding	 are	 limitations	 of	 cohort	 studies,	 which	 can	 to	 be	
minimized	by	using	high	power	for	sample	size	calculations,	as	well	as	complex	
statistical	 modeling	 to	 control	 for	 confounding.	 However,	 neither	 of	 these	
approaches	 is	 infallible.	Unknown	confounders,	 in	particular,	 are	 impossible	 to	
adjust	for.	In	addition	to	confounding,	effect	modification	should	also	be	sought	








and	weaken	 the	 subsequent	 analysis	 (Altman,	 1991).Loss	 to	 follow	 up	 among	
oncology	 patients	 included	 in	 CIPN	 cohort	 studies	 is	 common	 and	 rarely	
addressed	 in	 terms	 of	 statistical	 adjustment.	 The	 key	 concern	with	 this	 is	 the	
possibility	that	patients	lost	to	follow	up	are	somehow	different	with	regards	to	
the	 neurotoxicity	 risk.	 This	 is	 a	 difficult	 problem	 to	 overcome	 and	 should	 be	
discussed	in	the	presentation	of	CIPN	study	findings.	
	
Another	 potential	 limitation	 of	 cohort	 studies	 results	 from	misclassification	 of	
exposure	 or	 outcome.	 This	 can	 be	minimized	with	 the	 use	 of	 clear	 definitions.	
This	is	a	major	limitation	in	the	CIPN	literature	as	a	concrete	definition	of	CIPN	
diagnosis	is	still	lacking.	Progress	has	been	made	towards	unifying	how	CIPN	is	
measured	 and	defined	but	 this	 remains	 an	 ongoing	 issue	 in	 the	CIPN	 research	
community	(Cavaletti	et	al.,	2013).	
	
Finally,	 it	 is	 important	 to	 note	 that	 small	 single	 centre	 studies,	 which	 tend	 to	
represent	the	majority	of	CIPN	epidemiological	work,	tend	to	have	very	limited	




Due	 to	 the	 limitations	 listed	here	 observational	 studies	 can	 only	 ever	 describe	
associations,	 as	 opposed	 to	 causal	 relationships.	Despite	 these	 constraints	 in	 a	




























Various	 companies	 involved	 in	 the	 provision	 of	 the	 equipment	 used	 at	 CRIC		
were	 consulted	 including:	 Medoc,	 Siemens	 and	 NNL.	 Colleagues	 from	 other	
centers,	in	particular	Dr	Jon	Brooks	in	Bristol	who	helped	with	the	physiological	















phantom	 scans	 were	 performed	 to	 ensure	 acceptably	 low	 noise	 levels.	 Noise	
from	the	pathway,	possibly	acceptable	when	used	 in	 isolation,	was	 found	to	be	
amplified	by	the	NNL	goggles	as	described	below.	
	
3)	 The	 NNL	 goggles	 were	 found	 to	 amplify	 any	 noise	 present	 in	 the	 scanner	
room.	This	is	because	they	contain	ferrous	material	in	the	cable	connecting	them	








thermal	 data	 acquisition	 when	 the	 Medoc	 pathway	 was	 in	 used	 was	 likely	
unacceptable	(see	 figure	D.1).	Punctate	data	seemed	unaffected	by	noise	 to	 the	
same	degree.	
	

















Figure	 D.1.	Time	course	and	 spatial	map	 showing	high	 frequency	noise	 in	 the	
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There	 is	 evidence	 suggesting	 that	 low	 testosterone	 hormone	 levels	 are	
associated	 with	 greater	 pain	 experience	 (Vincent	 et	 al.,	 2013).	 Sex	 hormone	
impact	on	pain	perception	 is	 a	 complex	and	evolving	 field	of	 research	 (Bartley	




1) Is	 there	 a	 difference	 between	 testosterone	 level	 in	 patients	 who	
developed	CIPN	and	those	who	did	not?	
2) Does	 testosterone	 level	 correlate	 with	%	 BOLD	 signal	 change	 in	
the	RVM,	PAG,	MPRF	or	Thalamus?	




Salivary	 testosterone	 levels	was	collected	 from	patients	at	 the	 time	of	 the	scan	
and	 analysed	 by	 colleagues	 at	 the	 department	 of	 Clinical	 Biochemistry,	





was	 compared	 using	 a	 two-sided	 independent	 sample	 t	 test.	 Correlation	 was	
explored	using	Kendall’s	tau	non-parametric	correlation	recommended	for	use	in	
a	small	data	set.	 	Repeat	measures	ANOVA	was	used	to	explore	 the	association	
between	 CIPN	 development	 and	%	BOLD	 signal	 change	 to	 punctate	 stimuli,	 in	






















































Figure G.1 Testosterone Level Split by Sex. Blue denotes CIPN patients, red denotes 
non CIPN patients. Error bars represent 95% confidence intervals. Median 
represented by sold line in box plot. Please note the differences in the scale and 
spread of the y-axis. This relates to known higher testosterone levels in men, which 
occur physiologically.  
 
 
Correlation of testosterone level and ROI % BOLD signal change 
Assessment of correlations between salivary testosterone level and % BOLD signal 
	 216	
change in the ROIs, showed no significant correlations in men. In women there was a 
negative correlation between % BOLD signal change in the left RVM and 
testosterone level (τ = -0.42, p=0.04) and a positive correlation between % BOLD 
signal change in the right thalamus and testosterone level (τ = 0.45, p=0.03).  
 
Correlation of testosterone level and ROI % BOLD signal change, according to 
CIPN/NO CIPN classification  
When the group was split into those who developed CIPN and those who did not, 
females who developed CIPN had a negative correlation between serum testosterone 
level and % BOLD signal change in the left RVM (τ = -0.58, p=0.03) and right RVM 
(τ = -0.63, p=0.02). Males had no correlation between ROI % BOLD signal change 
and CIPN development. 
 
Testosterone as a covariate in the repeat measures ANOVA investigating ROIs 
Testosterone did not explain any of the observed variance in the increased MPRF 




There is tentative evidence that testosterone is correlated with % BOLD signal change 
in response to punctate stimuli in the RVM in women with cancer. This is a region of 
the descending pain modulatory system previously reported to be influenced by low 
testosterone levels in healthy females (Vincent et al., 2013). There is no clear 
relationship with this and CIPN development per se. Without measures of sharpness 
in a group with clinically insignificant pain ratings, and unknown menopausal status 
further interpretations of these findings are not possible. These results however 
suggest further work is warranted in terms of exploring the impact of testosterone on 
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EORTC QLQ CIPN-20 
 
Patients sometimes report that they have the following symptoms or problems. Please indicate 
the extent to which you have experienced these symptoms or problems during the past week. 
Please answer by circling the number that best applies to you. 
 
 








1 Did you have tingling fingers or hands? 1 2 3 4 
2 Did you have tingling feet or toes? 1 2 3 4 
3 Did you have numbness in your fingers or hands? 1 2 3 4 
4 Did you have numbness in your toes or feet? 1 2 3 4 
5 Did you have shooting or burning pain in your fingers or hands? 1 2 3 4 
6 Did you have shooting or burning pain in your toes or feet? 1 2 3 4 
7 Did you have cramp in your hands? 1 2 3 4 
8 Did you have cramp in your feet? 1 2 3 4 
9 Did you have problems standing or walking because of difficulty feeling the ground under your feet? 1 2 3 4 
10 Did you have difficulty distinguishing between hot and cold water? 1 2 3 4 
11 Did you have a problem holding a pen, which made writing difficult? 1 2 3 4 
12 Did you have difficulty manipulating small objects with your fingers (for example fastening small buttons)? 1 2 3 4 
13 Did you have difficulty opening a jar or bottle because of weakness in your hands? 1 2 3 4 
14 Did you have difficulty walking because your feet dropped forward? 1 2 3 4 
15 Did you have difficulty climbing the stairs or getting up out of a chair because of weakness in your legs? 1 2 3 4 
16 Were you dizzy when standing up form a lying or standing position? 1 2 3 4 
17 Did you have blurred vision? 1 2 3 4 
18 Did you have difficulty hearing? 1 2 3 4 








19 Did you have difficulty using the pedals? 1 2 3 4 
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MINT3 fMRI STUDY 
Eudract No. 2013-003968-31 
 
  A randomised, double-blind, controlled exploratory fMRI study of 
menthol gel versus placebo in the treatment of chemotherapy induced 
peripheral neuropathy. 
 
Case Report Form 
 
 









Patient’s Initials __ __ __    Subject No.  _ _ _ _ _ 
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ELIGIBILITY CHECKLIST  
  YES NO 
   INCLUSION CRITERIA   
a.   Has the patient received any neurotoxic chemotherapy? ! ! 
b.   Has the patient experienced post treatment Chemotherapy Induced Peripheral Neuropathy (CIPN)     pain for a minimum of 3 months?   ! ! 
c.   Does the patient report a distressing or uncomfortable neuropathic symptom (such as pain or        tingling) with a score of  ≥ 4 on a scale of  0-10 with 0 being none?  ! ! 
d.   Is the patient > 18 years of age?  ! ! 
e.   Does the patient’s Oncology team agree to the patient’s study participation? ! ! 
f.   Is the patient able to provide written informed consent to participation in the study after explanation     of the study protocol? ! ! 
g.   Does the patient have the ability to complete questionnaire assessments in the English language? ! ! 
h.   In the opinion of the Investigator, is the patient able to comply with study procedures? ! ! 
i.   Is the patient’s neuropathy confined to the distal extremities (distal to elbows and/or knees)? ! ! 
       EXCLUSION CRITERIA   
a.   Does the patient have a pre-existing history of peripheral neuropathy due to any cause other than     chemotherapy (diabetes, alcohol, toxin, hereditary etc)? 
! ! 
b.   Does the patient have any contraindication to using topical therapy or menthol? ! ! 
c.   Does the patient have any other neurological condition which may influence findings (such as     Multiple Sclerosis or residual signs/symptoms from a previous stroke)? 
! ! 
d.   Does the patient have any skin condition which would prevent assessment of the relevant areas      affected by peripheral neuropathy? 
! ! 
e.   Does the patient suffer from significant psychiatric illness which would hinder their completion of     the study? 
! ! 
f.   Does the patient have a general medical condition which is unstable or rapidly deteriorating, such     that they are unlikely to be able to contribute to the study? 
! ! 
g.   In the opinion of the Research Team or their usual medical team, would the patient be unable to        complete the study protocol for any other reason? 
! ! 
h. 
  Is the patient currently undergoing treatment of ≤ 30 days duration with anticonvulsants, tricyclic    
   antidepressants, MAO inhibitor, or other neuropathic pain medication agents such as  
   carbamazepine, phenytoin, valproic acid, gabapentin, lamotrigine or amifostine? 
! ! 
i.   Has the patient had topical lidocaine patches/ gel or capsaicin patches/ cream (to the limb      extremities) applied within the last 30 days? 
! ! 
j.  Does the patient have any other medical condition which, in the opinion of the treating physician/       allied health professional, would make this protocol unreasonably hazardous for the patient? 
! ! 





Medic Confirming Eligibility 
Name  Signature  Date  
 Person Taking Consent 
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     Status:  Patient withdrew consent to continue with trial 
 
 
   Patient unable to attend fMRI scan 
 
 
   Patient unable to tolerate scan (scan stopped early) 
  
 
   Unable to contact patient 
 
 
   Withdrawn by clinician 
 
 
   Patient died 
          (If patient died) 
                     Date of death 
                                             dd    mm    yy 
   
 
   
 
     Status change date: 
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     Cancer Diagnosis Date      
                                                                     dd        mm       yy     
 
Primary tumour site (tick one box only) 
 
Bladder        Gynaecological        Oesophageal      
Bone        Head and neck        Pancreatic       
Brain        Leukaemia         Prostate       
Breast        Liver          Renal       
Colorectal       Lymphoma          Testicular      
Dermatological      Lung          Thyroid      
       
Endocrine       Mesothelioma         Unknown      
Gastric/Stomach    Myeloma         Other         
   
   Current Status (tick one box only) 
No evidence   Local                  Loco-regionally               Metastatic  
of disease  disease      advanced            disease 
  
  
If ‘Metastatic disease’ is ticked,  
please specify Site(s) of metastases (tick all that apply) 
 
Brain     Lung             Bone         
 Liver        Lymph nodes       Other     
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 If ‘other’ please specify here:	
	 	 	 	 	 	
	 	 	 	 	 	
      
      
Patient Demographics:  Cancer Details 
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Radiotherapy History    
    
Has the patient received radiotherapy?                Yes                      No     
       
 
   If yes please give date of last radiotherapy:     
                                                                                       dd         mm       yy 
       
Chemotherapy History    
 
      Has the patient received chemotherapy?       Yes                      No     
       
If yes please list below: 
 
 












Paclitaxel (weekly)     
Carboplatin/Paclitaxel: 3 weekly     
Carboplatin/Paclitaxel: weekly     
Carboplatin/Oxaliplatin     
Docetaxel (3 weekly)     
Bortezumib     
Other (specify):     
     
     
     
     
     
 
	 If ‘other’ please specify here:	
      









MINT 3 fMRI   PT’S DOB:  __/__/__      Trial No:  _____ 
 
CRF 1 Completed by:                                                Print Name Here: 
 (Signature)                        ------------------------------------      (Block Capitals)      ------------------------------------ 
 










For how many months has the patient had peripheral neuropathy?  
 
Relevant Medical History 
 
 









































Dermatalogical:   
Mental Health:   
Other:   
   
 
Relevant Surgical History 
 
 







 Breast:   
 Gynaecological:   
 Lung:   
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<= 25 C 
storage 
confirmed? 
       
       
       
       
       
       
       
       
 
Drug Name 
(specify code according to 
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Weight (in kg)                                Height (in cm) 
 
 
NART Score                                                  DSST Score 
(National Adult Reading Test)                        (Digit Symbol Substitution Test)   
 
 
GCOS Score          Skin Temperature  (degrees C)  
(General Causality              (after first application of gel)  
  Orientations Scale)           
 
 
fMRI Scan Dates 
 
First Scan          Second Scan 
Date    Date 

















Drug Pack Number      
 
            
  
  





















































































Common Toxicity Criteria Details Used for Chemotherapy Dose Cessation or Reduction 
   
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